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CHAPTER 1 – INTRODUCTION 
1.1 Overview and Objectives 
Despite the many clinical advances in cancer treatment, lung cancer still remains 
one of the most prevalent cancers worldwide with 1.8 million new cases and 1.6 million 
deaths occurring in 2012.1 It remains as the second leading cancer in estimated new 
cases and the leading cause of cancer related deaths in the United States for both men 
and women.2 Most cases (57%) are diagnosed at the advanced stage of the disease 
(metastasized to other sites) which has kept the overall 5-year survival rate at diagnosis 
to 18.6% with half of those initially diagnosed expected to die within the year.3-5 Those at 
the metastatic stage (57% of cases) have only a five-year survival rate of 4.7%. Only a 
small decrease in lung cancer incidence and deaths (2.1% and 2.7%) has been seen in 
the past decade, which negatively compares with other forms of cancer such as prostate 
cancer which as seen a 10% annual decrease in incidence from 2010-2014 with 
colorectal cancer incidence rates declining 2-3% annually from 2005-2014.2, 3 Therefore, 
new therapeutic strategies to manage lung cancer are greatly needed.  
Not only does primary lung cancer pose a serious challenge, secondary lung 
tumors that metastasize to the lungs form other primary tumors can be found in 30-55% 
of all cancer patients.6 This is an indicator of advanced stages of cancer, in which 
treatment for such cases proves to be more challenging. Of these cancers, breast cancer 
(the second- leading cause of cancer-related deaths for women and 1st in estimated new 
cases)2 commonly metastasizes to the lung;7, 8 it is this metastatic stage –  the metastases 
themselves – and not the primary tumor that is the true leading cause of death in such 
patients.9, 10  Metastatic relapses to the lungs (primary or secondary)  is observed in 
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majority of patients, and chemoresistance that develops in most cases after clinical 
treatment including chemotherapy is what ultimately becomes the leading cause of death 
for these patients.6, 9, 11 Most metastasis cannot be cured.12 Therefore, current clinical 
intervention most often fails in these cases leading a significant need to propose 
alternative pathways for treatment.  
Current therapies often are used to slow tumor growth of alleviate symptoms.12 
The type of treatment strategy is highly dependent on tumor type and how advanced the 
stage of the cancer. For non-small cell lung cancer (comprises 85% of lung cancer 
cases)13 the most common treatment is surgery, radiation therapy, or chemotherapy, 
which can be given alone or in combination.14 In the advanced stages, radiation therapy 
chemotherapy, targeted therapy, or immunotherapy are used alone or in combination.14 
Usually a combination of two drugs is used to increase therapeutic effectiveness for 
chemotherapy intervention.11  Current therapies for breast cancer, as with lung cancer, 
also include surgery, radiation therapy, targeted therapy, and chemotherapy alone or in 
combination.15 In stage IV metastatic breast cancer, where secondary lung tumors can 
form, chemotherapy is the main treatment given.15 This includes triple-negative breast 
cancer, in which there are currently no effective targeted therapies that have yet been 
developed.15, 16 Also due to the unpredictability of metastasis development, 
chemotherapy is normally given as an adjuvant therapy in 80% of breast cancer cases.10  
Chemotherapy is the main modality for treatment of metastatic cancers as well. 
In recent years, significant advances in immunotherapy, especially in the field of 
immune-checkpoint inhibitors, has brought new hopes in clinical treatment for patients 
who suffer from primary and secondary lung tumors with several immune-checkpoint 
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inhibitors approved by FDA.17 Non-small cell lung cancer (NSCLC), which was once 
considered untreatable with immunological approaches, such as cancer vaccines, have 
now seen huge clinical benefit when in the advanced states of the disease with the 
treatment of immune checkpoint inhibitors.18, 19 However, only a small portion of the 
patients show response to this treatment, which includes a range of 15-25% of patients 
responding to immune various immune checkpoint inhibitors to cytotoxic T-lymphocyte–
associated protein 4 (CTLA-4) receptor, programmed death-1 (PD-1), or programmed 
death ligand-1 (PD-L1).20, 21 This may be due to the heterogenous nature of NSCLC 
tumors and various resistance mechanisms that are not yet clearly understood.19, 20 This 
type of treatment has also led to immune-related adverse events in which the 
pathophysiology remains unknown, but may be related to the role of immune checkpoints 
in immunologic homoeostasis.17 However, new alternative understanding in the tumor 
microenvironment (TME), and the search for alternative targets to mediate the 
immunosuppressive nature within the TME have kept advances in immunotherapies 
introduced in clinical trials.19, 20 
While new targets are being identified and issues related to long term side effects  
are still being understood, chemotherapy reamins a significant part of treatment for 
primary and secondary lung cancer patients alone or in combination with 
immunotherapy.14 Since chemotherapy is a commonly used treatment modality in most 
advanced forms of cancers, including the metastatic form, and chemoresistance develops 
in most cases, chemoresistance is truly a formidable problem to be addressed. Acquired 
chemoresistance from treatment of tumors with various chemotherapeutics leads to 
cancerous cells developing multidrug resistance (MDR).22, 23 MDR remains one of the 
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major issues still facing effective cancer treatment.23 Multiple genetic and environmental 
factors with tumors and the surrounding tumor microenvironment (TME) lead to the 
development of MDR and can vary from tumor to tumor.24 Many of the MDR mechanisms 
include increased drug efflux out of cancerous tumors, alterations to drug via cellular 
metabolic pathways inactivating the drug, alteration in drug targets making drug 
ineffective, reduced apoptosis, increased DNA repair, compartmentalization of drugs, 
changes within the cell (genetic or epigenetic) that can influence the surrounding TME, 
presence of cancer stem cells, and molecular and genetic heterogeneity of cancerous 
cells within the tumor.22-24 Most MDR  tumors utilize more than one of these resistant 
mechanisms simultaneously.24 Due to this complexity in various MDR mechanisms, new 
drug delivery strategies to overcome these challenges are currently being developed. 
This has led to the use of a variety of nanotechnologies in  the hope to overcome 
limitations seen by common chemotherapeutic treatments.24 
Nanotechnologies, such as polymeric nanocarriers (PNCs), have great potential in 
enhancing clinical treatment of cancers by improving drug availability and reducing 
systemic side effects by specific targeting of therapeutics to tissues of interest, which has 
proven to enhance clinical efficacy.25-27 Improved quality of life and longevity of patients 
has been demonstrated when specific targeting is used to selectively deliver 
chemotherapeutics towards malignancies, which has pushed many nanomedicines into 
the clinical phases for treatment of a variety of cancers.27, 28 Many PNCs can also be 
multifunctional, allowing for enhancement in many aspects of drug delivery including 
specific targeting, enhanced drug bioavailability, sustained drug release, decreased drug 
clearance, delivery of multiple drugs, controlled release of drug, and increased cellular 
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uptake, thus, enhancing overall drug efficacy and overcoming many resistance 
mechanisms to help address MDR.27-31  
Dendrimer nanocarriers (DNCs) represent a promising technology for delivery of 
chemotherapeutics.32 DNCs are tree-like polymers that have a central core with repeating 
branches.33-35 They have unique properties such high monodispersity,33 small nm-scale 
range,35 high density of surface groups that can be modified to increase solubility of 
therapeutic conjugated to the dendrimer,33 multifunctionality for attachment of other 
targeting moieties or solubilizing groups,34 controlled drug release,34 controlled and 
reproducible pharmacokinetics,36 enhanced targeting, and reduced systemic side effects 
to increase overall therapeutic efficacy.34 These unique properties make DNCs 
particularly attractive choices for the delivery of both small molecules and biologics in the  
treatment of advanced lung cancers and secondary lung tumors. 
DNCs can be synthesized via convergent of divergent synthesis strategies, and 
depending on the monomer chosen for synthesis, various classes of dendrimers have 
been formed including polyamidoamine (PAMAM), polypropyleneimine (PPI), poly-L-
lysine (PLL), poly(glycerol-co-succinic acid), melamine, poly(glycerol), 2,2-
bis(hydroxymethyl)propionic acid (Bis-MPA), poly(ethylene glycol) (PEG), and others.37 
Of those DNCs that have been formed, recently, polyester dendrimers made from Bis-
MPA have emerged a promising dendrimer chemistry, particularly for their 
biodegradability and decreased toxicity compared to other chemistries such as PAMAM 
dendrimers.38 A significant amount of work on the use of Bis-MPAs for biomedical 
purposes has been more recently published.39-41 Dendrons (Greek term for trees), is a 
class of dendritic architectures representing a branch or dendritic  wedge-shaped 
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fragment in the tree-like structure.42, 43 Malkkoch et al. has explored the synthesis of bis-
MPA polyester dendrimers by the conjugation of dendrons.44 The conjugation of surface 
modified dendrons can be used to achieve controlled, stereo-specific bifunctionality so as 
to further modulate their interaction with the physiological environment.45 Surface 
functionality plays a key role in in vitro cellular internalization and intracellular trafficking. 
It is known that the endocytic internalization and intracellular trafficking within cells can 
affect drug release and overall therapeutic performance as well as the biodistribution and 
pharmacokinetics,46 as seen in methotrexate conjugated to cationic vs anionic 
dendrimers.47  Consequently, choosing a desired surface functionality as well as linker 
between drug and dendrimer for conjugation can affect overall in vitro and in vivo 
therapeutic performance. Asymmetric dendrimers have been utilized for DOX delivery via 
hydrazone bond between dendrimer and DOX and polyethylene oxide conjugated to other 
side, and demonstrated less toxicity than free drug in vitro, however, demonstrated 
efficacy in vivo similar to that of Doxil.40 Nevertheless, little is known on how asymmetry, 
varying surface chemistries, and route of delivery can affect overall therapeutic 
performance against lung tumors, especially in context of MDR. While the synthesis 
remains complex, advantages in their unique bifunctionality makes them potentially 
attractive and unique options for treatment of such complex disease states such as MDR 
and metastatic tumors.  
Other strategies can be combined with drug conjugation to DNCs to help address 
MDR. The ability to target specific intracellular organelles can be used to repurpose 
cytotoxic drugs in cancer treatment. Mitochondria are intracellular organelles that 
maintain cellular homeostasis.48 Mitochondria in cancerous cells are functionally and 
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structurally different as compared to normal cells, and have been implicated in tumor 
initiation and progression.49 Since mitochondria regulate energy metabolism in the cell, 
production of reactive oxygen species (ROS), and apoptosis,50 therapies that can alter 
metabolic processes associated with cancer cell survival,51 increase ROS production,52 
induce apoptosis, or disrupt mitochondria integrity53 have the potential to be developed 
as alternative drug strategies for cancer treatment.  Mitochondrial targeting has been 
shown as an effective strategy to overcome MDR via attachment of mitochondrial 
targeting agent triphenylphosphonium (TPP) to small molecule cytoreductive agents.54-57 
Therefore, providing a platform for targeting DNC-drug conjugates toward mitochondria 
has the potential enhance chemotherapeutic outcome and potentially improve strategies 
to address MDR.  
Since acquired MDR can also come from treatment of chemotherapeutics, the use 
of an entirely different strategy, including the delivery of alternative therapeutic molecules, 
like short-interfering RNA (siRNA) can be also utilized alone or in combination to help 
address MDR as it can be used to modulate overexpression and assist in the induction 
of apoptosis.58 One of the main advantages of siRNA therapy is its specificity and 
versatility. It allows for specific targeting of gene of interest without impacting other 
genes/cellular functions. However, one major challenge in such therapies is the ability to 
deliver such biologics intact to the cell cytosol.  Nanotechnology seems to be particularly 
poised as a strategy to be able to address that challenge.59-61 62-64 Therefore, if a specific 
delivery strategy of siRNA is found effective, the versatile use of such strategy can be 
explored for the treatment of variety of gene targets to treat cancers as well as other 
disease states. Several nanoformulations have been explored for the delivery of siRNA 
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for cancer treatment, with some being tested in clinical trials.65 The co-delivery of siRNA 
with chemotherapy for the treatment of MDR has been a focus of many groups 
demonstrating a synergistic effect.58, 66 Of siRNA targets, Bcl-2 and Survivin, genes 
associated with cellular apoptosis pathways found to be upregulated in many tumor types, 
associated with poor prognosis, and found upregulated in MDR cells,60, 66-70  are, 
therefore, great therapeutic targets. For the treatment of lung cancer and secondary lung 
tumors, a viable strategy in which the siRNA (as well as other therapies) can be delivered 
locally to the lungs directly via the pulmonary route could lead to significant improvement 
in bioavailability of siRNA.  
Oral inhalation (OI) formulations for the treatment of lung metastasis and lung 
cancer remains a viable strategy to enhance overall efficacy of treatment. Since most 
chemotherapeutics used in lung cancer treatment are delivered intravenously (IV),71 
multiple unwanted side effects are associated with such cytoreductive therapies. This 
problem is compounded by the fact that only a small fraction of dose actually makes to 
the lungs, with typical doses being very high, which may force patients to discontinue 
treatment. The use of OI can improve in overall success in treatment by increasing dose 
to target site while reducing systemic exposure, thus lowering side effects.72, 73 Higher 
bioavailability of therapeutic can be found as well by lower enzymatic activity in the lungs 
compared to the first-pass hepatic metabolism when delivered IV.73, 74 Higher amount and 
bioavailability of drug also allows to lower required dose for administration.75 OI can also 
be utilized as strategy to deliver into systemic circulation non-invasively due to the large 
alveolar surface area an thin air-blood epithelial barrier73 8, 76. When combined with DNCs, 
high doses of therapeutic molecules have been found in the lymph nodes upon pulmonary 
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administration, which is a primary site for metastases from lung cancer, and very hard to 
target when drug is administered systemically.77, 78 Therefore, the use of OI strategy for 
delivery of therapeutics for the treatment of lung cancer and lung metastasis remains 
highly relevant. The use of such a strategy can also be used for the delivery of 
immunotherapies. Recent advances in immunotherapy for lung cancer treatment highlight 
the potential of the pulmonary route. For example immune checkpoint inhibitors alone or 
in combination with colony-stimulating factor 1 receptor inhibitors (CSF1Ri) have been 
shown very effective in the treatment of non-small cell NSCLC.79 However, both treatment 
strategies may induce liver toxicity,20 and the ability to reduce dose and target disease 
tissue may prove essential to broaden the applicability of such combination treatments. 
Immunotherapy with CSF1R inhibitors has recently been investigated in pre-
clinical studies and clinical trials for treatment of a variety of tumors demonstrating great 
promise and providing an alternative strategy of treatment from current chemotherapy. 
CSF1Ri work to inhibit CSF1R, a critical receptor found particularly on macrophages.20, 
80 Tumor associated macrophages (TAMs) are one of the main immune cells found within 
the TME.  TAMs can be described having two main polarizing phenotypes: M1 and M2.81 
M1 macrophages are immunostimulatory while M2 are immunosuppressive.81 M2 TAMs 
are known to promote tumor initiation, proliferation, metastasis, angiogenesis, modulate 
T cell responses, and correlated with resistance to conventional therapies. 20, 80 CSF1R 
signaling initiates myeloid cells to differentiate into M2 phenotype. M2 CSF1R+ cells are 
correlated with poor survival in a variety of tumor types including lung cancer.20, 82 CSF1Ri 
can modulate the expression of M2 phenotype by selectively reducing the number of M2 
and/or repolarization from M2 into M1 phenotype, therefore, increasing M1/M2 ratio.83 A 
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high M1/M2 ratio has been shown to correlate with increased survival for patients as a 
monotherapy or combination therapy.20, 80 Therefore, the direct delivery of CSF1Ri to the 
tumor site – lung cancer tumors or secondary lung tumors – by pulmonary delivery could 
enhance overall treatment efficacy by all advantages discussed previously, as a 
monotherapy or in combination with other treatments.  
Within this context, the objectives of this dissertation are as follows:  
Objective # 01: Develop mitochondrial-targeting dendrimer nanocarriers 
(DNCs) as a platform for the repurposing of chemotherapeutics with potential 
applicability in the treatment of MDR in primary and secondary lung cancer. 
Mitochondria play a crucial role in cellular homeostasis, including production of cellular 
energy, production of reactive oxygen species (ROS), and intrinsic apoptosis.48, 50, 84, 85  
Alterations in mitochondria occur in cancerous cells in which lead mitochondria to become 
dysfunctional or “resistant.”48, 67 Changes in cellular metabolism from aerobic respiration 
to aerobic glycolysis – an effect known as the Warburg effect – and alterations in intrinsic 
apoptotic pathways – impaired apoptosis – occur in these mitochondria.48 Since 
mitochondria play crucial roles in cell survival and proliferation in cancerous tumors, 
therapeutic agents that can be directed toward the mitochondria have great potential in 
elimination of such tumors49, 86 by altering metabolic processes essential in cancer cell 
survival,51 leading to mitochondrial destabilization to induce apoptosis.53  This direct 
targeting of therapies toward the mitochondria can also help overcome MDR, a major 
obstacle in current chemotherapy treatment by redirecting therapeutics, for example, 
whose nuclear target may have been compromised due to MDR, allowing the repurposing 
of that same molecule.67 We, therefore, designed a DNC platform to target the 
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mitochondria. We selected a known mitochondriotropic agent, the delocalized lipophilic 
cation triphenylphosphonium (TPP) ion, that was conjugated directly to  amine-
terminated, generation 4, poly(amidoamine) (PAMAM) dendrimer (G4NH2-TPP) 
nanocarriers or to G4NH2 through a polyethylene glycol (PEG) linker (G4NH2-PEGTPP). 
The synthesis, in vitro cellular uptake, cytotoxicity, and mitochondrial colocalization of 
conjugates was investigated. The conjugation of TPP to various nanocarriers for 
chemotherapeutic delivery87-91 or to the drug/therapeutic themselves52, 54-57, 92 has 
demonstrated increased cytotoxicity and enhanced efficacy in vitro87, 88, 90, 91, anti-tumor 
activity in vivo,87, 88, 93 and the ability to overcome drug resistance.54, 56, 57, 94.  The details 
on the studies of the G4NH2-TPP modified and G4NH2-PEGTPP modified dendrimers will 
be further discussed in the following chapters.  
Objective # 02: Develop siRNA/TPP-DNCs as a platform for pulmonary 
delivery of siRNAs with potential applicability in the treatment of MDR in primary 
and secondary lung cancer. The inactivation of apoptosis through the increase in anti-
apoptotic genes expression including is one of the known mechanisms employed in MDR 
cells.22-24 Bcl-2 and Survivin overexpression have both been implicated with poor survival 
and drug resistance in many cancer types including lung and breast cancer.22, 66, 67, 69 
Therefore, the downregulation of these genes can induce a synergistic interaction with 
other therapies66, 95 and potential in overcoming MDR. However, the delivery of siRNA to 
the lungs has remained a challenge including finding efficient and safe vectors for siRNA 
delivery to lungs, extracellular and intracellular barriers that prevent efficient siRNA 
transport to target lung tissues,96-99 and challenges for their formulations into portable oral 
inhalation devices – including pressurized metered dose inhalers (pMDIs) and dry 
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powdered inhalers (DPIs). Therefore, we designed an efficient platform for the delivery of 
siRNA to the lungs. Firstly, an TPP-modified G4-NH2 PAMAM dendrimer was synthesized 
and complexed with siRNA (TPP-dendriplexes) to enhance the transfection efficiency of 
siRNA in an in vitro model of pulmonary epithelium. Secondly, particle engineering 
strategies for the efficient formulations of such complexes for pMDIs and DPIs were 
developed. The details of synthesis, characterization, in vitro gene knockdown and 
inhalation formulations will be further described in the following chapters.  
Objective # 03: Develop novel asymmetric polyester dendrimers for 
increasing efficacy of chemotherapeutics with potential applicability in the 
treatment of MDR in primary and secondary lung cancer. Despite the many 
advantages that PAMAM dendrimers possess, they have some limitations in terms of 
toxicity well-documented in various cell lines.100-103 PAMAM dendrimers are also not 
degraded under physiological conditions.104 Therefore, a push for a less toxic and more 
biodegradable option of dendrimers have led to the design of dendrimers made from 2,2-
bis(hydroxymethyl)propionic acid (Bis-MPA) – a polyester based material with 
demonstrated decreased toxicity and biodegradability.38 Also the requirement of 
dendrimers to become multifunctional has led to the design of heterobifunctional 
(asymmetric) dendrimers for biomedical applications.45 However, the synthesis of such 
asymmetric remains a challenge.45 There are no studies that have shown the effect of 
asymmetry in the role of cellular internalization and intracellular trafficking and how that 
may play a role in drug internalization, release, overall efficacy, and intracellular targeting. 
Because drug conjugation may alter the interaction of the DNC with the physiological 
environment, the ability to create highly controllable structures through dendrons may 
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provide for a pathway for enhanced cellular targeting and yet ability to co-locate with 
desired organelle, and thus yet another strategy in the repertoire to target MDR.105 In 
order to realize such potential, we designed a facile way for modification of surface of 
polyester Bis-MPA dendrons with various surface groups containing different surface 
properties (cationic, anionic, neutral hydrophilic, hydrophobic). We combined this 
dendron side with another dendron side where a power cytoreductive agent broadly used 
in chemotherapy treatment of a variety of tumors (doxorubicin = DOX) is conjugated 
through a degradable peptide bond. The final product is an asymmetric dendrimer 
containing DOX on one side and varying surface chemistries on the other. The details on 
the synthesis and characterization of dendrons and dendrimers will be discussed in the 
following chapters.   
Objective # 04: Develop pulmonary delivery strategy for TAM-targeting 
immunotherapy with potential applicability in the treatment of MDR in primary and 
secondary lung cancer. Chemotherapy remains the main modality to treat metastatic 
cancers. However, MDR is typically developed along cytoreductive treatment.22 IV 
delivery of small molecule chemotherapeutics and other therapeutics used in the 
treatment primary and secondary lung tumors also leads to unwanted side effects, 
limitations in drug dose and bioavailability, and small portion of drug making to the lung 
tumor site.73-75, 106 Therefore, alternative types of therapies and routes of delivery to treat 
these tumors may are critically needed to bring about innovations that may help address 
MDR and to improve overall treatment efficacy. We have thus tested a combination 
chemo- and immuno- therapy strategy for the treatment of lung cancers that combines a 
small molecule CSF1Ri and a cytoreductive agent.  We established an in vivo mouse 
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model of metastatic breast cancer to the lungs and tested the efficacy of such combination 
therapy upon local delivery to the lungs. This study will be described in detail in the 
following chapters. 
 The rest of this document is organized as described next. In Chapter 2 we present 
a literature review about the following topics: lung cancers and other common cancers 
that metastasize to the lung; current treatment strategies for primary and secondary lung 
tumors; challenges in MDR; dendrimers’ role as effective polymeric nanocarriers for 
therapeutic delivery, mitochondrial targeting of chemotherapeutics as an effective 
strategy for primary and secondary lung tumors and MDR; siRNA delivery to lungs and 
potential use in overcoming MDR; advantages in direct pulmonary delivery of for 
treatment of lung tumors; and immunotherapy to modulate tumor associated TAMs as a 
treatment strategy.   
 In Chapter 3 we discuss the mitochondrial targeting ability of TPP-modified G4-
NH2 PAMAM dendrimers. The goal of this work was to establish a platform for 
mitochondrial targeting that may open up possibilities for drug repurposing in MDR. 
Conjugation of TPP was either directly conjugated to the surface of G4-NH2 PAMAM 
dendrimer (G4NH2-TPP) or via a PEG linker (G4NH2-PEGTPP). The synthesis and 
characterization are fully described. Their biological activity was tested at various surface 
densities of TPP or PEGTPP in an in vitro model of human alveolar carcinoma cell line 
(A549). This included the testing of cellular uptake by flow cytometry, cytotoxicity by MTT 
assay, and mitochondrial colocalization by confocal microscopy in vitro. The main effects 
on the type of TPP conjugation (direct or through a PEG linker) were assessed for each 
dendrimer conjugate. This chapter is based on the published manuscript:  Bielski, E. R., 
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Zhong, Q., Brown, M., & da Rocha, S. R. Effect of the conjugation density of 
triphenylphosphonium cation on the mitochondrial targeting of poly (amidoamine) 
dendrimers. Molecular Pharmaceutics, 2015,12, (8), 3043-3053.  
In Chapter 4 we discuss the formation and oral inhalation formulations of TPP-
dendriplexes as a siRNA delivery strategy to the lungs. siRNA delivery to the lungs 
remains a huge challenge due to the poor bioavailability of siRNA when administered IV 
and difficulty in maintaining siRNA integrity and activity when formulating for use in 
portable inhalation devices.107 G4NH2 PAMAM dendrimers were modified at various TPP 
densities (G4NH2-TPP) to enhance in vitro transfection ability when delivery siRNA to an 
in vitro model of the pulmonary epithelium. G4NH2-TPP dendrimers were complexed with 
siRNA to form TPP-dendriplexes and were characterized by light scattering and SEM. 
Varying TPP densities and N/P ratios were analyzed. The complexation efficiency of 
various TPP-dendriplexes were assessed by gel electrophoresis and polyanion 
competition assay. The in vitro toxicity and gene knockdown efficiency were evaluated 
against eGFP-expressing A549 cells. TPP-dendriplexes were engineered into micron 
particles utilizing spray drying. These particles were characterized by Light Scattering and 
SEM, their in vitro gene knockdown ability was assessed, and their aerosol characteristics 
for both pMDIs and DPIs was determined by Anderson Cascade Impactor. This chapter 
is based on the published manuscript: Bielski, E., Zhong, Q., Mirza, H., Brown, M., Molla, 
A., Carvajal, T., & da Rocha, S. R. TPP-dendrimer nanocarriers for siRNA delivery to the 
pulmonary epithelium and their dry powder and metered-dose inhaler 
formulations. International Journal of Pharmaceutics, 2017, 527, (1-2), 171-183. 
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In Chapter 5 we discuss the synthesis and characterization of surface 
modifications for polyester Bis-MPA dendrons. Surface modifications of dendrimers have 
been demonstrated to affect cellular internalization and intracellular trafficking in various 
cell lines. Cationic and neutral PAMAM dendrimers were found to be internalized via non-
clathrin, non-caveolae-mediated mechanisms endocytosis., anionic dendrimers were 
seen to be internalized in A549 cells by a caveolae-dependent mechanism108 Hydrophilic 
PEG modification of dendrimers has shown to decrease the rate of cellular uptake of 
dendrimers but does not reach saturation in cellular internalization at short times.78 
Hydrophobic lauryl modifications have been demonstrated to increase internalization of 
G3-PAMAM dendrimers by caveolae-dependent endocytosis and micropinocytosis in HT-
29 cell line,109 and increase transport across Caco-2 cells via transcellular and 
paracellular routes.110 However, little is known about the cellular internalization and 
intracellular trafficking of asymmetric dendrimers, in which critical understanding of these 
pathways has the potential to increase drug efficacy in vitro and in vivo. For example, one 
dendron can be used to carry drug or drug-intracellular targeting agent, while the other 
dendron may lead to enhanced uptake. Also, synthesis of asymmetric dendrimers still 
remains highly complex as well and new protocols may support their development.45 
Therefore, a facile way to modify polyester dendrons is described. The azido-G5-OH (N3-
G5-OH) polyester Bis-MPA dendrons were synthesized and characterized with 
unmodified hydroxyl (-OH), anionic carboxyl (-COOH), cationic (-NH2), hydrophilic PEG 
(-PEG) and hydrophobic lauryl (-LA) functionalities. The synthesis and characterization 
by 1H NMR, MALDI-TOF, and Light Scattering of modified dendrons is described. The 
attachment of DOX via peptide (-GFLG-) and linked to Acet-G5-SA modified dendron is 
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also discussed. The use of click chemistry to conjugate the Acet-G5-OH and N3-G5-OH 
dendrons to form dendrimers as potential strategy for formation of asymmetric dendrimers 
is described.  
In Chapter 6 we describe the pulmonary delivery of a CSF1Ri (PLX3397) for the 
treatment of lung tumors, in this case using an in vivo model of secondary lung tumors 
developed from a murine model of stage IV metastatic breast cancer. The efficacy of 
PLX3397 (PLX) delivered via pulmonary route, also its combination with 
chemotherapeutics (DOX) had not been previously explored. In this study we transduced 
a mouse (Balb/c) breast cancer (4T1) cell line to contain fluorescence and 
bioluminescence vectors (luc-tdtomato-4T1). Cell sorting following by fluorescence 
expression determination by flow cytometry and bioluminescence expression determined 
by IVIS imaging were utilized to establish the cell line. An in vivo, syngeneic (4T1/Balb/c) 
immunocompetent tumor model of lung metastasis was established with the transformed 
cells. The effectiveness of PLX and DOX treatment delivered via pulmonary route was 
assessed in vivo by measurement of tumor burden via IVIS imaging. Macrophage 
polarization induced by PLX was assessed by flow cytometry.  
 In Chapter 7 we conclude the work as we try to unify all the treatment strategies 
discussed above as potential means to address MDR in lung cancers and propose next 
steps that can be taken in each project based on the knowledge acquired during the 
execution of these multifaceted projects.  
1.2 Relevance and Innovation 
The relevance of this work stems from the fact that the development of MDR 
remains the greatest challenge in the management of primary and secondary lung 
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cancer.6, 7 Therefore, new therapeutic strategies that can increase efficacy of overall 
treatment are needed. Here we present several different platforms that have the potential 
to treat highly metastatic tumors and overcome MDR. Firstly, mitochondrial intracellular 
targeting of therapeutics has been demonstrated by others to overcome MDR in some 
MDR-cell lines in vitro and enhanced efficacy in vivo - for small molecules only.54-57 We 
are the first group to assess the effect of TPP and PEGTPP density on dendrimers in 
general, and the impact of such modification on their cellular internalization and 
mitochondrial targeting, thus demonstrating their potential as a platform for delivery of 
therapeutics to overcome MDR. We are also the only group to demonstrate the ability of 
dendrimer-TPP conjugates to enhance in vitro transfection ability of siRNA in lung 
alveolar cells and the successful aerosol formulations of such complexes in both pMDIs 
and DPIs. This provides for a strategy for local targeting of siRNA to lungs that can also 
potentially be used alone or in combination to address MDR. We are also the first group 
to synthesize and characterize various surface modifications to N3-G5-OH polyester 
dendrons for the formation of asymmetric dendrimers containing DOX and varying 
surface chemistries. The study of cellular internalization and cellular trafficking on effect 
of drug release and efficacy in vitro and in vivo biodistribution and pharmacokinetics has 
many implications in improving overall polymer-drug design and enhanced treatment 
efficacy in metastatic and MDR tumors. Lastly, we are the first group to test the delivery 
of PLX via pulmonary route as potential treatment of metastatic tumors in the lungs, 
demonstrating potential immunotherapy route by direct pulmonary administration to the 
lungs that can enhance efficacy of treatment in metastatic tumors in the lung as well the 
potential to address MDR.   
19 
 
 
 
CHAPTER 2 – LITERATURE REVIEW 
2.1 Lung Cancer and Other Common Cancers that Metastasize to the Lung 
 Lung cancer is the second most diagnosed cancer with estimated new cases 
comprising of 13.5% (with 14% for men and 13% for women) with 6.2 percent of the 
population will be diagnosed at some point in their lifetime.2, 3 It  still remains the leading 
cause of cancer-related death in the United States regardless of gender or ethnicity 
comprising of 25.3%  (~155,000 Americans) - 26% for men and 25% for women.2, 3 Lung 
cancer has been the leading cause of death for women since 1987, killing almost twice 
as many woman than breast cancer.111 More lives are lost to lung cancer than colorectal, 
breast, and prostate cancer combined.111 The five-year survival rate after initial prognosis 
is 18.6%.3 There are few to no symptoms in most reported cases of lung cancer, 
therefore, leading most patients being diagnosed at the advanced stage of the disease; 
about 57% of cases diagnosed when lung cancer is in the distant stage (metastasized to 
distant sites) in which the 5-year survival rate drops down to 4.7%.3, 4 Although a slow 
progression in decrease of lung cancer incidence (2.1%) and deaths (2.7%) in the past 
decade, it still remains the top in cancer-related deaths, which can be reflected from only 
6% of government money funded for cancer research is dedicated to lung cancer.2, 3  
Not only lung cancer that remains a critical in terms of cancer-related incidences 
and deaths, metastasis to the lung by other cancer types also remains a major challenge. 
Metastasis is most commonly the final and fatal progressive step in solid tumor 
progression.6, 7 Metastasis is the spread of cancer from the primary (original) tumor site 
that travels through the body and forms a new tumor in another organ or tissue type 
(Figure 2.1A).112 This tumor is known as the metastatic tumor and is the same type of 
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cancer as the primary tumor. The metastatic process includes several steps including: 
cell intravasation, survival in circulation, extravasation to distant organ/tissue site, 
angiogenesis, and uninhibited growth (Figure 2B).6, 8 The molecular mechanisms of the 
primary tumor to metastasize to other organ sites is tissue-specific, and the tendency of 
primary tumors to metastasize to specific organs has been observed for more than a 
century.6, 7 
 Secondary lung tumors and are metastatic tumors found in the lung. These 
secondary lung tumors can be found in 30-55% of all cancer patients, though the 
frequency of these tumors depends on the cancer type of the primary tumor.6 Cancer 
spread to the lungs is often a marker of the disease being advanced. Almost any cancer 
can has the ability to spread to the lungs, however, some more commonly do so and 
Figure 2.1. A) Metastasis. Metastasis in cancer is when primary tumor cells break away 
from initial tumor, travels through the blood or lymph system to form new tumors 
(metastatic tumors) in other tissues or organs within the body;112 B) Steps of 
Metastasis. Several steps are required for metastasis. First, the cell breaks free from 
primary tumor and through the stroma to reach the vasculature - intravasation. Once in 
the bloodstream (or lymph), the cancer cells express certain markers, circulate, and 
distribute to distant sites depending on the interaction of cancer cells and secondary 
organs in which they colonize. After reaching a secondary target organ site, they cancer 
cells can exit the bloodstream, and begin to proliferate by releasing pro-inflammatory 
compounds, inducing angiogenesis, and releasing other growth factors.8  
A B 
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include the following: bladder cancer, melanoma, breast cancer, colon cancer, prostate 
cancer, head and neck cancer, thyroid cancer, renal cell cancer, choriocarcinoma, 
testicular cancer, osteosarcoma, Ewing sarcoma, Wilms tumor, Rhabdomyosarcoma, 
and neuroblastoma.6 Of these primary cancers, breast cancer is the leading new 
estimated cases for women in the US in 2018 at 30% (266,120) and 2nd in estimated 
deaths for women – 14% (40,920).2  It metastasizes most commonly to the lymph, bone, 
liver, and lung, in which bone and lung are the most common targets of breast cancer 
metastasis in humans.7, 8 Not the primary tumor of breast cancer, but the metastatic form 
is the leading cause of death in these patients and where current clinical intervention has 
failed.9, 10 
Secondary lung tumors can be from the initial spread of primary tumors before 
clinical intervention, however, it can also be as a consequence from treatments itself 
(chemotherapy or radiotherapy).6 Once metastasis is found, few patients can be cured by 
surgical intervention or other treatment modalities.8 Chemoresistant malignancies is the 
leading cause of death for patients, in which adjuvant chemotherapy, often accompanied 
by surgery has failed  and led the development of resistance.9, 11 Across any cancer type, 
the five-year survival rate for patients exhibiting metastatic form of cancer is 20%.8 
Therefore, new interventions for these patients are much desired.  
2.2 Current Therapies and Therapeutic Challenges in Addressing Drug Resistance 
and Metastasis to the Lung  
 The aim of current treatment strategies is to stop or slow the growth of tumor or to 
relieve symptoms.12 Current therapies for cancers is highly dependent on the tumor type 
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(primary tumor) and how progressive the disease state is. When it comes to metastasis, 
some types can be cured by current treatment, however, most cannot be cured.12  
The treatments offered for lung cancer (more specifically non-small cell lung 
cancer - NSCLC) is normally a regimen of surgery, chemotherapy, and/or radiation 
therapy or a combination of these.11 For advanced stage-lung cancer, radiation therapy, 
chemotherapy, or a combination is the main treatment.14 The standard 
chemotherapeutics given in this case include platinum-based drugs Cisplatin and 
Carboplatin.11, 14 Other common drugs include Paclitaxel, Albumin-bound paclitaxel, 
Docetaxel, Gemcitabine, Vinorelbine, Irinotecan, Etoposide, Vinblastine, and 
Premetrexed.14 Normal chemotherapy regimen usually comprises of a combination of two 
drugs, usually with cisplatin or carboplatin plus a secondary drug or gemcitabine with 
vinorelbine or paclitaxel.14 The combination of two drugs is to mitigate unwanted side 
effects of any one particular drug by reducing total amount and increasing overall 
therapeutic effectiveness.11 However, combination of three drugs has not shown much 
clinical benefit, which has kept standard treatment to a combination of two drugs.14 
Treatments are given intravenously in cycles – 1 to 3 days with rest lasting for 3 to 4 
weeks. If the lung cancer is in the advanced stage, the combination of chemotherapy is 
given up to 4 to 6 cycles.14 If the initial treatment fails to garner a response, a second-line 
chemotherapeutic such docetaxel or pemetrexed,  a targeted therapy, or immunotherapy 
treatment is given.14  
Current therapies for breast cancer also include surgery, radiation therapy, 
chemotherapy, or a combination of these as for lung. If the breast cancer is found in Stage 
I-III, surgery and radiation therapy followed by chemotherapy is normally given either 
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before or after surgery.15 If found in stage IV (metastatic breast cancer), chemotherapy is 
the main treatment modality.15 All chemotherapies are typically given intravenously (IV).71 
However, unlike lung cancer, treatments are dependent on the genetic status of the tumor 
including the expression of estrogen receptor (ER), progesterone receptor (PR) and 
HER2.15  If positive for ER or PR (tumor highly expresses ER or PR), then they are more 
likely to grow in the presence of the hormones estrogen and progesterone and more likely 
to respond to hormone therapy, and hormone therapy will be included after first-line 
treatment of surgery, chemotherapy, and/or radiation therapy.16 If the breast tumor has 
more expression of HER2 (human epidermal growth factor 2) protein, a receptor protein 
that promotes growth (seen in ~20% of cases), trastuzumab, along with chemotherapy is 
commonly given after surgery.16 However, 10-20% cases where these proteins are not 
overexpressed is known as triple-negative breast cancer. This type of breast cancer is 
more aggressive, and chemotherapy is the standard treatment given.15, 16 Currently, there 
are not targeted therapies yet developed for this type.16 
Chemotherapy for breast cancer is given as a neoadjuvant, adjuvant therapy, and 
for the advanced form of the disease.71 It is difficult to predict the risk of metastasis 
development, therefore, more than 80% of patients are given chemotherapy as an 
adjuvant therapy.10  In most cases, chemotherapy is effective when chemotherapeutics 
are given in combination. However, there is no set clear combination that has proven to 
be generally effective in all patients.71 The most common drugs given for adjuvant and 
neoadjuvant therapy are anthracyclines –  doxorubicin and epirubicin, taxanes – 
paclitaxel and docetaxel, 5-fluorouacil, Cyclophosphamide, and Carboplatin. A 
combination of these drugs (2 or 3) are usually given.71  When breast cancer is in the 
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advanced stages, the drugs that are given include taxanes – paclitaxel, docetaxel, 
albumin-bound paclitaxel, antracylines – doxorubicin, pegylated liposomal doxorubicin, 
epirubicin, platinum agents – cisplatin, carboplatin, and others such as vinorelbine, 
capecitabine, gemcitabine, ixabepilone, and eribulin.71 Unlike early stages of breast 
cancer, the advanced stage is usually treated with a single chemotherapeutic.71 In all 
cases when chemotherapy is added to the treatment regimen, the chemotherapy cycles 
will depend on the drug administered. These usually occur by giving dose of drug once – 
few times a week followed by a rest period. The cycles usually last 2 to 3 weeks.71 
Neoadjuvant and adjuvant therapy is normally given for a total of 3 to 6 months.71 If in the 
advanced state, the length you are in treatment depends on health status of patient and 
how well it is working.71 
As one can denote, chemotherapy is one major modality of treatment for cancer, 
especially metastatic cancer. One of the major problems in effectiveness of 
chemotherapy treatment is the ability of chemoresistance to develop. Chemoresistance 
can be broadly divided into two major categories: intrinsic or acquired.22 Intrinsic 
resistance refers to resistance that already exists within the tumor prior to 
chemotherapeutic treatment, thus the tumor containing resistance factors that make the 
therapy ineffective.22 Secondly, acquired resistance in which a tumor develops various 
mechanisms of resistance in response to chemotherapeutic treatment.  Exposure to 
chemotherapeutic agents can lead to drug resistance in multiple cytotoxic drugs – known 
as multidrug resistance (MDR) – which continues to be a dominant obstacle in cancer 
therapy.23 The reason for numerous failures in patients with metastatic cancer is due to 
this spectrum of mechanisms that lead to MDR, whether intrinsic or acquired.23 
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MDR and chemoresistance develop from a multiple and various molecular 
mechanisms and is governed by both genetic and environmental factors within tumors 
and the tumor microenvironment (TME).24 Figure 2.2 summaries some of these 
mechanisms and include increased rates of drug efflux, alterations in drug metabolism 
and drug targets, alterations in signaling pathways to reduce apoptosis, enhanced DNA 
repair, drug compartmentalization, genetic and epigenetic changes that influence the 
local TME, molecular and genetic heterogeneity within the tumor as well as presence of 
cancer stem cells.22-24 Generally, cancerous tumors utilize several of these resistance 
mechanisms either sequentially or concurrently.24 
One well-known mechanism of MDR is drug efflux by cell membrane transporter 
proteins. The most-well known group of transporters is the ATP-binding cassette (ABC) 
transporter family that can transport a variety of diverse substrates out of cells.22-24 49 
Figure 2.2. Various Mechanisms of multidrug resistance. This includes efflux 
pumps, enhanced DNA repair, inactivation of drugs by metabolic pathways or mutation 
or altered drug targets, drug compartmentalization, and inactivation to apoptosis.23   
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ABC transporters have been identified in humans, with 15 known to export 
chemotherapeutics out of cells.23 The most notable ones include the multidrug resistance 
protein 1 MDR1 (ABCB1, p-glycoprotein- P-gp), MDR-associated protein 1 (MRP1, 
ABCC1), and breast cancer resistance protein (BCRP, ABCG2).22-24 These three have 
broad and overlapping substrate specificity and can eliminate many hydrophobic 
chemotherapeutics including taxanes (paclitaxel, docetaxel), topoisomerase inhibitors 
(doxorubicin), and anitmetabolites.22 Rapid upregulation and overexpression of the ABC 
transporters has been seen in a variety of tumors and demonstrated resistance to a 
variety of chemotherapeutics.22-24 Overexpression in MDR1 and its correlation to 
chemoresistance has been seen in kidney, colon, liver cancers, lymphomas, and 
leukemias.22 MRP1 overexpression is seen in prostate, lung, and breast cancer leading 
to MDR.22 BCRP overexpression has led to chemoresistance in both leukemia and breast 
cancer.22 
An alternative resistance mechanism besides efflux pumps normally assist in 
resistance to chemotherapy treatment including alteration in drug targets. Such 
alterations in drug targets can include mutations to the drug target itself or changes in 
expression level.22, 24 Downregulation of target gene is one common mechanism of 
resistance. For example, this can be seen for the effect of doxorubicin and downregulation 
of topoisomerase IIα, its target protein.24 Other common resistance mechanism includes 
mutation in target protein including mutations in topoisomerase IIα, and it is commonly 
seen in receptor tyrosine kinases when targeted therapies are utilized.22, 24 
Another important resistance mechanism employed by MDR cells included the 
downregulation or inactivation of apoptosis.22-24 The pathways that regulate apoptosis are 
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known to become dysfunctional in cancer, and can also lead to MDR. A key feature to 
resistance is signaling that allows for cell survival and prevents cell death.24 This can 
occur usually by the upregulation of anti-apoptotic proteins – such as overexpression of 
Bcl-2 gene,22, 23 inhibitor of apoptosis proteins (IAPs),22 and FLIP (a caspase 8 inhibitor).22 
The role of Bcl-2 gene and its family members in response to chemotherapy has been 
the most extensively studied, and has shown to play a role in chemoresistance.22 
There are many other important factors that can lead to MDR, and many can be 
implemented sequentially or concurrently.24  This includes (but not limited to) drug 
inactivation by cancer cellular metabolism, enhanced DNA repair, and 
compartmentalization of drugs.22-24  Altered metabolism can lead to drug resistance by 
inactivation of drug itself. These metabolic pathways are more specific each drug and its 
mechanism of action. One example includes platinum-based drugs (Cisplatin, 
carboplatin, oxaliplatin) can be inactivated by presence of glutathione in which glutathione 
can bind to platinum decreasing its ability to bind to site of action – cisplatin binding to 
DNA.22, 113 DNA damage can be caused by a variety of chemotherapeutic drugs either 
directly (platinum-based drugs) or indirectly (topoisomerase inhibitors), and as cancer 
progresses, an increased repair to DNA damage occurs and can lead to resistance.22, 24 
Compartmentalization of chemotherapeutics away from target site can also occur. Drugs 
can be sequestered into organelles like lysosomes keeping the drug away from site of 
action, in which lysosomes release drug outside the cell via exocytosis.23  
Tumor heterogeneity and the TME also influence drug effectiveness and 
resistance.114 Genetic instability of within cancer cells themselves and epigenetic 
alterations can lead to genomic and phenotypic heterogeneity in the tumor.23 This can 
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occur due to the positive selection of resistant phenotypes due to treatment and the 
adaptation garnered based on signaling from the tumor microenvironment (TME).22, 23 
The TME  contains a variety of cells including tumor cells, cancer stem cells, extracellular 
matrix, cancer-associated fibroblasts, immune cells, inflammatory cells, and blood 
vessels.22  The presence of cancer stem cells (CSCs)  or tumor-initiating cells within the 
tumor are known to evade chemotherapy and allow for resistance to build.24 The tumor 
stroma with increased expression of extracellular matrix has been shown to play a crucial 
role in invasiveness and metastasis as well as sensitivity of tumor to drug treatments.114 
TME can lead to hypoxic regions, which increases expression in genes related to 
angiogenesis and cell survival, which have been shown to play a role in drug resistance.23, 
114 Signaling and interaction of various cell types with the tumor cells can lead to signaling 
(cytokines and growth factors) to activate a variety of cell survival pathways, enhance 
invasiveness and metastasis potential, and evade immune system.22, 115 Therefore, the 
acknowledgement of the complexity of the TME as well as an understanding the roles 
and mechanisms at play that lead to drug resistance is vitally important in order to 
enhance current chemotherapy treatment.  
Due to the complexity of cancer as a disease and multiple mechanisms for drug 
resistance, new drug delivery strategies to overcome these challenges have emerged 
including the use of nanotechnology. Nanomedicines have been able to overcome some 
limitations of current chemotherapy including unwanted side effects, low bioavailability 
due to the hydrophobic nature of most chemotherapeutic agents, invasiveness of 
chemotherapy treatment, and non-specific in delivery killing normal and cancerous 
tissue.11, 23 Nanomedicines have been able to enhance delivery of chemotherapeutics to 
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tumor site and address drug resistance by passively and actively targeting tumor tissues, 
increase solubility of hydrophobic drugs, delivery of combination of drugs/biologics, and 
control drug release at target tumor site.23  
2.3 Dendrimers and Dendrons as Polymeric Nanocarriers and Their Roles for 
Treatment of Primary and Secondary Lung Tumors and MDR 
Nanotechnology, or more specifically, polymeric nanocarriers (PNCs), can be 
utilized to improve drug availability and efficacy, reduce toxicity and systemic side effects 
by enhancing specific targeting of the drugs to the diseased tissue of interest,25, 30 and 
have shown improved clinical efficacy,26 therefore, they hold great potential in the 
chemotherapy treatment.25, 27 The specific targeting and selectivity of chemotherapeutics 
towards malignant tissues is directly correlated to improved quality of life and survival of 
patients,28 allowing for many nanotechnological carriers entering clinical practice and 
numerous studies conducted on optimizing the application of nanomedicines for the 
treatment of cancer.27  PNCs remain a relevant strategy due to the majority of cancer 
chemotherapeutics, including 40% of active substances being identified through 
combinatorial screening programs,25 are poorly water soluble limiting their dose, 
administration, and bioavailability;11 Polymeric nanocarriers have the potential to increase 
the solubility and bioavailability of such newly discovered agents.  PNCs also offer an 
opportunity to improve drug efficiency by mediating the interaction with the various 
extracellular barriers until their target tissues and intracellular targets can be reached.31  
Desirable PNCs are preferably multifunctional, allowing for targeting a specific diseased 
tissue with increasing local concentration at that site, avoidance of biological barriers, 
increase cellular uptake, and enhancement in drug efficacy 27, 28, 30, 31. 
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Among the different PNCs, dendrimer nanocarriers (DNCs) are a promising 
carriers for the delivery of chemotherapeutics.32 DNCs are polymeric hyper-branched 
tree-like structures of nanometer sizes comprising of a central core, repeated branches 
increasing with each generation, with a large number of functional groups on the surface 
as seen in Figure 2.3.33-35 Safety and drug loading capacity are major factors in 
determining if a PNC can be used as an efficient drug delivery vehicle.116 While some 
PNCs may be limited in their drug loading efficiency,30 DNCs hold unique promise due to 
the presence of multiple attachment sites, where both therapeutics and other relevant 
ligands including solubilization enhancers such as polyethylene glycol (PEG), and ligands 
for targeting specific cell types or tissues, making them a desired multifunctional 
nanocarrier for targeted drug delivery33, 34, 36, 117-122. 
Other unique properties that make DNCs desirable drug delivery candidates 
include increased solubility and bioavailability of the therapeutic attached,36, 116, 123 they 
preserve their physical and structural integrity within biological systems,33, 121 they are 
monodisperse,33, 36, 42, 108, 121, 122, 124-126 biocompatible,33, 42, 121, 125 have a tunable size,33, 
36 reproductive pharmacokinetics,36, 42, 121, 125 increased cellular uptake,36, 124 non-
Figure 2.3. Representation of dendrimers demonstrating their structure. They comprise 
of a central core, repeating branches, and increase in number of surface groups with 
each generation.35  
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immunogenic,36, 118, 125 can control or program drug release,34, 36, 37, 116, 124 and have 
potential for targeted delivery to reduce systemic side effects and increase efficacy of 
drug at targeted tissue site.34  These numerous characteristics and properties make 
DNCs a desirable choice for the targeted treatment of lung cancer and lung metastasis. 
DNCs are synthesized by divergent or convergent synthesis strategies, which 
allows for precise control on dendritic architecture and monodispersity, allowing for its 
predictable properties. Depending on the monomer used for synthesis, various classes 
of dendrimers have been made including polyamidoamine (PAMAM), polypropyleneimine 
(PPI), poly-L-lysine (PLL), poly(glycerol-co-succinic acid), melamine, poly(glycerol), 
poly[2,2-bis(hydroxymethyl)propionic acid] (Bis-MPA), poly(ethylene glycol) (PEG), and 
others.37 Of these PAMAM and PPI have been the most extensively investigated.37 
Specifically, PAMAM dendrimers have remained the most studied dendrimer for 
anticancer drug delivery strategies.37  PAMAM dendrimers have been utilized to 
conjugate/encapsulate doxorubicin (DOX),77, 117, 127-135 docetaxel,136 5-Fluorouracil (5-
FU),137-139 Cisplatin,140-142 methotrexate,143-147 paclitaxel,148-150 chlorambucil,151, 152 
gemcitabine,153-155 Trastuzumab,156, 157 and others.  
Although PAMAM dendrimers have been the most widely utilized in anticancer 
drug delivery, PAMAM dendrimers have some limitations.  Known cytotoxicity of PAMAM 
dendrimers across various mammalian cell lines has be well-documented.100-103 PAMAM 
dendrimers demonstrated higher toxicity in various cell lines with increasing 
generation.100-102  The toxicity is also highly dependent on surface charge, in which 
cationic demonstrating the most toxicity, 100, 101 including in vivo situations.103, 158 
Neurotoxicity was also noted for  G5 cationic PAMAM dendrimers causing irreversible 
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membrane effects on neuronal cells not demonstrated with G4.5 anionic PAMAM 
dendrimers.159 Surface modifications of cationic PAMAM dendrimer, such as 
acetylation,160 pegylation,100 and addition of lauryl,100 can overcome some of these 
issues.  However, due to their nature, they are not biodegradable and must be cleared 
intact by body through renal excretion (for low generation PAMAM dendrimers) or cleared 
by liver if surface contains charge or has a hydrophobic nature.104 Therefore, a push for 
alternative dendrimers that are less toxic and more biodegradable have led to the 
synthesis of polyester dendrimers based on bis-MPA.   
Bis-MPA polyester dendrimers hold great promise including all same unique 
features of other dendrimers in addition to their unique properties including 
biodegradability and biocompatibility. Bis-MPA polyester dendrimers were first 
characterized by Ihre et al.161 For the utilization of such dendrimers for biomedical 
applications, an assessment its biocompatibility, immunotoxicity, and biodegradability of 
and its potential fragments, Bis-MPA monomer, and trimethylpropane core were 
evaluated in vitro and compared to G4 PAMAM dendrimers.38  Feliu et al. were able to 
demonstrate biodegradability a physiological pHs and body temperature (37°C) allowing 
the macromolecule to  degrade within a few days, unlike PAMAM dendrimers that are 
resistant to hydrolysis.38 They were also able to demonstrate that polyester Bis-MPA 
dendrimers and its components were not toxic to a few human cell lines including 
macrophages, which cationic G4 PAMAM dendrimers did acquire a time and dose-
dependent toxicity demonstrating its great potential as a nanomaterial for biomedical 
applications.38  Various biomedical applications utilizing this polyester Bis-MPA dendrimer 
has been investigated including its investigations in vivo,39, 162 its use for positron emitting 
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probes for in vivo imaging,163 for use in pressurized metered-dose inhalers (pMDIs),164 
and delivery of chemotherapeutic drugs.40, 165, 166 
Dendrons, a class of dendritic architectures, has been utilized to form a variety of 
dendrimers. The use of bis-MPA polyester dendrons for form dendrimers have been 
explored by Malkkoch.44 Due to the increased interest in dendrimers to contain 
multifunctionality, the heterobifunctional or asymmetric dendrimers have now been 
explored.45 Fréchet et al. was the first to describe Bis-MPA heterobifunctional dendrimers 
made from two connecting dendrons called “bow-tie” or Janus-type dendrimers in which 
the convergent and divergent synthesis were used.167 Further refinement in synthesis 
techniques and use of CuAAC Copper-click chemistry and strain promoted azide-alkyne 
cycloaddition (SPAAC) has been utilized to synthesize a variety of heterobifunctional 
dendrimers.168-171  A few studies utilizing these bifunctional dendrimers in biomedical 
applications and drug and gene delivery has recently been explored.39-41 However, its 
major drawback remains in the complexity of the synthesis of such dendrimers.45 Much 
potential remains in exploring the use of such asymmetric dendrimers as multifunctionality 
in dendrimers remains a high priority in successful drug delivery strategies, especially in 
treatment of complex disease states such as metastatic cancers.  
2.4 Mitochondrial Targeting of Chemotherapeutics as an Effective Strategy to Treat 
Primary and Secondary Lung Tumors and Address MDR 
Mitochondria are cellular organelles that maintain cellular homeostasis and are 
critical players in cellular life and death.48, 49  It has been implicated in multiple aspects of 
tumorigenesis and its progression,49 since mitochondria are structurally and functionally 
different in cancer cells compared to normal cells.48  This includes the Warburg effect in 
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which there is a metabolic reprogramming of cancer cells from aerobic respiration to 
aerobic glycolysis.51 Limitless proliferative potential, enhanced anabolism, decreased 
autophagy, and impaired apoptosis have also been linked to mitochondrial dysfunction.48  
Mitochondria are essential in regulation of energy metabolism, production of reaction 
oxygen species (ROS), and apoptosis.50  Many of the changes seen associated with 
mitochondria in cancer are summarized in Figure 2.4.67  Since mitochondria are essential 
in these key aspects, agents and therapies that can directly target the mitochondria have 
tremendous potential in the elimination of cancerous tumors49, 86 by altering metabolic 
processes required for cancer cell survival,51 increasing ROS production and oxidative 
stress,52 and through mitochondrial destabilization,53 ultimately leading to the induction of 
apoptosis.  
Direct and indirect targeting of the mitochondria to induce apoptosis in cancerous 
cells is a promising area in cancer-based therapy and may help to overcome drug 
resistance.67 Figure 2.5 demonstrates promising targets for cancer therapy, which include 
Figure 2.4. Mitochondrial changes seen in cancer cells including transformed 
metabolism and alterations that make them resistant to apoptosis.67 
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direct and indirect routes of modulating mitochondrial function.67   Both direct and indirect 
targeting of the mitochondria can help overcome resistance of cancer cells to apoptosis 
by directly inducing apoptosis through direct targeting of mitochondria or by gene 
modulations in which a down-regulation of certain pro-survival genes that are 
overexpressed in cancer by utilizing systems like RNAi mechanism.  Therefore, by directly 
and indirectly altering mitochondrial function within cancer cells may be able to overcome 
resistance of cancerous tumors that evade cell apoptosis.  
Many studies have begun to explore targeting specific agents by direct conjugation 
of the targeting moiety and therapeutic agent toward the mitochondria to enhance their 
efficacy in treating various cancers.  One of the most common targeting moieties used 
are delocalized lipophilic cations such as the triphenylphosphoniuim (TPP) ion,50, 84 which 
have been shown to accumulate specifically in the inner mitochondrial membrane into the 
Figure 2.5. Promising direct and indirect targets for cancer therapies to induce 
apoptosis. ROS: reactive oxygen species, ER: endoplasmic reticulum, Nox: NADPH 
oxidase, OXPHOS: oxidative phosphorylation, TPSO: translocator protein, cypD: 
cyclophilin D, HKII: hexokinase II, VDAC: voltage-dependent anion channel, MMP: 
mitochondrial membrane permeabilization.67  
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mitochondrial matrix50 due to their lipophilic delocalized  positive charge allowing them to 
permeate through membrane bilayers and electrostatic attraction to the mitochondrial 
membrane due to the large negative membrane potential across it.172  They have also 
been shown to accumulate more specifically to cancerous cells because mitochondria 
within these cells have an increased mitochondrial membrane potential ~ 60 mV, showing 
a tenfold increase in accumulation.84  
The utilization of TPP targeting by direct conjugation to specific therapeutic 
molecule has been investigated. Dual targeting using folic acid (FA) and 
triphenylphosphonium (TPP) cation via direct conjugation of pro-apoptotic peptide has 
been demonstrated, and it was shown able to be internalized into mitochondria, causing 
induction of apoptosis within these cells, demonstrating great potential in targeting 
specific peptides to mitochondria for cancer treatment.92  TPP conjugated to a Vitamin E 
succinate (α-tocopheryl succinate) was shown to have increased efficacy for this 
compound compared to untargeted compound by increasing ROS production, modulating 
Bcl-family of proteins (proteins involved in cell death), and triggering of mitochondria-
dependent apoptosis.52  Direct conjugation of TPP to DOX to form DOXTPP, was shown 
to increase cytotoxicity in a DOX-resistant cell line with increase in apoptosis induction in 
both the DOX-resistant and wild-type cell lines.54 Recently, DOXTPP loaded into  
hyaluronic acid nanoparticles also demonstrated improved anticancer effects, enhanced 
tumor apoptosis, and better safety profile when compared to free DOX in vivo in mice 
bearing MCF-7/ADR (DOX-resistant) tumors.55 Also the combination of DOX delivery with 
DOXTPP has also been utilized as strategy for dual intracellular targeting of nucleus 
(DOX) and mitochondria (DOXTPP) to overcome drug resistance.56, 57 Direct conjugation 
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of targeting moieties like TPP have shown increased efficacy of various anticancer 
therapeutics. 
An alternative strategy has included the use of targeted nanocarriers 
encapsulating a variety of anticancer therapeutics for their delivery to the mitochondria.  
This has included modified liposomes or with TPP87-89 or rhodamine-123173 and loaded 
with common chemotherapeutics such as paclitaxel,87, 88 or doxorubicin,89 demonstrating 
increased cytotoxicity in cancer cells compared to free drug and non-targeted 
liposomes87, 88, 173 and anti-tumor efficacy in mouse experiments.87, 88 Another 
mitochondrial-targeted liposome system delivered resveratrol to the mitochondria of lung 
cancer cells and apoptosis resistant lung cancer cells and in a xenograft mouse model 
demonstrating enhanced anticancer efficacy.174  Targeted carbon nanotubes have 
superior efficacy in delivering an encapsulated platinum(IV) pro-drug of cisplatin and a 
chemo-potentiator, 3-bromopyruvate compared to free drug.175  The use of PLGA-b-PEG-
TPP nanoparticles with encapsulated lonidamine and α-tocopheryl succinate has been 
shown to improve therapeutic index for cancer treatment.176 A polymer-based nanocarrier 
system where TPP was conjugated to hyper-branched poly(ethylene imine) (PEI) and 
encapsulated chemotherapeutic doxorubicin or a combination of doxorubicin with a 
chemosensitizer chloroquine was shown to possess rapid and severe cytotoxicity in 
prostate carcinoma cells.90, 91 Self-assembled nanoparticles with Tryphenylphosphonium 
conjugated-cyanostilbene demonstrated enhanced mitochondrial targeting of DOX, 
increased ROS generation, and decreased mitochondrial membrane potential in 
cancerous tissues, also suppressing tumor growth in vivo in a xenograft model.93  Micelles 
targeting DOX have also been investigated.  DOX was shown to94, 177 accumulate more 
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rapidly towards the mitochondria in resistant cells in vitro and resistant tumors in vivo, 
thus indicating that targeting DOX to the mitochondria could help overcome some 
resistant cancer types.94. The accumulation of DOX toward the mitochondria was shown 
to increase mitochondrial-mediated cell apoptosis in drug resistant cells using 
nanoparticles.177 These various studies have demonstrated that targeting specific 
anticancer agents towards mitochondria can lead to higher efficacy of the agent including 
overcoming multidrug resistance and may avoid unwanted side effects as seen with free 
chemotherapeutics.  
 Doxorubicin (DOX) is a widely used chemotherapeutic to treat a variety of cancers.  
It is an antitumor anthracycline antibiotic that was first isolated from Streptomyces 
peucetius in 1967.178  DOX has shown to interact with the nucleus, mitochondria, and 
biological membranes affecting all cells.178  The main mechanisms of action include: 1) 
intercalation into the DNA, which inhibits protein synthesis and DNA replication; 2) ROS 
production leading to DNA, protein, lipid damage; 3) DNA binding, cross-linking, and 
alkylation; 4) interference in helicase activity and DNA unwinding and separation; 5) 
disruption of bilayer structure of the membrane, and 6) inhibition of topoisomerase II 
leading to DNA damage.178 The major side effect of DOX is cardiotoxicity with decline in 
cardiac function, and chronic or delayed cardiomyopathy, which can ultimately lead to 
congestive heart failure.178-180 This has limited its therapeutic efficacy.180 Therefore, as 
discussed above, several drug delivery systems, such as polymeric nanoparticles,90, 91, 
93, 177, 181 liposomes, 89 and micelles,94 have been used to reduce these side effects and 
increase therapeutic efficacy of DOX.  
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 It has also been shown that when DOX has been targeted towards the 
mitochondria, it can overcome drug resistant cancer cells and tumors.54-57, 94, 177, 182  
However, the entire mechanism of how DOX interacts with various processes in the 
mitochondria is not yet known.  It has been proposed that mitochondrial Complex I 
transforms DOX into a more reactive semiquinone radical resulting in increased ROS 
production and higher oxidative stress.178, 179  Also, the inhibition of the election transport 
chain (required for the synthesis of ATP- energy source of cells) by DOX via inhibition of 
complexes I and II may also lead to increased ROS production.179  The increase of ROS 
production by DOX can lead to redox modifications to proteins, lipids, and DNA within the 
mitochondria affecting its structural integrity and function, and can ultimately lead to 
mitochondrial-induced apoptosis.179  Short term incubation of DOX to cancerous cells also 
brought about rapid changes in mitochondrial function including changes in mitochondrial 
redox potentials towards an increased oxidative state, depolarization of the inner 
mitochondrial membrane, increased matrix calcium levels, and increased mitochondrial 
ROS production.183  Long term effects included an inhibition of respiration, ATP depletion, 
and increased production of proteins association with cell cycle arrest and cell death.183  
Also, DOX’s ability to intercalate with DNA may affect the integrity of mtDNA, which could 
also contribute to a decrease in electron transport chain complexes and overall electron 
transport chain (ETC) function. A synergistic effect of prodrug nitrooxy-doxorubicin 
demonstrated a targeting ability of prodrug to localize to the mitochondria and induce 
oxidative and nitrosative stress and activation of apoptotic factors.184  The DOXTPP drug 
also demonstrated an increase in apoptosis induction indicated by an increase in 
apoptotic proteins PARP and caspase 3 as well as showing an increase in efficacy against 
40 
 
 
 
DOX-resistant cell lines.54, 56 The fact that is has been demonstrated by previous studies 
to be effective in resistance cancer cells makes DOX a highly relevant choice to target 
towards the mitochondria.  
2.5 siRNA Delivery Strategy to Address Drug Resistance for Primary and 
Secondary Cancer Treatment 
The delivery of short interfering RNAs (siRNAs) utilizes the RNAi mechanism and 
can be used to indirectly target the mitochondria to help induce intrinsic apoptosis.  The 
RNAi mechanism, a unique form of post-transcriptional gene silencing provides a way to 
downregulate specific target proteins or oncogenes, many of which are overexpressed in 
cancers, and thus may be used to help induce apoptosis.58, 185-187  The RNAi mechanism, 
as seen in Figure 2.6,188 can be exploited to induce gene silencing by the delivery of 
siRNAs, which are double-stranded RNA molecules that are 19-25 nucleotides long.58, 186  
The siRNA is incorporated into a RNA induced silencing complex (RISC), which unwinds 
the two strands with the passenger strand being discarded and the guide strand is used 
for messenger RNA (mRNA) recognition. The binding of guide strand of the siRNA with 
mRNA recognition in RISC allows for site-specific cleavage of the mRNA, degradation of 
mRNA, and the silencing of the gene expression.  The siRNA loaded RISC is then allowed 
to find another mRNA within the cytoplasm leading to a reduction in amount of overall 
protein being made within the cell without modifying the cell’s DNA.186  By using the RNAi 
mechanism, specific pro-survival proteins associated with mitochondrial-controlled 
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apoptosis such as Bcl-2 can be downregulated in order to help induce cell death within 
cancerous tissues. 
For efficient delivery of siRNA to the cell, however, the siRNA must be able to cross 
the lipid bilayer of the cell membrane.  Free siRNA has low transport across the lipid 
membrane as it is a negatively charged macromolecule.58 Therefore, a carrier is often 
required to help siRNA cross the plasma membrane and protect the siRNA from 
degradation by nucleases.  The most likely mechanism of internalization into the cell will 
be non-receptor mediated endocytosis, where the siRNA and nanocarrier must avoid 
endosomal/lysosomal degradation and escape to the endolysosomal compartments in 
order to be released in the cytoplasm. 58  Therefore, many researchers have been looking 
at utilizing nanotechnology to efficiently deliver siRNA to the cytoplasm.  
Figure 2.6. the RNAi mechanism. The double-stranded RNA is cleaved by Dicer protein 
into siRNAs in ATP-dependent process. The siRNAs are incorporated in RISC complex, 
which unwinds the double stranded siRNA (also requiring ATP). Once unwound, the 
guide siRNA strand guides RISC to mRNA that has a complementary sequence, which 
leads to cleavage of the target mRNA.188 
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Several groups have explored the use RNAi mechanism for cancer treatment by 
delivering siRNA incorporated into nanoformulations to the cell cytoplasm.  Some groups 
have focused on delivering one type of siRNA to inhibit EGFR, c-myc, survivin, Bcl-2 
expression using liposome-polycation nanoparticles, gold nanoparticles, and dendrimers 
complexes as nanocarriers.66, 189-191 This has led some of these nanosystems 
incorporating siRNA into Phase I or Phase II clinical trials.65 However, because of the 
complexity of cancer, crosstalk in multiple signaling pathways, the co-delivery of multiple 
siRNAs or siRNAs with chemotherapeutic agents has been more recently the focus, 
especially in cancer cells that exhibit multidrug resistance (MDR).58, 192  The various 
nanocarriers include liposome-polycation nanoparticles, polymeric nanoparticles, 
liposomes, mesoporous silica nanoparticles, lipid-nanocarriers, micelles, chitosan 
nanoparticles, and PEI-Graphine oxide to deliver various siRNAs targeting P-gp, MRP1, 
Bcl-2, VEGF, mTERT, c-myc, survivin, and Mcl-1 in conjunction with chemotherapeutics 
such as Doxorubicin, Paclitaxel, and Cisplatin.60, 185, 187, 192-203  These formulations have 
seen higher effectiveness in treatment of cancer due to the synergistic effect siRNA and 
chemotherapeutic agents can bring by targeting multiple cell-signaling pathways and help 
overcome MDR. Therefore, a combination of treatments to directly target a 
chemotherapeutic to the mitochondria and indirectly modulate signaling proteins 
associated with the mitochondria by delivering siRNAs may contribute to a synergistic 
effect for cancer treatment.  
The siRNAs of interest that are involved in intrinsic apoptosis include Bcl-2 and 
Survivin.  Bcl-2 is a protein that belongs to Bcl-2 family of proteins that regulate cell 
survival and cell death.204  Bcl-2 prevents intrinsic (mitochondrial-dependent) apoptosis 
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by interacting with other members of Bcl-2 family of proteins on the outer mitochondrial 
membrane as seen in Figure 2.7 205.   Bcl-2 upregulation has been associated with poor 
cancer prognosis and drug resistance and has also been implicated in preventing cell 
death by its ability to modulate cellular redox status and mitochondrial metabolism.22, 67 
Survivin is a 16.5 kDa intracellular protein that belongs to the Inhibitor of Apoptosis Protein 
(IAP) family.68, 206 It is another protein that promotes cell survival and inhibits cell death 
by inhibiting caspases, the protein executioners of programmed cell death.95, 206, 207  It 
also has roles in regulation of cell division and has  also been implicated to play a role in 
angiogenesis as well as cell motility increasing the ability of tumor growth and metastasis 
to occur.68, 206, 208  Survivin is also usually not found in normal adult tissues, but commonly 
expressed in high levels in cancerous tumors including lung cancer (more specifically 
NSCLC) and breast cancers as well as a variety of others.66, 95, 206-211  Overexpression of 
survivin has been linked to unfavorable outcome of the disease, increased rates of 
Figure 2.7. General scheme of how Bcl-2 regulates intrinsic (mitochondrial) apoptosis. 
Bcl-2 is found on the outer mitochondrial membrane and interacts with Bak/Bax 
proteins, which prevents apoptosis form occurring. Stress induces BH3-only proteins 
to interact with Bcl-2, which allows Bcl-2 to disassociate from Bak/Bax proteins. The 
Bak/Bax proteins can oligomerize and initiate mitochondrial outer membrane 
permeabilization, release of cytochrome c and other pro-apoptotic factors that initiate 
caspases and lead to programmed cell death.205 
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recurrences, resistance to treatments, and poor survival in patients with NSCLC.66, 206, 209  
It has also been implicated that increased survivin expression was associated with 
increase overexpression of MDR1 resulting in multidrug resistance MCF-7 breast cancer 
cells,69 as well as elevated erbB3 expression in paclitaxel-resistance in breast cancer 
cells.70 Decreased expression of survivin using siRNA results in apoptosis within these 
cells and sensitized these cells to anti-cancer therapeutics.66, 95  Bcl-2 and survivin are 
known to be overexpressed in a wide variety of cancerous tumors, associated with poor 
prognosis, and have been correlated with multidrug resistance, making them both great 
therapeutic targets60, 66-68.  Therefore, the indirect mitochondrial targeting of Bcl-2 and 
survivin by downregulation using siRNA holds promise as a treatment strategy, including 
its co-delivery with mitochondrial-targeted anticancer agents and regional delivery to the 
lungs.  
2.6. Direct Pulmonary Drug Delivery for the Treatment of Primary and Secondary 
Lung Tumors 
Oral inhalation (OI) is a promising route of administration to directly target 
therapeutics to (regionally) and through (systemically) the lungs.  The use of OI is a non-
invasive way to directly target the lungs,72 increased selectivity, and lower systemic 
exposure,73 thus resulting in fewer side effects compared to other commonly used routes, 
including intravenous (IV) injection– i.e., IV administration of nanocarriers has been 
shown to significantly accumulate into the liver, thus significantly reducing the amount 
that reaches the tumor site.74, 75, 106 The low enzymatic activity in the lungs also allows for 
higher bioavailability of drug and can bypass the first-pass hepatic metabolism as 
compared to IV, therefore, the required dose can be reduced as well as lowering costs.73-
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75, 212, 213 A higher absorption rate and rapid onset of action also make the pulmonary 
route a desired route of delivery.212-214 Some other advantages to pulmonary delivery 
include large surface area-to-mass of the lungs (> 100 m2), epithelial permeability 
(epithelium layer – 0.2-1 µm thick), and small aqueous volume at the absorptive surface 
74, 213, 215-217.  OI also represents a non-invasive alternative for systemic delivery of 
therapeutics due to the lungs providing a large alveolar surface area and thin epithelial 
air-blood barrier providing a rapid absorption of molecules from the alveolar space to the 
blood stream, 73 which can be attractive to treat lung cancer metastasis that accounts for 
majority of the cases diagnosed. 8, 76  Due to these advantages, OI for treatment of lung 
cancer and lung metastases is the most appropriate route for administration of drugs.75  
Despite all the advantage OI brings, there are also challenges when delivering 
drugs directly to the lungs. The lung physiology itself provides extracellular barriers when 
it comes to the delivery of therapeutics to the lungs.  This includes the fact that the lungs 
have a branched architecture and the type of lung epithelium found in each region (Figure 
2.8) 216.  The lungs bifurcate 16 times in the conducting airways followed by 6 bifurcations 
of the respiratory bronchioles 73. The particles will be deposited into the airways depends 
Figure 2.8. Comparison of different lung epithelium at different lung regions. Aerosol 
particles can penetrate deeper in the lungs as the epithelium becomes thinner.216  
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on the force that dominates the particles, in which aerodynamic size of the particles plays 
a huge importance 216.  The branched architecture and type epithelium affect clearance 
mechanism (mucocilliary and cough) encountered when the particles are deposited, the 
lung surfactant encountered (alveolar region), as well as the immune response and 
clearance mediated by macrophages. 73, 216 Therapeutic drugs can be rapidly cleared by 
mucocilliary escalator, metabolized locally, diffuse across lung epithelia to penetrate 
bloodstream, or taken up by resident alveolar macrophages.214 Therefore, the 
nanocarriers must possess desired characteristics that enable them to be deposited in 
specific region of lungs and overcome these challenges to be effective.  They must be 
designed to bypass the above-mentioned clearance mechanisms of the lungs, provide 
prolonged residence times of the therapeutic within correct targeted lung tissue.73 They 
must possess the correct aerodynamic size, contain a neutral surface charge and be 
hydrophilic in nature to allow for passive diffusion and prevent strong interactions with 
negatively-charged molecules within the mucus, and be nonimmunogenic to avoid 
macrophage clearance, target specific cell lung populations, protect the therapeutic from 
degradation, enhance therapeutic solubility of hydrophobic therapeutics, and control 
therapeutic release.73, 216, 218  If these challenges can be overcome, one must be able to 
design nanocarrier in suitable aerosol formulations for portable inhalers.  
The two most widely used portable inhalers include pressurized metered dose 
inhalers (pMDIs) and dry powder inhalers (DPIs). pMDIs contain a formulation in which 
the therapeutic is dissolved or suspended in a propellent – commonly 
hyrodrofluroralkanes (HFAs).213 The device, when actuated, a metered volume of 
propellant and therapeutic are pushed through a valve system, in which the propellant 
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aerosolizes the therapeutic.213 Dosing with this device  is very uniform and is more 
reproducible compared to DPIs.74, 213 However, pMDIs are limited in some respects 
including high breath coordination of patient, limited dose per actuation, and high oral 
deposition.74 DPIs are devices are breath-actuated devices that aerosolize dry powder 
through shear-induced force.213 DPIs do not depend on coordination of patient breaths, 
however, the amount of dose delivered is highly dependent on the inspiratory flow rate 
making dose replication difficult.74, 213 Also, dry powder formulations tend to have 
electrostatic interactions between the particles  and/or hygroscopic phenomena, which 
can inhibit aerosolization.74, 213  Despite these limitations, DPIs are typically easier to use 
not requiring coordination of actuation and inhalation (like pMDIs) and do not require 
propellant.213 Therefore, both pMDIs provide various advantage and disadvantages that 
need to be optimized with formulation development.  
Nanotechnology has made significant enhancements in the in vitro and in vivo 
performances of aerosol formulations for pMDIs and DPIs. In pMDIs, nanoparticle 
formulations have been able to provide better dose uniformity and lowering dose 
requirements.219 Nanoparticle suspension formulations have minimized potential in vivo 
toxicity by lowering solvent presence in formulation.219 For DPIs, nanoparticle 
formulations provide a lower density compared to dense particles of same size, which 
results in a lower mass median aerodynamic diameter (MMAD) allowing for deeper lung 
deposition, and improves powder flowability.220 In both cases, nanoparticle formulation 
have shown to increase residence time of drug into lungs and reduced mucociliary 
clearance.74 Nanoparticles do provide these advantages listed here, but still require to 
have micron sized 1-5 µm to be considered optimal for deep lung deposition.214 Therefore, 
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in some situations, nanoparticles can be up formulated into suitable aerosol sizes using 
such techniques as spray-drying in which nanoparticles are spray-dried in sugar 
excipients to achieve optimal aerosol sizes of micron size. Our group has demonstrated 
the use of PAMAM dendrimers and polyester Bis-MPA dendrimers can be formulated for 
aerosol delivery in pMDIs or DPIs with or without use of spray drying technique including 
delivery of chemotherapeutic doxorubicin and siRNA.96, 127, 134, 164, 221 Therefore, use of 
dendrimers in aerosol formulations provides a relevant strategy for the noninvasive 
delivery of therapeutics for the treatment of lung cancer and lung metastases. 
2.7 Immunotherapy Strategies by Macrophage Modulation in the Tumor 
Microenvironment as Treatment Strategy for Primary and Secondary Lung Tumors 
While the tumor microenvironment (TME) includes cancerous cells, leukocytes, 
fibroblasts, vascular endothelial cells, immune cells comprise of a major component of 
cell type found.81 These immune cells interact with tumor cells to influence various 
processes including tumor initiation, growth, and metastasis.80 Of these immune cells, 
there is the present of highly plastic cell type present: macrophages. Macrophages 
present within the TME are known as tumor-associated macrophages (TAMs) and 
influence a variety of activities within the TME.80 TAMs are derived from circulating 
monocytes and are one of the most abundant normal cells within the TME.81 Recently, 
tumor-associated macrophages (TAMs) have been considered an attractive target for 
therapy against many types of cancers. It has been demonstrated by preclinical and 
clinical studies that TAM number and density is associated with poor prognosis.81, 222 
Many preclinical studies have demonstrated that therapy response can be enhanced 
when macrophage entry to TME is blocked or phenotype of these TAMs is manipulated.81 
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Macrophages have spectrum of phenotypes, however, for simplicity, are 
characterized into two polarized types: M1 or M2. M1 macrophages, or classically 
activated macrophages, are known to be proinflammatory, immunostimulatory, or 
antitumor.81 They are activated by cytokines interferon-γ and produce proinflammatory 
and immunostimulatory cytokines such as interleukin-12 (IL-12) and IL-23.80 TAMs are 
believed to resemble more M2-polarized macrophages, in which they are anti-
inflammatory, proangiogenic, immunosuppressive, and protumor.80, 81 The presence of 
TAMs – or M2-like macrophages – are seen in early stages of cancer as well as the 
metastatic type, and especially when tumors have been treated with 
chemotherapeutics.20, 81 M2 macrophages (TAMs) are stimulated by Th2 cytokines (I-L4, 
IL-10, and IL-13) within the TME and are known to promote tumor proliferation, invasion, 
metastasis, angiogenesis, inhibit tumor response mediated by T cells, allow for tumor 
progression, and demonstrate resistance to therapy.20, 80 The regulation and pathways 
between of the two TAM phenotypes and interaction with tumor cells is summarized in 
Figure 2.9.20  
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The colony-stimulating factor 1 receptor (CSF1R) is a critical receptor for 
mononuclear phagocyte system, and in particular macrophages and macrophage 
polarization.20, 80 CSF1R belongs to a type III tyrosine kinase receptor family, in which 
CSF1 or IL-34 can bind to receptor causing homodimerization and subsequent activation 
and rapid endocytosis.20, 223 The details of activation can be seen in Figure 2.10.224 
Figure 2.9. Stimulation or suppression of the immune system by TAMS. Depending on 
the TME, the cytokines emitted by tumor cells, fibroblasts or other stromal cells, immune 
cells, and macrophages themselves can polarize TAMs to M1-like or M2-like. M2 TAMs 
promote tumor growth (not illustrated here) as well as suppress various immune effector 
cells directly or through other immune cells that lead to tumor cell elimination. M1 TAMs 
can either directly kill tumor cells or stimulate/inhibit other immune cells to kill tumor cells 
by releasing of various cytokines/chemokines. M2 TAMs are known to express colony-
stimulating factor 1 receptor (CSF1R) and is essential to their function, making CSF1R 
a desirable therapeutic target to eliminate/repolarize these cells.20  
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CSF1/CSF1R signaling promotes proliferation and differentiation of myeloid cells into M2 
TAMs and recruitment into tumors, and CSF1R+ macrophages have been correlated with 
poor survival in several types of tumors.20, 82 Therefore, inhibition of CSF1R by the use of 
various inhibitors (seen in Figure 2.11)222 have recently been testing preclinically and 
clinically.80 The inhibition of CSF1R can lead to the elimination of M2 TAMs or their 
repolarization to M1 phenotype.  Therefore, the change in M1/M2 ratio by increasing M1 
phenotype and decreasing M2 phenotype is thought to increase efficacy of treatment.  
Figure 2.10. CSF1R activation. CSF1/IL-34 bind to ligand causing homodimerization. 
Subsequent phosphorylation (P) and ubiquitination (Ub) lead to receptor to be fully 
activated. Phosphorylation of 550 residue and ubiquitination are critical in further 
tyrosine phosphorylation and activation.224 
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Of these CSF1R inhibitors, the small molecule PLX3397 an oral tyrosine kinase 
inhibitor has shown great promise in increasing efficacy preclinically with current clinical 
trials taking place. Its target is intracellular (Figure 2.11) by inhibiting the phosphorylation 
of the kinase domains, therefore, preventing the CSF1R activation.222, 225 It has been 
shown to repolarize M2 TAMs to M1 TAMs or eliminating M2 TAMs to alter the overall 
M1/M2 ratio.83 It has been demonstrated efficacy in vivo and is currently in clinical trials 
for use as a monotherapy and combination therapy.20, 80 As a monotherapy, it is currently 
in ongoing or complete clinical trials for c-kit-mutated melanoma, glioblastoma, prostate 
cancer, sarcoma, neurofibroma, classical Hodgkin lymphoma, and leukemias.20  
Combination therapies include PLX3397 in combination with chemotherapeutics, 
Figure 2.11. Examples of various CSF1R signaling blocking agents. PLX3397 is a 
tyrosine kinase inhibitor.222  
53 
 
 
 
irradiation, anti-angiogenic molecules, as well as other cancer immunotherapies for 
treatment of variety of cancers including prostate cancer, breast cancer, glioblastomas, 
and melanomas, and various other solid tumors .20, 82 Of the clinical trials, CSF1R 
inhibitors in combination with various immunotherapies (immune-checkpoint inhibitors, 
which has shown great promise in over conventional therapy including for NSCLC) is the 
dominant combination group being tested.20 For PLX3397, it is being combined with aniti-
PD1 monoclonal antibody Pembrolizumab for the treatment of various tumors including 
NSCLC, solid tumors, malignant melanoma, and others.20 The efficacy and various 
combinations of most effective treatment has not been concluded and may depend on 
tumor type. Currently, research on effectiveness in various situations and desired 
synergistic combinations is yet to be discovered.  
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CHAPTER 3 – EFFECT OF THE CONJUGATION DENSITY OF 
TRIPHENYLPHOSPHONIUM CATION ON THE MITOCHONDRIAL TARGETING OF 
POLY(AMIDOAMINE) DENDRIMERS 
 
3.1 Introduction 
Mitochondria are responsible for maintaining cellular homeostasis and producing 
cellular energy (adenosine triphosphate - ATP) via oxidative phosphorylation.84, 85  They 
are also key players in the production of reactive oxygen species as well as regulating 
calcium homeostasis and the intrinsic apoptotic pathway.48, 50, 84  Mitochondria are 
organelles of great relevance in a variety of important highly energy-dependent tissues, 
including brain, heart, and muscle.84, 226  As a consequence, mitochondrial dysfunction 
has been linked to a range of diseases in these tissues (and others) including 
neurodegenerative and neuromuscular disorders, cancer, ischemia-reperfusion injury, 
metabolic diseases such as diabetes and obesity, chronic autoimmune inflammatory 
diseases, kidney and liver diseases, and aging.50, 53, 84, 227-230  In spite of the clinical 
relevance of these mitochondrial-related diseases many still lack effective therapeutic 
options.84, 231  The ability to design mitochondrial-targeting systems may therefore provide 
valuable alternative strategies to enhance therapeutic outcomes of mitochondrial-related 
diseases while at the same time minimizing side effects associated with the therapeutic 
molecules.232 
One major class of mitochondrial-targeting molecules is delocalized lipophilic 
cations (DLCs).  Triphenylphosphonium cation (TPP),50, 84 one of the most common 
DLCs, has been shown to accumulate preferentially at the inner mitochondrial 
membrane,50 at concentrations approximately 5-10 fold greater in the cytoplasm 
compared to the extracellular environment, with a further accumulation of hundreds of 
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times within the mitochondria when compared to the cytoplasm.226  The colocalization 
efficiency of TPP with the mitochondria is related to its lipophilic nature and delocalized 
positive charge, which allows TPP to permeate through membrane bilayers (hydrophobic) 
that have large negative potentials such as that of the mitochondria - 150-180 mV.172, 233 
The unique properties of TPP has been explored to help target a number of therapeutic 
agents to mitochondria including antioxidants,176, 226, 229, 234 anticancer agents,54, 87, 90, 176, 
235, 236 peptides,92 nucleic acids,237 and photosensitizers for photodynamic therapy238-240 
through direct conjugation to the drug or via a versatile nanocarrier.  The ability to combine 
the targeting properties of DLCs with nanocarrier systems may thus result in the 
development of new drug delivery technologies with the potential to address 
mitochondrial-related disorders as higher payloads, spatially and temporally controlled 
drug release, and improved pharmacokinetics can be potentially achieved by controlling 
the chemistry of the nanocarrier.231 
Within this context, poly(amidoamine) (PAMAM) dendrimers are very relevant 
nanocarrier candidates as they possess a large density of surface functional groups,34, 35, 
231 which can be used to conjugate therapeutic molecules of interest.  Drug conjugation 
to the dendrimers may also help increase the solubility and bioavailability of the 
conjugated therapeutic36, 116, 123 and the preservation of their physical and structural 
integrity within biological systems.121, 231  Dendrimers also display highly reproducible 
pharmacokinetic profiles due to their uniform structure.36, 42, 121, 125  They are also a very 
relevant option for the delivery of combination therapies, which is highly significant for the 
treatment of multidrug resistant (MDR) cancers.192 . Their surface groups can also be 
modified with ligands that may help further enhance the solubility of the drug-dendrimer 
56 
 
 
 
conjugates,36, 116, 123 increase circulation time, 116, 241  reduce toxicity,42, 241 and also act as 
flexible linkers to targeting moieties such as TPP.242, 243  
Considering the challenges and opportunities stated previously, the goal of this 
study was to systematically investigate the effect of the number density of TPP 
conjugated to PAMAM dendrimer nanocarriers (DNCs) on the mitochondrial-targeting 
ability of such nanocarriers.  More specifically, we report here the synthesis, cellular 
uptake, cytotoxicity, and mitochondrial colocalization of TPP-modified, amine-terminated, 
generation 4 PAMAM (G4NH2) dendrimer nanocarriers on an in vitro model of the human 
alveolar epithelium (A549 cells).  We study the effect of the type of conjugation between 
TPP and dendrimer: direct (G4NH2-TPP) vs. that through a flexible poly(ethylene) glycol 
(PEG) linker (G4NH2-PEGTPP).  We also determine the impact of the number density of 
conjugated TPP (TPP or PEGTPP) on the interaction of the DNCs with A549 cells and 
their mitochondrial colocalization.  Three levels were investigated for G4NH2-TPP: no (0 
TPP); low (5 TPP); and medium (10 TPP); and three for G4NH2-PEGTPP: low (5 
PEGTPP); medium (10 PEGTPP) and high (21 PEGTPP).  
3.2 Materials and Methods 
3.2.1 Materials 
Generation four, amine-terminated, poly(amidoamine) (PAMAM) dendrimer 
(G4NH2) provided in methanol at 9.8% w/w was purchased from Dendritech Inc. (Midland, 
MI).  G4NH2 dendrimer was heated at 70°C for 30-40 minutes and dried under vacuum 
to remove methanol solvent prior to further reaction.  Methylsulfoxide (DMSO) anhydrous 
(Acros), Fluorescein isothiocyanate (FITC) (Pierce), N-Hydroxysuccinimide (NHS) 
(Acros), sodium chloride (NaCl), phosphate buffered saline (PBS, 10x), and (4-(2-
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hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES) were purchased from Thermo 
Fischer Scientific (Rockford, IL).  (3-Carboxypropyl)triphenylphosphonium bromide 
(TPP), P-toluenesolfonic acid (p-TSA) and triethylamine (TEA) were purchased from 
Sigma Aldrich (St. Louis, MO).  N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide (EDC) 
was purchased from Advanced ChemTech Inc. (Louisville, KY).  NH2-PEG1000Da-
COOH (PEG) was purchased from Jenkem Technology (Plano, TX).  All chemicals were 
used as received unless otherwise specified.  Spectra/Por cellulose ester membrane 
dialysis tubing was purchased from Spectrum Laboratories, Inc. (Rancho Dominguez, 
CA).  Deuterated DMSO (d-DMSO) and Deuterium Oxide (D2O) were purchased from 
Cambridge Isotope Laboratories (Tewksbury, MA).  Hank’s Balanced Salt Solution 
(1xHBSS) supplemented with 0.01 M HEPES was prepared according to recipe provided 
by Irvine Scientific (Santa Anna, CA).  Deionized (DI) water (resistivity of 18.2 MΩ.cm) 
was obtained from NANOpure® Diamond UV ultrapure water system (Barnstead 
International - Lake Balboa, CA).  Amicon Centrifugal Filters were purchased from EMD 
Millipore (Billerica, MA).  Dulbecco's Modified Eagle Medium 1× high glucose (DMEM), 
Penicillin–Streptomycin, Mitotracker® Deep Red FM (Molecular Probes®, Invitrogen), 
NucBlue™ Live Cell Stain (R37605) (Molecular Probes®), Trypan Blue (0.4 %), and 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from 
Life Technologies (Grand Island, NY).  Fetal Bovine Serum (FBS, non-heat inactivated) 
was purchased from Atlanta Biologicals (Flowery Branch, GA).  Trypsin-EDTA (1x) 
(Corning®), and 24-well and 96-well cell culture plates (Corning®) were purchased from 
VWR International.  
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3.2.2 Conjugation of FITC to G4NH2 Dendrimer 
G4NH2 (437 mg) was dissolved in dimethyl sulfoxide (DMSO, 44.24 mL) with the 
addition of p-TSA (118.05 mg) and FITC (20.06 mg) was stirred at room temperature for 
24 hours to form the G4NH2-FITC conjugate.  The product was dialyzed against DI water 
for 24 hours using a Spectra/Por dialysis membrane (MWCO 1000 Da), and further 
purified using an Amicon Ultra 15 centrifugal filter (MWCO 3000 Da) against a 1xPBS, 1 
M NaCl solution (pH 7.2) followed by DI water.  The product was then frozen overnight 
and lyophilized to obtain solid product - G4NH2-FITC conjugate.  The G4NH2-FITC 
conjugate was characterized by 1H-NMR (Varian Mercury 400 mHz).  Light Scattering 
(LS, Malvern Zetasizer) was used to obtain the hydrodynamic diameter (HD) and zeta 
potential (ζ) of the conjugates.  1H-NMR analysis was conducted with 9.91 mg dissolved 
in d-DMSO.  1 mg/mL of G4NH2-FITC dissolved in DI water and analyzed for LS.  The 
G4NH2-FITC conjugate was then used as reactant in the addition of TPP or PEGTPP, as 
described below, or kept as the G4NH2-FITC-0TPP (also called G4NH2-0TPP), a negative 
control group (no mitochondrial-targeting TPP).  The G4NH2-0TPP product was left in 
DMSO and frozen at -20°C until needed. 
3.2.3 Conjugation of TPP to G4NH2-FITC 
TPP was activated using EDC/NHS coupling reaction adding 1.2:1 molar ratio of 
both EDC and NHS to TPP dissolved in anhydrous DMSO and allowed to stir at room 
temperature for 3 hours to obtain activated TPP.  G4NH2-0TPP conjugate was added to 
the activated TPP dissolved in DMSO and the reaction mixture was allowed to proceed 
at room temperature for 3 days.  TPP was conjugated to G4NH2-FITC at various TPP 
densities by increasing the molar feeding ratios of activated TPP to G4NH2-FITC to form 
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G4NH2-FITC-TPP – also called G4NH2-TPP.  The reaction mixture was then dialyzed 
against distilled water using a using a Spectra/Por dialysis membrane (MWCO 8000 Da).  
The product was further purified using an Amicon Ultra 15 centrifugal filter (MWCO 3000 
Da) against a 1xPBS, 1 M NaCl solution (pH 7.2) and again against distilled water.  The 
G4NH2-TPP conjugates were characterized by 1H-NMR and LS as discussed above. 
3.2.4 Conjugation of Bifunctional PEG1000 to TPP 
The conjugation of TPP to NH2-PEG1000-COOH to form PEGTPP was achieved 
by activating TPP using EDC/NHS coupling reaction with 1:1 molar ratio of TPP:EDC and 
TPP:NHS in anhydrous DMSO and stirred at room temperature for 12 hours.  NH2-
PEG1000-COOH (70 mg) was dissolved in anhydrous DMSO with TEA (34.2 µL) at a 
molar ratio of 2:1 of TEA:PEG and added to the reaction mixture of activated TPP and 
allowed to stir at room temperature for 24 hours.  The DMSO was removed using vacuum 
pump for 24 hours. 
3.2.5 Conjugation of PEGTPP to G4NH2-FITC 
Once the PEGTPP product was synthesized, PEGTPP was dissolved in 
anhydrous DMSO and activated using and EDC/NHS coupling reaction with a 1:1 molar 
ratio of PEGTPP:EDC and PEGTPP:NHS.  The mixture was let to stir at room 
temperature for 10 minutes.  The activated PEGTPP was added to the G4NH2-FITC 
conjugate at increasing molar feeding ratios to form G4NH2-FITC-PEGTPP (also called 
G4NH2-PEGTPP) at several PEGTPP densities, and then stirred at room temperature for 
5 days.  The reaction mixture was then dialyzed against 1xPBS for 24 h and DI water for 
an additional 48 h using a Spectra/Por dialysis membrane (MWCO 8000 Da).  The 
G4NH2-PEGTPP products were frozen overnight and lyophilized to form solid products.  
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The G4NH2-PEGTPP conjugates were characterized by 1H-NMR and LS as discussed 
above. 
3.2.6 Cell Culture 
A459 lung adenocarcinoma cells were grown in DMEM supplemented with 10% 
fetal bovine serum (FBS) and 1% Penicillin Streptomycin (100 U/mL Penicillin and 100 
µg/mL Streptomycin) antibiotics (AB) and cultured at 37°C with 5% CO2. 
3.2.7 Cytotoxicity of Dendrimer Conjugates 
A549 cells were seeded at a density of 5,000 cells/well in a 96-well plate in DMEM 
supplemented with 10% FBS and 1% AB and incubated for 24 hours under 5% CO2 at 
37°C.  Dendrimer conjugates were added at concentrations varying from 0-20 µM in fresh 
culture medium (DMEM) and incubated for an additional 24 hours under 5% CO2 at 37°C.  
DMEM with no dendrimer conjugates were placed in wells and used as the controls.  Cell 
viability was analyzed using MTT Cell Proliferation Assay (Molecular Probes). Briefly, 
medium from each well was removed.  Subsequently 110 µL of 1 mM MTT solution was 
added to each well and incubated for 4 hours at 5% CO2 at 37°C.  85 µL was removed 
from each well and replaced with 75 µL of DMSO and let to incubate for 1 additional hour.  
The absorbance was measured at 540 nm using a microplate reader (Spectra MAX 250) 
and analyzed by SOFTmax PRO software. Cell viability was calculated as (absorbance 
of treated cells/absorbance of control cells) x 100%. 
3.2.8 Cellular Internalization of the Dendrimer Conjugates Analyzed by 
Fluorescence Activated Cell Sorting (FACS) 
A549 cells were seeded at 300,000 cells per well in a 24-well plate in DMEM 
medium supplemented with 10% FBS and 1% AB and cultured at 37°C with 5% CO2. The 
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following day, the cells were pre-incubated in 1xHBSS (Hank’s Balanced Salt Solution) 
for 30 minutes prior to incubation of various dendrimer conjugates at 1 µM in 1xHBSS 
adding 500 µL per well at various time points ranging from 0.25 hours to 5 hours.  Cells 
were then washed with 1xHBSS (pH 7.2) and 0.2 mL of 0.1% w/v of Trypan Blue was 
added to each well to quench any fluorescence associated the conjugates that are 
retained on the surface of cells.  The cells were then again washed with 1xHBSS and 
removed from each well.  The cells were then centrifuged at room temperature at 1500 
rpm for 5 min to form a pellet.  The pellet was resuspended in 1XHBSS buffer to be 
analyzed via FACS using a HWCRC 615- BD LSR II Analyzer. The data was analyzed by 
FlowJo software.  The median fluorescence intensity (MFI) of FITC was used as to 
analyze the rate of cellular internalization of dendrimer conjugates into the cells as a 
function of the dendrimer chemistry and time after incubation. 
3.2.9 Colocalization of Dendrimer Conjugates by Confocal Microscopy 
A549 cells were seeded at 300,000 cells per well in a 24-well plate containing a 
circular cover glass in each well 24 hours prior to treatment.  500µL of a 2µM dendrimer 
conjugate solution in 1xHBSS was added to each well and incubated for 5 hours at 5% 
CO2 and 37°C.  The cells were then stained with 100 nM of Mitotracker Deep Red FM 
(Life Technologies) for 30 minutes followed by Hoechst 3342-Nuc Blue stain for 15 
minutes.  The cells were washed twice with 1xHBSS between each staining.  The cells 
were then fixed with 4% p-Formaldehyde for 15 minutes.  The colocalization of the 
dendrimer conjugates to the mitochondria was analyzed using a Zeiss LSM 780 confocal 
microscope with a 40x oil objective lens.  The Pearson’s Correlation Coefficient (PCC) 
was determined by analyzing each image using Volocity Software to quantify the degree 
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of colocalization between the dendrimer conjugates (FITC) and the mitochondria 
(Mitotracker Deep Red FM).  
3.2.10 Statistical Analysis 
All data is presented as a mean ± standard deviation.  The mean was calculated 
from a minimum of three independent trials for each measurement (n ≥ 3).  One-way 
analysis of variance (ANOVA) followed by Tukey’s Multiple Comparison Test or an 
unpaired t-test was performed using GraphPad Prism 5 software.  Means were 
considered statistically significant if p < 0.05.  
3.3  Results 
3.3.1 TPP and PEGTPP Conjugation  
FITC was conjugated to the primary amines of G4NH2 to prepare fluorescently-
labeled dendrimers (G4NH2-FITC), as shown in Scheme 3.1A. 
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Scheme 3.1. Synthesis of A) FTIC-labeled, generation 4, amine-terminated 
poly(amidoamine) dendrimer (G4NH2-FITC); B) TPP-conjugated, FITC-labeled 
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The conjugation of FITC was confirmed by 1H NMR, as shown in Figure A1 in 
Appendix A.  The results indicate 2 FITC molecules conjugated per dendrimer on average 
as calculated by peak area represented by protons on FITC in peak at 6.4 ppm (labeled 
FITC – Figure A1).  Conjugation of FITC is done in order to follow the rate of cellular 
internalization and co-localization of the nanocarriers.  The size (HD) and ζ of the FITC-
conjugated G4NH2 (also called G4NH2-0TPP) is shown in Table 3.1. 
Table 3.1. The hydrodynamic diameter (HD) and surface charge (zeta 
potential, ζ) of the dendrimer conjugates measured by light scattering (LS).  
Measurements were performed in water.  Data expressed as mean ± 
standard deviation (n ≥ 3).  All carriers have an average of 2 FITC per G4NH2. 
Compound 
Light Scattering 
HD ± s.d# (nm) ζ ± s.d# (mV) 
G4NH2-0TPP 6 ± 2 30 ± 7 
G4NH2-5TPP 7 ± 3 34 ± 7 
G4NH2-10TPP 6 ± 2 43 ± 8 
G4NH2-5PEGTPP 8 ± 2 53 ± 8 
G4NH2-10PEGTPP 9 ± 3 18 ± 6 
G4NH2-21PEGTPP 12 ± 4 14 ± 5 
 
TPP and PEGTPP were subsequently conjugated to G4NH2-FITC, as shown in 
Scheme 1B and C, respectively.  Two TPP densities were targeted.  An average of 5 and 
10 TPP molecules were attached to each G4NH2-FITC dendrimer, as confirmed by 1H 
NMR in deuterium Oxide (D2O) solvent measured at 400 MHz on Aligent Mercury 
Spectrometer - shown in the 1H NMR spectra Figure A1, Appendix A. The peak areas 
representing the protons found on the phenyl rings on TPP (two peaks found between 
7.6-7.8 ppm, peak f – Figure A1) and peak found on alkyl chain of TPP (peak at 1.8-1.9 
ppm, peak e – Figure A1) were used to calculate the average numbers of TPP per 
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dendrimer (Figure A1).  These conjugates were termed as follows: G4NH2-5TPP, and 
G4NH2-10TPP.  The HD and ζ of the TPP conjugates are also shown in Table 3.1. 
The G4NH2-TPP conjugates all had similar sizes, between 6-7 nm in diameter.  
The ζ for all the G4NH2-TPP conjugates was positive.  A slight increase in ζ from G4NH2-
0TPP to G4NH2-5TPP to G4NH2-10TPP was observed, but it was not statistically different 
between each of the conjugates (Table 3.1).  Therefore, each of the G4NH2-TPP 
conjugates was similar in size as well as containing similar positively-charged surfaces. 
To evaluate the effect of PEG on the surface properties and mitochondrial targeting 
of G4NH2 dendrimers, TPP was conjugated to PEG to form PEGTPP, which in turn was 
conjugated to G4NH2-FITC dendrimers to form G4NH2-FITC-PEGTPP – also called 
simply G4NH2-PEGTPP.  The successful conjugation PEGTPP to G4NH2-FITC was also 
confirmed by 1H NMR, as shown in Figure A1 in Appendix A. The peak areas representing 
the phenyl rings on TPP (7.6-7.8 ppm, peak f – Figure A1), the peak area representing 
PEG chain (3.6 ppm, peak g – Figure A1) and peak area of CH2 group near the amide 
bond between the dendrimer and PEG (4.0 ppm, peak h – Figure A1) were used to 
estimate the average numbers of PEGTPP molecules added per dendrimer.  An increase 
in PEGTPP to G4NH2-FITC-0TPP feeding ratio resulted in an increase in density of 
PEGTPP.  An average of 5, 10, and 21 PEGTPP molecules were attached to each G4NH2 
dendrimer, as confirmed by 1H NMR spectra as seen in Figure A1 in Appendix A. 
The HD and ζ of these conjugates were also determined and shown in Table 3.1.  
The HD of the conjugates increased slightly from 8 nm to 12 nm, as the density of 
PEGTPP conjugated to G4NH2 increases from 5 PEGTPP to 21 PEGTPP.  The ζ for 
G4NH2-5PEGTPP increased to +53 ± 8 mV, being the highest ζ of all conjugates.  
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However, as the PEGTPP density increases from 10 (G4NH2-10PEGTPP) to 21 (G4NH2-
21PEGTPP), the ζ of the conjugates decreased to +18 ± 6 mV and +14 ± 5 mV, 
respectively, remaining overall positively charged (Table 3.1). 
3.3.2 Cytotoxicity of the Dendrimer Conjugates 
The cytotoxicity of the various dendrimer conjugates was determined using the 
MTT assay.  TPP- and PEGTPP-conjugates were incubated with A549 cells for 24h at 
increasing concentrations of the respective conjugates, and their cellular viability 
assessed.  The results are summarized in Figure 3.1.  
 
Figure 3.1. Cell viability of A) G4NH2-TPP conjugates and B) G4NH2-PEGTPP 
conjugates measured by MTT assay at 24h incubation and increasing nanocarrier 
concentration. *, **, *** represents the statistical analysis between the control group 
indicated at 0 µM representing 100% viability. ●, ●●, and ●●● represents the 
statistical analysis between G4NH2-0TPP group and other indicated dendrimer 
conjugates (*/● p < 0.05, **/●● p < 0.01 ***/●●● p < 0.001). 
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The results demonstrate that the density of TPP as well as that of PEGTPP does have 
an effect on the toxicity of the dendrimer conjugate.  As the TPP density increases to 10 
TPP molecules per dendrimer, a greater cellular toxicity is observed when compared to 
G4NH2- 0TPP, at all concentrations investigated.  Furthermore, a statistical difference 
between that and control is seen at a much lower concentration (2.5 µM), which is not 
observed for the other G4NH2-TPP conjugates.  On the other hand, G4NH2-5TPP did not 
show a significant increase in cytotoxicity when compared to G4NH2-0TPP.  These two 
groups had similar differences to control (100% cell viability) with toxicity (statistical 
difference from control) only observed at 10 µM or greater concentration.  The G4NH2-
5TPP conjugate demonstrated a decreased toxicity compared to G4NH2-0TPP at 2.5 and 
5 µM concentrations and no statistical difference at all the other concentrations tested.  
Therefore, a low enough TPP density (5 or below) has no significant effect on the toxicity 
of the dendrimer. 
The attachment of PEG as a linker between the TPP targeting moiety and the 
G4NH2 dendrimer also had an effect on toxicity.  The G4NH2-5PEGTPP is significantly 
more cytotoxic than G4NH2-0TPP.  Of all the groups, G4NH2-5PEGTPP was the most 
toxic early on, showing a statistical difference from 100% cell viability as early as 1.25 µM 
and being statistically different from G4NH2-0TPP at all concentrations but 20 µM, where 
there was no statistical difference in toxicity.  However, the dendrimer conjugates 
containing a higher density of PEGTPP showed a decrease in cytotoxicity compared to 
G4NH2-0TPP.  G4NH2-10PEGTPP only showed a statistical difference from 100% cell 
viability at 20 µM.  The G4NH2-10PEGTPP conjugate only demonstrated a significant 
difference in cytotoxicity at 2.5, 10, and 20 µM, being less cytotoxic than G4NH2-0TPP.  
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G4NH2-21PEGTPP did not show any significant difference in cytotoxicity when compared 
to G4NH2-0TPP when both are compared to 100 % cell viability, with both groups showing 
a statistical difference at 10 µM.  The only statistical difference between G4NH2-0TPP 
and G4NH2-21PEGTPP was seen at 20 µM. Therefore, the addition of PEGTPP at a 
density greater than 5 PEGTPP did (positively) affect the toxicity of the dendrimer 
conjugates; it decreased their toxicity, showing statistical differences compared to 
G4NH2-0TPP at higher concentrations tested (those concentrations where G4NH2-0TPP 
showed a statistical difference from 100% viability). 
3.3.3 Cellular Internalization of Dendrimer Conjugates Analyzed by FACS 
The extent and rate of internalization of the dendrimer conjugates was determined 
by FACS.  The effect of TPP density as well as PEGTPP density was analyzed.  The 
median fluorescence intensity (MFI) as a function of contact time between the various 
conjugates and A549 cells is summarized in Figures 3.2A and B. 
As the density of TPP in G4NH2-TPP increases, the rate and extent of 
internalization of the conjugate is observed to increase dramatically (Figure 2A).  G4NH2-
5TPP showed a 3.5 ± 0.3-fold increase in internalization over the various time points when 
compared to G4NH2-0TPP, while the MFI of G4NH2-10TPP increased 10.0 ± 2.0-fold 
(except at 0.25 hour, which showed a ~20-fold increase) in internalization as compared 
to G4NH2-0TPP at the various time intervals measured. G4NH2-10TPP also showed a 
3.4 ± 0.9-fold increase in internalization compared to G4NH2-5TPP at various time points.  
Similar trends are seen when the rates of internalization are compared.  The 
internalization rates for G4NH2-0TPP, G4NH2-5TPP, and G4NH2-10TPP are 214.01 
a.u./hr, 681.4 a.u./hr, and 2050.5 a.u./hr, respectively.  A clear increase in rate with the 
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increase in TPP density of the dendrimer is seen: ~ 3-fold increase for G4NH2-5TPP when 
compared to G4NH2-0TPP and a ~ 10-fold increase for G4NH2-10TPP compared to 
G4NH2-0TPP.  Also, there was a ~ 3-fold increase in rate when comparing G4NH2-10TPP 
group with G4NH2-5TPP group. 
Therefore, the conjugation of TPP to dendrimer is seen to lead to an increase in the rate 
and extent of internalization of the dendrimer. 
The effect of PEGTPP on internalization of the dendrimers on A549 cells was also 
analyzed.  The results are compared against those for G4NH2-0PEGTPP (Figure 2B).  As 
seen in Figure 2B, at the final time point (5 h), no statistical difference in the extent of 
Figure 3.2.  Cellular uptake of A) G4NH2-TPP conjugates and B) G4NH2-PEGTPP 
conjugates analyzed by FACS.  The median fluorescence intensity (MFI) provided by 
FITC labeling of the various conjugates was compared to bare FITC-labeled 
dendrimer (0 TPP) at various time points (* p < 0.05, ** p < 0.01 *** p < 0.001). 
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internalization is seen between G4NH2-5PEGTPP and G4NH2-0PEGTPP.  However, the 
MFI is seen to decrease when compared to G4NH2-0PEGTPP as the density of PEGTPP 
increased to 10PEGTPP, and further decrease at 21PEGTPP (Figure 2B).  G4NH2-
10PEGTPP showed a 3.0 ± 1.3-fold decrease in MFI and G4NH2-21PEGTPP showed a 
5.0 ± 2.0-fold decrease in MFI at various time points when compared to G4NH2-
0PEGTPP.  By 5 hours, the internalization decreased to 1.7-fold for G4NH2-10PEGTPP 
and 3.0-fold for G4NH2-21PEGTPP.  There is also a 1.8 ± 0.2-fold decrease in 
internalization at various time points when comparing G4NH2-21PEGTPP to G4NH2-
10PEGTPP.  The rates of internalization for G4NH2-5PEGTPP, G4NH2-10PEGTPP, and 
G4NH2-21PEGTPP are as follows: 196.3 a.u./hr, 125.3 a.u./hr, and 69.5 a.u./hr, 
respectively. There is no significant change in the rate of internalization between G4NH2-
5PEGTPP and G4NH2-0TPP, while a decrease in rate of ~2 between G4NH2-10PEGTPP 
and G4NH2-0TPP and decrease of ~3 between G4NH2-21PEGTPP and G4NH2-0TPP 
was observed.  A ~2-fold decrease in rate of uptake is observed when comparing G4NH2-
21PEGTPP and G4NH2-10PEGTPP.   
The effect of TPP attached to the end of PEG on the internalization of the 
conjugates was also evaluated by comparing the internalization of G4NH2-10PEGTPP to 
that of G4NH2-10PEG (no TPP), as shown in Figure 3.3.  
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After 1 h, a significant increase in the extent of internalization is seen for the conjugate 
containing TPP.  At 1 hour, the internalization of G4NH2-10PEGTPP is 2.8-fold greater 
than that for G4NH2-10PEG.  From 2 h to 5 h, the internalization G4NH2-10PEGTPP is 
4.0 ± 0.3-fold that of G4NH2-10PEG.  When comparing the rates of internalization, 
G4NH2-10PEGTPP (125.3 a.u./hr) is ~ 4-fold greater than that for the G4NH2-10PEG 
conjugate (29.5 a.u./hr).  Thus, the presence of TPP on PEG does affect the 
internalization of the dendrimer by increasing its rate and extent of cellular uptake.  
3.3.4 Colocalization of Dendrimer Conjugates 
The mitochondrial targeting ability of the dendrimer conjugates was evaluated by 
confocal microscopy.  The dendrimer conjugates were labeled with FITC in order to 
quantify their colocalization with the mitochondria, which were stained with Mitotracker 
Deep Red FM.  Figure 3.4 shows the results of the incubation of the FITC-labeled 
dendrimer conjugates with mitochondria in A549 cells.  
 
Figure 3.3.  A comparison of the cellular uptake of G4NH2-10PEG and G4NH2-
10PEGTPP conjugates analyzed by flow cytometry.  The MFI provided by FITC 
labeling of the various conjugates was compared between the two groups using two-
tailed t test (* p < 0.05, ** p < 0.01 *** p < 0.001).  
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Figure 3.4. Colocalization between dendrimer (green) and mitochondria (red) to assess 
the targeting ability of the various G4NH2-TPP and G4NH2-PEGTPP conjugates. The 
blue represents the nucleus (Hoeschst 3342-Nuc Blue stain), the red represents 
mitochondria (Mitotracker Deep Red FM) and green represents the dendrimer (FITC).  
The yellow color represents the overlap between the dendrimer and mitochondria 
signals. The dendrimer conjugates are seen in the following order: A) G4NH2-0TPP, B) 
G4NH2-5TPP, C) G4NH2-10TPP, D) G4NH2-5PEGTPP, E) G4NH2-10PEGTPP, and F) 
G4NH2-21PEGTPP. 
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The last (fourth) panel indicates the merged areas of co-localization between the 
green signal from the FITC-labeled dendrimer conjugates (first panel) with the red signal 
from stained mitochondria (second panel).  The co-localization produced a yellow color.  
The third panel shows the nuclei in blue.  The degree of co-localization was quantified 
with the help of the Pearson’s correlation coefficient (PCC) for the various conjugates.  
The results are summarized in Figure 3.5.  
 
All dendrimer conjugates demonstrated an increased targeting toward the 
mitochondria compared to G4NH2 bearing no TPP targeting moiety.  The dendrimer 
conjugate that showed the highest targeting ability was G4NH2-10TPP – statistically 
significant enhancement in targeting as compared with all other conjugates.  All other 
dendrimer conjugates, excluding G4NH2-10TPP, had the same ability to target 
mitochondria, which was significantly greater than the control.  Therefore, the presence 
Figure 3.5. Pearson’s Correlation Coefficient (PCC) of various dendrimer conjugates 
comparing the overlap of FITC (dendrimer) with Mitotracker Deep Red FM 
(mitochondria) based on confocal microscopy.  *** compares each dendrimer 
conjugate with G4NH2-0TPP dendrimer. ●●● represents the comparison between 
indicated groups.  Data represents a mean ± standard deviation (***/●●● p < 0.001, 
n.s.d. = not statistically different). 
 
74 
 
 
 
of PEG as a flexible linker between the dendrimer and TPP did not affect the mitochondrial 
targeting ability of the conjugates. 
3.4 Discussion  
Cellular organelle drug targeting has many potential advantages including a 
decrease in the side effects as well as enhancement of the efficacy of the chosen 
therapeutic molecules.232  Mitochondrial targeting continues to gain attention in the 
scientific community since the discovery that many diseases of great medical relevance 
are associated with mitochondrial dysfunction.50, 53, 84, 227-230  Mitochondrial dysfunction 
can occur due to mutations in mitochondrial DNA (mtDNA) or alterations in mitochondrial 
signal transduction pathways.231  Due to a lack of therapeutic options for many 
mitochondrial diseases, there is a great need for the development of alternative 
therapeutic strategies that target mitochondria.84, 231 
TPP has been explored as a mitochondrial targeting agent due to its delocalized 
cationic and lipophilic nature.  TPP is attracted to and tends to cross cellular and 
mitochondrial membranes to preferentially accumulate in the mitochondria.50, 84, 172, 233  
TPP has been utilized to target a range of therapeutics, including antioxidants,176, 226, 229 
anticancer agents,54, 87, 90, 176, 235 peptides,92 nucleic acids,237 and photsensitizers238, 239 
towards the mitochondria.  These have included TPP conjugated directly to therapeutic 
of choice 54, 92, 226 as well as TPP conjugated to a nanocarrier87, 90, 176, 235, 237, 239 for targeted 
therapeutic delivery.  Nanocarriers are of great interest in the delivery of a variety of drugs 
as they can be used to effectively alter the behavior of the drug in vivo,35 improve efficacy 
of the drug,35, 36 minimize side effects,35, 36 target specific tissues,35 control drug  release, 
35 and show great promise in the treatment of a variety of diseases.36 
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In this work we seek to further recent work that has demonstrated that the direct 
attachment of TPP to G4NH2 leads to an enhancement in targeting of the mitochondria231 
by systematically investigating the effect of the number density of TPP conjugated to 
G4NH2 on the mitochondrial targeting ability of the DNCs.  We propose two conjugation 
strategies: (i) the direct conjugation of TPP to dendrimer, and (ii) the conjugation of TPP 
to G4NH2 through a PEG linker.  PEG is relevant in many ways.  PEG may act as a 
flexible linker thus potentially providing for a greater opportunity for the conjugated TPP 
to interact with the mitochondrial membrane – perhaps at lower number density.  
PEGylation also helps enhance aqueous solubility of the nanocarrier,116, 122 increase 
biocompatibility,116, 241 mediate the interaction of the dendrimer drug carrier with the 
physiological environment,116, 122 and enhance its pharmacokinetic profile.116, 241 
Three levels of direct TPP conjugation were investigated: no TPP (G4NH2-0TPP); 
5 TPP (G4NH2-5TPP) and 10 TPP (G4NH2-TPP).  We observe from Table 3.1 that the 
direct conjugation of TPP to the dendrimer did not have a significant effect on the size 
(HD) or surface charge (ζ) of the nanocarriers.  The HD remained around 6-7 nm for all 
G4NH2-TPP.  The ζ seems, on average, to increase as the density of TPP increases with 
a value of +43 mV for G4NH2-10TPP and +34 mV for G4NH2-5TPP, while in the absence 
of TPP, the surface charge was +30 mV.  While under physiological conditions (where 
pH = 7.4) the primary (surface) amine groups of NH2 are expected to be fully protonated 
to NH3+,244-246 at the conditions where ζ was measured (water), the pH increases during 
protonation, and an equilibrium is reached before full protonation.  The conjugation of 
TPP as a delocalized cation should thus result in an increase in the overall surface charge 
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of the system, as it will tend to substitute amine groups that would potentially otherwise 
not be protonated. 
There is a direct correlation between the surface charge of the nanocarriers and 
their rate and extent of cellular internalization within A549 cells (Figure 3.2).  The 
internalization of G4NH2-5TPP is statistically significantly higher than that for G4NH2-
0TPP, and so is that for G4NH2-10TPP, which was also higher than that for G4NH2-5TPP.  
A similar trend was observed in terms of the rate of internalization.  This increase in rate 
and extent of internalization with increase in TPP density can be attributed to the cationic 
and lipophilic nature of the TPP that allows it to interact with the cellular membrane given 
its negative potential and hydrophobic nature.50, 84, 172, 233  A similar correlation was 
observed in terms of co-localization with the mitochondria (Figures 3.4 and 3.5).  While in 
the absence of TPP (G4NH2-0TPP) the PCC was only 0.15 ± 0.09, PCC for G4NH2-5TPP 
was 0.50 ± 0.06, and that for G4NH2-10TPP 0.66 ± 0.12, being both statistically 
significantly higher than control - and at 10 TPP higher than at 5 TPP.  However, as the 
density of TPP increases so does the toxicity of the conjugate. A comparison of the half 
maximal inhibitory concentration (IC50), the concentration of conjugate required to inhibit 
biological function (in vitro potency – A549 % cell viability) clearly demonstrates this.  
G4NH2-10TPP has an IC50 of 2.95 µM, while G4NH2-0TPP’s IC50 is found at significantly 
higher concentrations (greater than 20 µM) (54 ± 9 % at 20 µM) ~ 7 fold greater (Figure 
3.1).  At the same time, it is observed that the addition of 5 TPP does not affect the toxicity 
profile of the conjugate – no statistical difference compared to G4NH2-0TPP. 
In conclusion, the direct conjugation of TPP is seen to promote the rate and extent 
of cellular internalization as well as the mitochondrial targeting.  However, the maximum 
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density of TPP is limited by toxicity effects.  For the series of conjugates investigated in 
this work, it seems that 5 TPP represents the optimum number of TPP, where a significant 
enhancement in targeting is observed, while the toxicity profile of the conjugate is not 
altered relative to the bare dendrimer. 
In order to address potential limitations of the direct TPP conjugation strategy 
discussed earlier, the conjugation of TPP through a PEG linker to G4NH2 is also 
proposed.  Three levels of PEGTPP density, plus the control were investigated: (i) no 
PEGTPP (control, G4NH2-0TPP); (ii) 5PEGTPP (G4NH2-5PEGTPP); (iii) 10PEGTPP 
(G4NH2-10PEGTPP); and (iv) 21PEGTPP (G4NH2-21PEGTPP). 
The addition of PEGTPP is seen to lead to a significant change in the HD and ζ of 
the dendrimers – Table 3.1.  The HD of the dendrimers is seen to increase with an 
increase in PEGTPP density with a dendrimer HD at 6 ± 2 nm for G4NH2-0TPP and 
increasing to 8 ± 2 nm, 9 ± 3 nm, and 12 ± 4 nm for G4NH2-5PEGTPP, G4NH2-
10PEGTPP, and G4NH2-21PEGTPP, respectively.  The addition of PEGTPP, as 
expected,122, 247 leads to an increase in the overall HD as the PEG forms an outer polymer 
layer.  This PEG layer may has been shown to either interact with the protonated amines, 
extend outward, or a mix of both depending on the density and size of PEG.122, 247 
The surface charge for G4NH2-10PEGTPP and G4NH2-21PEGTPP decreased 
compared to the control - G4NH2-0TPP.  One could expect that the conjugation of PEG 
alone would lead to a decrease in the overall system charge, but since the delocalized 
cation TPP is conjugated to PEG, this effect should be somewhat mute.  Nevertheless, 
the ether oxygen of PEG may also interact with the amine groups of G4NH2, further 
reducing the system charge,122, 241 and this is the mechanism we expect to be operating 
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here.  However, surprisingly, G4NH2-5PEGTPP has a ζ that is larger than the ζ seen for 
all the dendrimer conjugates investigated in this work.  The reasons for such a large ζ 
have not been fully elucidated yet, but one could hypothesize that at higher PEG densities 
of 10PEGTPP and 21PEGTPP (but not too high), the protonated amines can interact with 
a large number of ether oxygens247 without requiring the positively charged TPP ions 
conjugated at the end of PEG to get to close to the positively charged surface of the 
G4NH2 dendrimer.  There is also a greater chance of the ether groups of PEG to interact 
and bury TPP counterions.  At lower PEGTPP densities, the interaction between 
protonated amines from the dendrimer and ether oxygen will more likely lead to the close 
approximation of the charged TPP to NH3+ groups on the dendrimer surface, which is 
unfavorable.  In that case, the presence of TPP would reduce the neutralization of the 
amine groups of dendrimers by PEG ethers, thus increasing the overall ζ.  The synthesis 
and characterization of these conjugates were repeated several times and by different 
group members to confirm this behavior.  The toxicity and internalization of these carriers 
also follow a trend based on ζ, further supporting the results discussed here.  Therefore, 
the PEGTPP density plays a critical role in terms of characteristics of G4NH2. 
The use of the PEG as a linker to TPP is seen to produce the desirable 
characteristic of reduced cytotoxicity compared to the conjugates formed with the direct 
TPP conjugation, except for G4NH2-5PEGTPP (Figure 3.1).  G4NH2-10PEGTPP and 
G4NH2-21PEGTPP do not show any toxicity up to 5 µM concentration.  At high 
concentrations, they were also significantly less toxic than the non-conjugated G4NH2-
0TPP control (bare dendrimer).  The toxicity profile of G4NH2-5PEGTPP seems to 
correlate with its high surface charge, showing some toxicity at low concentrations, and 
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being significantly more toxic than the non-conjugated control (G4NH2-0TPP) at all 
concentrations studied.  While a reduction in toxicity is achieved for the TPP-conjugated 
dendrimers by using a PEG linker, the presence of PEG negatively affects the dendrimer 
internalization (Figure 3.2).  As the density of PEGTPP increases, the rate and extent of 
internalization in A549 cells decreases, except for G4NH2-5PEGTPP, which remains 
relatively unchanged compared to the non-conjugated control (G4NH2-0TPP).  It is 
interesting to note that when compared to the control of PEGylated dendrimer with no 
TPP (Figure 3 – G4NH2-10PEG vs. G4NH2-10PEGTPP), it is observed that the presence 
of TPP significantly enhances the rate and extent of internalization indicating the 
relevance of TPP as a potentially general strategy for the enhancement of cellular 
internalization of PEGylated dendrimers. 
G4NH2-FITC-5PEGTPP had similar characteristics to that of bare dendrimer 
(G4NH2-FITC-0TPP) in terms of internalization and cytotoxicity.  This can be attributed to 
a balance between the TPP increasing internalization while the PEG decreasing 
internalization.  Therefore, both groups contain similar properties.  However, the main 
difference between these groups is the localization of the dendrimer into the mitochondria 
which is seen in the G4NH2-FITC-5PEGTPP group and not in the G4NH2-FITC-0TPP 
group.  Therefore, the G4NH2-FITC-5PEGTPP group acts very similarly in vitro as bare 
dendrimer while localizing in the mitochondria.  This can be a useful strategy if similar 
dendrimer properties (surface charge, rate of internalization, biodistribution, etc.) are 
required for a particular application.  However, if the application requires a higher solubility 
of therapeutic, increased circulation time, reduced toxicity (as seen with PEGylated 
dendrimers) then a higher density of PEGTPP can be used, which would alter these 
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various parameters while maintaining the mitochondrial targeting ability of the 
nanocarrier.   
While the presence of PEG as a linker to TPP in G4NH2-PEGTPP decreases the 
rate and extent of cellular internalization at higher densities (10 PEGTPP and above), co-
localization results (Figure 3.4 and 3.5) demonstrate that they are still actively targeting 
mitochondria with PCC similar to G4NH2-5TPP and statistically significantly higher than 
G4NH2-0TPP.  The PCC of G4NH2-PEGTPP is not affected by the density of PEGTPP 
and is only smaller to that of G4NH2-10TPP, which had pronounced toxicity.  The ability 
of the G4NH2-PEGTPP to target mitochondria equally well, irrespectively of the density 
of TPP, may be hypothesized to be due to the fact that TPP is further expanded from the 
surface of the nanocarrier when conjugated to PEG and also due to the flexibility of the 
linker that may allow as many TPP as possible to better interact with its target – the 
mitochondria. 
The use of TPP conjugated directly or through a PEG linker has shown to 
effectively target dendrimer nanocarriers toward the mitochondria, which present a useful 
strategy for delivery of therapeutics to the mitochondria.  The direct conjugation of TPP 
to the dendrimer only requires a small density of TPP (~ 5 TPP) in order to be effective in 
targeting the dendrimer to the mitochondria as well as increasing internalization without 
producing toxic effects.  The use of PEG can also modulate various properties of the 
dendrimer (solubility, biocompatibility, interaction of dendrimer with physiological 
environment, pharmacokinetic profile) and is thus a promising linker between the 
dendrimer nanocarrier and TPP.  In this case we show that the presence of PEG helps 
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decrease toxicity of the nanocarriers while still maintaining their mitochondrial targeting 
ability. 
3.5 Conclusions 
The in vitro characteristics of mitochondrial targeting G4NH2 conjugates were 
assessed in this work using a human alveolar carcinoma cell model (A549 cells).  Two 
strategies of conjugation of the mitochondrial targeting moiety TPP were investigated: 
direct TPP conjugation (G4NH2-TPP) or conjugation of TPP to G4NH2 through a flexible 
PEG linker (G4NH2-PEGTPP).  Both strategies result in significant enhancement in 
mitochondrial targeting relative to the non-conjugated control.  While direct TPP 
conjugation shows a direct correlation between targeting and TPP number density, the 
conjugation of TPP through a PEG linker results in high targeting for all TPP densities 
with targeting not being affected by the degree of PEGylation.  Therefore, both direct and 
indirect conjugation, separately or in combination, are potential strategies for the delivery 
of therapeutics to address mitochondrial dysfunctions.  The conjugation of PEGTPP may 
be used to enhance the cellular internalization of PEGylated dendrimers and target 
mitochondria, so as to reach high local concentration of drug-conjugated therapeutics 
near the mitochondria such as, for example, ROS scavengers.226  This is relevant as often 
times PEGylation is a required motif in the design of the nanocarriers so as to improve 
their function – e.g. aqueous solubility of the conjugate116, 122 or to modulate the 
interactions with the physiological environment.116, 122 Direct TPP conjugation may be 
used in those cases where small molecules need to reach not only high local 
concentration near the mitochondria, but also be internalized.  For example, the 
conjugation of doxorubicin (DOX) to TPP (DOX-TPP) has been recently demonstrated as 
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a potential strategy to fight multi-drug resistant cancer, with DOX-TPP enhancing levels 
of apoptosis in both wild-type and DOX-resistant human breast carcinoma cell line as 
compared to DOX alone.54  The direct conjugation of many DOX-TPP (or other small 
molecules) to dendrimers may thus result in enhanced therapeutic efficacy. As more 
evidence accumulates the involvement of mitochondrial signaling process, bioenergetics, 
and biosynthesis in tumorigenesis,248 the major challenges  still remain to design 
therapeutic strategies that increase the presence of anticancer drugs that can directly 
target the mitochondria,  which the TPP-targeted dendrimer has great potential in 
addressing. 
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CHAPTER 4 - TPP-DENDRIMER NANOCARRIERS FOR SIRNA DELIVERY TO THE 
PULMONARY EPITHELIUM AND THEIR DRY POWDER AND METERED-DOSE 
INHALER FORMULATIONS 
 
4.1 Introduction 
Synthetic small interfering RNA (siRNA) is a promising therapeutic for the 
treatment of a variety of lung diseases including asthma,249 chronic obstructive pulmonary 
disease (COPD),250 cystic fibrosis,251 viral infections,252-254 pulmonary tuberculosis,255 
lung cancer,190, 256 and also for the treatment of the so called “non-druggable” diseases.257 
Despite recent developments and the many promising applications of siRNA therapeutics, 
there are still many challenges that hinder the efficient and safe use of siRNA to treat 
pulmonary disorders including the formulation of siRNA and their vectors for efficient local 
lung delivery, 96, 97 and the extra and intracellular barriers that exist for the transport of 
bioactive siRNA to the cytoplasm of relevant cells in the lungs.98, 99 
Non-viral vectors such as cationic polymers represent one of the promising 
approaches for the efficient delivery of siRNA.59 Amine-terminated, poly(amidoamine) 
(PAMAM) dendrimers have been widely investigated as gene delivery vectors including 
carriers of siRNA, 64 and their use in oral inhalation to the lungs.96, 127, 258  PAMAM 
dendrimers are hyperbranched polymers with uniform structure and size and with 
multifunctional modifiable surface groups.34 Amine-terminated PAMAM dendrimers carry 
a positive surface charge due their protonatable surface primary amines and can thus 
serve to induce the formation of complexes with anionic siRNA via electrostatic 
interactions.64, 259  Such nanoscale structures, termed dendriplexes, have been shown to 
promote cellular internalization of siRNA. However, gene knockdown efficiency is 
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relatively low, and cytotoxicity profiles in models of the pulmonary epithelium are not very 
favorable.96, 99  
In order to increase the transfection efficiency and biocompatibility of PAMAM 
dendrimers, a variety of modifications to the dendrimer surface have been explored.260 Of 
these modifications, the use of a triphenylphosphonim (TPP) ion has been recently 
reported via direct conjugation to PAMAM dendrimers.33, 237, 261 TPP is a delocalized 
lipophilic cation and well-known mitochondrial-targeting agent.233 The conjugation of TPP 
to PAMAM dendrimers enhances mitochondrial targeting, as well as internalization and 
accumulation of dendrimers into cells while exhibiting relatively low cytotoxicity.33, 261 TPP 
conjugation has led to enhanced delivery of DNA/dendrimer complexes in vitro and their 
improved transfection ability.237 Therefore, the modification of TPP to amine-terminated 
PAMAM dendrimers holds great promise in enhancing the transfection ability and 
biocompatibility of dendrimers for siRNA delivery to the lung tissue.  
Oral inhalation (OI) is promising route for local siRNA delivery to the lungs as it 
avoids systemic degradation262 and poor lung targeting associated with i.v. 
administration.263 Pressurized metered dose inhalers (pMDIs) and dry powder inhalers 
(DPIs) are the two most widely used portable inhalation devices.97, 264 In a pMDI, the 
therapeutic particles are suspended in the propellant (hydrofluoroalkanes – HFAs).97 The 
propellant aerosolizes the therapeutic for inhalation when the device is actuated.97, 264 
DPIs allow for the inhalation of dry powders as an aerosol cloud upon breath actuation.97 
In order to achieve successful delivery of siRNA to the lungs using such portable inhalers, 
the nanoscale dendriplexes must be formulated into particles that form aerosols with 
optimum aerosol diameters within the range of 1-5 µm.  This process must be done 
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without compromising the biological activity of siRNA.99 We have previously reported 
successful use of spray drying technique with sugar excipients to formulate dendriplexes 
into suitable micron-sized particles that results in optimum aerosol sizes when formulated 
in pMDIs.96 The use of spray drying can also be easily extended for preparation of DPI 
formulations as well, and has been shown to work successfully to formulate micron 
particles of PLGA-siRNA nanoparticles via spray drying with sugar excipients.265 
Considering the challenges and opportunities stated above, the goal of this study 
was twofold: (i) to design a PAMAM-based dendrimer conjugate that led to improvements 
in gene knockdown efficiency in an in vitro model of the pulmonary epithelium when 
compared to the unmodified amine-terminated counterpart, (ii) and to develop efficient 
strategies for the formulation of such dendriplexes in portable oral inhalation devices.  We 
conjugated generation 4, amine-terminated PAMAM dendrimers (G4NH2) with increasing 
TPP densities (0, 4, 8, 12 TPP/dendrimer).  Complexes of G4NH2-TPP dendrimers with 
siRNA (G4NH2-TPP-dendriplexes) at various N/P ratios were prepared and 
characterized. The gene knockdown efficiency and toxicity of these G4NH2-TPP-
dendriplexes (simply, TPP-dendriplexes) was tested in an in vitro model of the pulmonary, 
namely stably-transfected, green fluorescent protein (GFP) expressing A549 cells. The 
most effective TPP-dendriplex system was selected to be formulated in portable OI 
devices.  Micron-sized particles of the TPP-dendriplex were prepared using mannitol as 
an excipient and spray dried.  The aerosol characteristics of the mannitol-TPP-dendriplex 
particles formulated in pMDIs and DPIs were assessed using an Anderson Cascade 
Impactor (ACI). This study demonstrates the successful use of TPP-targeted PAMAM 
dendrimers as vectors for siRNA delivery for a model of the pulmonary epithelium, and 
86 
 
 
 
their formulations using pMDIs and DPIs for direct and noninvasive siRNA delivery to the 
lungs. 
4.2 Materials and Methods 
4.2.1 Materials 
Generation four, amine-terminated, poly(amidoamine) (PAMAM) dendrimer 
(G4NH2) in methanol at 9.8% w/w was purchased from Dendritech Inc. (Midland, MI).  
Double-stranded Dicer substrate siRNA targeting eGFP ((+) siRNA) and double stranded 
respective mismatch as a negative control ((-) siRNA) was obtained from Integrated DNA 
Technologies (Leuven, Belgium).96 Dimethyl sulfoxide (DMSO) anhydrous (Acros), N-
Hydroxysuccinimide (NHS) (Acros), agarose, sodium chloride (NaCl), potassium chloride 
(KCl), potassium phosphate, monobasic, anhydrous (KH2PO4), potassium hydroxide 
(KOH) agarose, and (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES) were 
purchased from Thermo Fischer Scientific (Rockford, IL). Sodium phosphate, dibasic, 
anhydrous (Na2HPO4) was purchased from EMD Chemicals, Inc. (Gibbston, NJ). (3-
Carboxypropyl) triphenylphosphonium bromide (TPP), P-toluenesolfonic acid (p-TSA), D-
Mannitol (98%), and heparin sodium salt (194 U/mg) were purchased from Sigma Aldrich 
(St. Louis, MO). N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide (EDC) was purchased 
from Advanced ChemTech Inc. (Louisville, KY). Diethylpyrocarbonate (DEPC) and 
ethylenediaminetetraacetic acid (EDTA) (pH 8, 0.5 M, sterile) were acquired from 
Amresco (Solon, OH, United States). Dymel 227 ea/P hydrofluoroalkane (HFA227) 
propellant was a gift from DuPoint (Fort Worth, Texas, United States). Spectra/Por 
cellulose ester membrane dialysis tubing was purchased from Spectrum Laboratories, 
Inc. (Rancho Dominguez, CA).  Deuterium Oxide (D2O) were purchased from Cambridge 
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Isotope Laboratories (Tewksbury, MA). Hank’s Balanced Salt Solution (1xHBSS) 
supplemented with 0.01 M HEPES was prepared according to the recipe provided by 
Irvine Scientific (Santa Anna, CA).  Deionized (DI) water was obtained from NANOpure® 
Diamond UV ultrapure water system (Barnstead International - Lake Balboa, CA).  
Amicon Centrifugal Filters were purchased from EMD Millipore (Billerica, MA).  Trypsin-
EDTA (1x) (Corning®), and 24-well and 96-well cell culture plates (Corning®) were 
purchased from VWR International. SeaKem LE Agarose was purchased from Lonza 
Group Ltd (Rockland, ME, United States).  Ethidium bromide (98%, 10 mg/mL) was 
supplied by IBI Scientific (Peosta, IA, United States).  
4.2.2 Conjugation of TPP to G4NH2 Dendrimer to Form G4NH2-TPP Conjugates 
G4NH2 PAMAM dendrimer (95.08 mg) was dissolved in 9.5 mL of DMSO with the 
addition of p-TSA (25.97 mg) and left to stir at room temperature for 24 h. TPP was 
activated using EDC/NHS coupling reaction adding 2:1 molar ratio of both EDC and NHS 
to TPP dissolved in anhydrous DMSO and allowed to stir at room temperature overnight 
to obtain activated TPP.  G4NH2/p-TSA mixture was added to the activated TPP dissolved 
in DMSO and the reaction mixture was allowed to proceed at room temperature for 3 
days. The molar ratios of activated TPP to G4NH2 were varied to conjugate different TPP 
densities to G4NH2 to form G4NH2-TPP conjugates in separate reactions. The reaction 
mixtures were then dialyzed against distilled water followed by Phosphate Buffered Saline 
(1xPBS – pH 7.2) solution using a using a Spectra/Por dialysis membrane. The products 
were further purified using an Amicon Ultra 15 centrifugal filter against a 10xPBS solution 
(pH 7.2) and again against distilled water. The G4NH2-TPP conjugates were frozen and 
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lyophilized to remove water, then characterized by 1H-NMR in D2O (Varian Mercury, 400 
mHz).  
4.2.3 Preparation and Characterization of TPP-Dendriplexes 
G4NH2-TPP-dendriplexes (or simply TPP-dendriplexes) were formed by a 
dropwise addition of GNH2-TPP conjugates (10-4,100 µg/mL, 20 nM Tris-HCl pH 7.4) to 
siRNA (17 pmol-80 pmol, RNase-free distilled water) and vortexed for 1 min. The TPP-
dendriplexes were incubated for 30 minutes at room temperature to ensure complete 
complexation. The concentrations of G4NH2-TPP conjugates were varied in order to 
obtain the desired N/P ratio – the molar ratio between the remaining unconjugated 
primary amine groups (N) of G4NH2-TPP conjugates and phosphate groups (P) on the 
siRNA sugar backbone.  
The size (hydrodynamic diameter, HD) and zeta potential (ζ) were evaluated for 
each TPP-dendriplex at various N/P ratios using Light Scattering (LS, Malvern ZetaSizer 
Nano ZS). HD was based on the intensity measurement provided by LS. Each sample 
contained 80 nM of siRNA and was performed at 25°C diluted in buffer for size, and in 
DI-water for ζ utilizing the refractive index, viscosity, and dielectric constant of DI water. 
A minimum of three independent measurements were taken for each sample to obtain an 
average size and ζ. A representative scanning electron microscopy (SEM) image was 
taken of the 12TPP-dendriplex, and geometric size based on ~340 particles was 
evaluated (Zeiss EVO 50 XVP SEM). TPP-dendriplexes were prepared as described 
earlier, with minor change that both the TPP-dendrimer and siRNA were dissolved in DI 
water. The final concentration of TPP-dendriplexes contained 80 nM of siRNA.  
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4.2.4 RNA Gel Complexation Assay 
The complexation efficiency of G4NH2-TPP conjugates to form TPP-dendriplexes 
was analyzed by gel electrophoresis. Various TPP-dendriplexes were formed as 
described previously using the equivalent of 300 ng of siRNA (RNase free DI-water) and 
G4NH2-TPP conjugates containing an average of 0, 4, 8 and 12 TPP (20mM Tris-HCl 
buffer at pH of 7.4) at N/P ratios of 0, 0.2, 0.8, 1, 2, 3, 5, 10, 20, and 30. Each TPP-
dendriplex sample was run in a 1.5% w/v agarose gel (1.5% w/v in tris base, acetic acid, 
and EDTA (TAE) 1X pH 8) at 90 V (E0160-VWR Mini Gel Electrophoresis) for 30 min. 
The migration of non-complexed siRNA was visualized under UV irradiation and images 
were obtained (Gel DocTM EZ, Bio-Rad). 
4.2.5 siRNA Release via Polyanion Competition Assay 
The release of siRNA from TPP-dendriplexes due to the addition of competing 
polyanionic heparin was determined as a measure of complex stability.266  Briefly, TPP-
dendriplexes with an N/P ratio of 30 were formed (200 ng siRNA) and incubated at room 
temperature for 30 min. The dendriplexes were then incubated with increasing 
concentrations of heparin (0, 5, 10, 15, 20, 25, 30, 35 µg/µg, heparin/siRNA) under 5% 
CO2 at 37°C for 1 hour. The samples were loaded onto a casted non-denaturing agarose 
gel and subjected to electrophoresis as stated previously. Non-complexed siRNA was 
loaded as a reference in each gel. The gels were subsequently imaged under UV 
irradiation and images were recorded using the Gel DocTM EZ (Bio-Rad). The binding for 
each G4NH2-TPP conjugate was performed at least in 2 independent experiments. 
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4.2.6 In Vitro Gene Knockdown 
The knockdown efficiency of the various TPP-dendriplexes were analyzed in vitro 
against A549 cells stably expressing GFP – eGFP-A59 cells. The development of eGFP 
A549 was described previously.96 TPP-dendriplexes containing a scramble (-) siRNA 
sequence were used as a negative control to account for any off-target effects.  These 
were also compared to non-complexed siRNA ((-) and (+) sequences) and to the 
commercial reagent Lipofectamine® 2000 (Life Technologies), the positive control. 
Briefly, eGFP-A549 cells were cultured in Dulbecco's Modified Eagle Medium 1 x high 
glucose (DMEM, Life Technologies) supplemented with 10% (v/v) fetal bovine serum 
(FBS, Atlanta Biologicals) and 2.5 µg/mL of puromycin selective antibiotic (Toku-E 
Biotechnology), and non-eGFP expressing A549 cells (AATC) were cultured in DMEM 
supplemented with 10% FBS and 1% Penicillin Streptomycin (100 U/mL Penicillin and 
100 µg/mL Streptomycin) antibiotics (AB, Life Technologies). Both were cultured at 37°C 
with 5% CO2 and used once culture reached 90% confluency. 50,000 cells per well (2 
wells with A549, 22 wells with eGFP-A549 cells) were seeded in 24 well plate and 
incubated for 24 hours at 37°C and 5% CO2. The cells were then washed with 1xPBS and 
250 µL of transfection solution (dendriplexes of +siRNA (n=3) and –siRNA (n=3) dissolved 
in 250µl of DMEM + 10%FBS + 1%AB) was added to each well and allowed to incubate 
for 6 hours, followed by the replacement of 500 µL of fresh culture medium. The TPP-
dendriplexes were made as discussed earlier. Each TPP-dendriplex contained 20 pmol 
of siRNA.  An appropriate amount of TPP-dendrimer (1.2-11.5 µg) was added to culture 
medium to a final volume of 250 µL. The 12TPP-dendriplexes were encapsulated into 
mannitol to form microparticles were also tested with same amount of siRNA (20 pmol) – 
91 
 
 
 
to assess the impact of the particle formation strategy on the biological activity of the 
siRNA. Some transfection solutions contained no TPP-dendriplexes for controls. The cells 
were then allowed to incubate at 37°C and 5% CO2 for 48 hours. The cells were then 
removed from the 24 well plate and resuspended in Attune® Focusing Fluid (1X). The 
median fluorescent intensity (MFI) from the GFP was measured using flow cytometry 
(AttuneTM Flow Cytometer, Thermo Fisher Scientific). MFI of non-eGFP A549 cells used 
as a negative control to take away any artifacts of fluorescence not produced by GFP and 
the average MFI from the negative control was subtracted from MFI of all the other 
samples – MFISample. eGFP A549 cells alone were used as a positive control – MFI+control. 
Data was analyzed using Attune® Cytometric Software v2.1. Percent (%) eGFP 
knockdown was calculated as follows in Equation (4.1):  
 
% 𝑒𝐺𝐹𝑃 𝐾𝑛𝑜𝑐𝑘𝑑𝑜𝑤𝑛 =  (
𝑀𝐹𝐼+ 𝑐𝑜𝑛𝑡𝑟𝑜𝑙− 𝑀𝐹𝐼𝑠𝑎𝑚𝑝𝑙𝑒
𝑀𝐹𝐼+ 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 
) × 100%   (4.1) 
 
4.2.7 In Vitro Cytotoxicity  
A549 cells were seeded using a 96 well plate at a density of 5 x 103 cells per well. 
The cells were allowed to grow in DMEM + 10% FBS + 1% AB (v/v) for 24 hours at 37°C 
and 5% CO2. TPP-dendriplexes (0.2 mL) were formed as previously stated at N/P ratio of 
30 and at the same concentrations utilized for in vitro gene knockdown experiment. Also, 
12TPP-dendriplex at N/P 30 was further analyzed by increasing siRNA concentration (0-
0.4 µM) and 12TPP-dendriplex concentration (0-12 µM) in DMEM + 10% FBS +1% AB. 
These TPP-dendriplexes were incubated with the cells for an additional 48 hours under 
5% CO2 at 37°C in DMEM + 10% FBS +1% AB.  Wells with no TPP-dendriplexes were 
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used as the control. Cell viability was analyzed using CellTiter 96® Aqueous Non-
Radioactive Cell Proliferation Assay (Promega). Briefly, the cells were rinsed twice with 
1xHBSS and 120 µL of MTS/PMS solution made in DMEM medium was added to each 
well and incubated for an additional 4 hours at 37°C and 5% CO2.  The absorbance was 
read at 490 nm using ELISA plate reader (Multiskan™ GO Microplate Spectrophotometer, 
Thermo Fisher Scientific). Cell viability was calculated using Equation 4.2 (n=5). 
 
% 𝐶𝑒𝑙𝑙 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =  
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑐𝑒𝑙𝑙𝑠
𝑥100%, (4.2) 
 
4.2.8 Preparation and Characterization of 12TPP-Dendriplex/Mannitol 
Microparticles  
The 12TPP-dendriplex (N/P=30) was prepared as described earlier.  A known 
volume (600 µL) of the 12TPP-dendriplex solution (30 µg siRNA equiv.) was mixed up 
with 2.4 mL RNase-free DI H2O with D-mannitol (90 mg equivalent).  The mixture was 
immediately spray-dried using Mini Spray Dryer B-290 (BUCHI) with the following setup: 
inlet temperature = 45°C, outlet temperature = 31-36°C, atomizing nitrogen flow rate 40 
mm (473 L/h), pump ratio 5% (1.5 mL/min), aspiration rate 70% (approximately 35 m3/L 
= 100%), and nozzle cleaning 0.  The 12TPP-dendriplex/mannitol microparticles were 
collected at the end of the gas cyclone.  The collected microparticles were lyophilized 
overnight to remove any residual H2O and were then placed in desiccator for future use. 
 The yield of the spray drying was calculated by Equation 4.3:  
 
𝑌𝑖𝑒𝑙𝑑 =
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑐𝑜𝑙𝑙𝑒𝑐𝑡𝑒𝑑 𝑚𝑖𝑐𝑟𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 (𝑚𝑔)
(90+0.03) (𝑚𝑔)
 (n=3) (4.3) 
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The payload of siRNA in 12TPP-dendriplex/mannitol microparticle was determined by 
incubating a certain amount of microparticles with 0.1 mL heparin aqueous solution (450 
U) for 0.5 h followed by analysis with agarose gel electrophoresis and densitometry (n=3).  
The geometric diameter of spray-dried 12TPP-dendriplex/mannitol particle was 
measured with scanning electron microscopy (SEM).  The microparticles were sprayed 
onto copper tape and then were sputtered with gold for 30 s.  The SEM was performed 
at 5 kV.  To measure the solvated diameter (SD) of the 12TPP-dendriplex/mannitol 
microparticles, a dispersion of the mircroparticles was prepared in 2H,3H-
perfluoropentane (HPFP) and measured by light scattering using Nano ZS Zetasizer 
(Malvern Instruments, United Kingdom), (n ≥ 3). To measure the hydrodynamic diameter 
(HD) and zeta potential (ζ) of “reconstituted 12TPP-dendriplex”, 12TPP-
dendriplex/mannitol microparticles were redissolved in RNase-free DI H2O (1 mg/mL) and 
then sonicated for 30 s at room temperature.  HD and ζ were determined immediately 
with Nano ZS Zetasizer (Malvern Instruments, United Kingdom), (n ≥ 3).  
4.2.9 Preparation and in vitro Aerosolization of the pMDI Formulation of 12TPP-
Dendriplex/Mannitol Microparticles 
The 12-TPPdendriplex/mannitol microparticles formulated as described earlier 
were weighed in pressure-proof glass vial (West Pharmaceutical Services) and manually 
crimped with 63 µL metering valves (Bespak). HFA227 was filled with a glass vial using 
a manual syringe pump (HiP, 50-6-15) and home-built high-pressure filler to make a final 
particle concentration of 2 mg/mL. The glass vial was placed in VWR PC250 sonicator 
bath at 5-10°C (VWR International) for 20 min.  The stability of the formulation was 
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performed by visually monitoring the dispersion of the microparticles in propellant as a 
function of time. 
An Andersen Cascade Impactor (Copley Scientific) with a USP induction port (IP) 
and eight stages was used to test the in vitro aerosol characteristics of the prepared pMDI 
formulation.  The in vitro aerosol performance was assayed at a flow rate of 28.3 L/min, 
25°C and 75% relative humidity.  First several shots were fired to waste and then 40 
actuations were puffed into the ACI with 10 s intervals between every two shots.  The ACI 
was disassembled soon after the last shot.  The actuator, IP, and the plates on each of 
the 8 stages were rinsed carefully with 10 mL RNase-free DI H2O and stored in separated 
centrifuge tubes.  These 12TPP-dendriplex/mannitol microparticles were frozen and then 
lyophilized.  The particles in each tube were carefully weighed for further analysis.  The 
microparticles collected from each tube were redissolved in 100 µL heparin-containing 
TE buffer (heparin 455 U/mL, pH 8.0, 1X) and the incubation was performed for 30 min 
at 37°C.  10 µL of the above buffer solution was loaded into an agarose gel.  The gel 
electrophoresis was performed at 60V for 40 min.  The amount of siRNA was quantified 
with densitometry using ImageJ 1.42q (National Institutes of Health). Respirable fraction 
(RF, Equation 4), fine particle fraction (FPF, Equation 5), mass median aerodynamic 
diameter (MMAD), and geometric standard deviation (GSD) were calculated with two 
methods: mass method and densitometry method.  In the mass method, the net weight 
of microparticles deposited on each stage was used to determine RF and FPF from 
Equations 4 and 5.  In the densitometry method, the mass of siRNA was assessed from 
densitometry and used in Equations 4.4 and 4.5.  
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𝑅𝐹 =
𝑀𝑎𝑠𝑠 𝑓𝑟𝑜𝑚  𝑆𝑡𝑎𝑔𝑒 0 𝑡𝑜 𝐹𝑖𝑙𝑡𝑒𝑟
𝑇𝑜𝑡𝑎𝑙 𝑀𝑎𝑠𝑠 𝑅𝑒𝑙𝑒𝑎𝑠𝑒𝑑 𝑡𝑜 𝐴𝐶𝐼
     (4.4) 
 
𝐹𝑃𝐹 =
𝑀𝑎𝑠𝑠 𝑓𝑟𝑜𝑚 𝑆𝑡𝑎𝑔𝑒 3 𝑡𝑜 𝐹𝑖𝑙𝑡𝑒𝑟
𝑀𝑎𝑠𝑠 𝑓𝑟𝑜𝑚 𝐼𝑛𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑃𝑜𝑟𝑡 𝑡𝑜 𝐹𝑖𝑙𝑡𝑒𝑟
  (Aerodynamic diameter ≤4.7 µm) (4.5) 
 
MMAD and GSD were calculated as described previously.267 
4.2.10 Preparation and in vitro Aerosolization of the DPI Formulation of 12TPP-
Dendriplex/Mannitol Microparticles 
The aerosolization of the DPI formulations was also determined with an 8-stage 
Andersen Cascade Impactor (Copley Scientific Limited) to which a pre-separator (Copley 
Scientific Limited) was attached to prevent large particles or aggregates from reaching 
the stages. A dose of 12TPP-dendriplex/mannitol microparticles (10-20 mg) was loaded 
into a capsule and inserted into Rotahaler® device (Cipla Limited), and then dispersed at 
an inspiration rate of 28.3 L/min for 4 s.  The plates from each stage were carefully rinsed 
with 20 mL RNase-free H2O.  The collected aqueous solution was frozen and then 
lyophilized for 72 hours.  The lyophilized particles from the inhaler device, induction port, 
and 8 plates were individually dissolved in 100 µL heparin TE 1X solution (455 U/mL) for 
0.5 h and the siRNA amount was quantified by agarose gel electrophoresis and 
densitometry.  Emitted dose (ED) was considered as the difference between the initial 
mass and the mass of microparticles left in the inhaler or capsule after the inspiration 
process.  The RF, FPF, MMAD and GSD were calculated as previously noted. 
4.2.11 Statistical Analysis   
All data are presented as a mean ± standard deviation.  The means were calculated 
from a minimum of three independent trials for each measurement (n ≥ 3).  One-way 
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analysis of variance (ANOVA) followed by Tukey’s Multiple Comparison Test or an 
unpaired t-test was performed using GraphPad Prism 5 software.  Means were 
considered statistically significant if p < 0.05. 
4.3 Results 
4.3.1 Conjugation of TPP to G4NH2 Dendrimer. 
TPP was conjugated to the primary amines of G4NH2 (Scheme 4.1).  
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Scheme 4.1. Schematic of the TPP conjugation to the amine-terminated, generation 
4 poly(amido)amine (PAMAM) dendrimer (G4NH2). A) TPP is activated using 
EDC/NHS coupling to form TPP-NHS in DMSO. B) G4NH2 was then later added to 
the activated TPP (TPP-NHS) in DMSO and allowed to react to form G4NH2-TPP 
dendrimer conjugate. The amount of TPP-NHS added to the reaction mixture 
determined the conjugation density with the final density of TPP per dendrimer of ~ 0, 
4, 8, 12 TPP.  
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The conjugation of TPP to G4NH2 to form G4NH2-TPP was confirmed by 1H NMR D2O 
(Figure 4.1).  
G4NH2 with increasing density of TPP were prepared to assess the effect of TPP on the 
gene knockdown efficiency of the dendriplexes. The results indicate that an average of 4, 
8, and 12 TPP molecules were conjugated per dendrimer. 
4.3.2 Preparation and Characterization of TPP-Dendriplexes 
TPP-dendriplexes were prepared by combining positively-charged G4NH2-TPP 
conjugates with negatively-charged siRNA. The TPP-dendriplexes were named based on 
the TPP conjugation density to G4NH2: 0TPP-dendriplex, 4TPP-dendriplex, 8TPP-
dendriplex, and 12TPP-dendriplex. They were characterized for their size (HD), and 
surface charge (ζ) via LS (Table 4.1). 
Figure 4.1. 1H NMR characterization of G4NH2-TPP conjugates in D2O.  The 
chemical structure is shown above with the corresponding peak shifts labeled within 
the spectrum.  
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Table 4.1. Characterization of G4NH2-siRNA complexes by Light Scattering.  
Hydrodynamic diameters (HD), Polydispersity Index (PDI), and zeta potential (ζ) are 
summarized as a function of number density of TPP per G4NH2 (0-12) and also as a 
function of N/P ratio (5-30). HD was based on intensity measurements. HD = mean ± s.d., 
PDI = mean ± s.d., ζ = mean ± s.d.  
 0 TPP 4 TPP 8 TPP 12 TPP 
N/P 
ratio 
HD 
(nm) 
PDI ζ 
(mV) 
HD 
(nm) 
PDI ζ 
(mV) 
HD 
(nm) 
PDI ζ 
(mV) 
HD 
(nm) 
PDI ζ 
(mV) 
5 172 
± 26 
0.44 
± 
0.04 
37± 
7 
304 
± 75 
0.47 
± 
0.08 
16 ± 
5 
372 
± 29 
0.52 
± 
0.04 
43 ± 
8 
310 
± 12 
0.30 
± 
0.08 
22 ± 
2 
10 129 
± 3 
0.31 
± 
0.02 
33 ± 
3 
367 
± 
120 
0.50 
± 
0.15 
12 ± 
7 
323 
± 20 
0.47 
± 
0.06 
25 ± 
8 
218 
± 42 
0.36 
± 
0.07 
33 ± 
5 
20 343 
± 20 
0.38 
± 
0.08 
33 ± 
3 
327 
± 34 
0.45 
± 
0.07 
42 ± 
10 
379 
± 26 
0.56 
± 
0.09 
31 ± 
10 
382 
± 37 
0.56 
± 
0.06 
23 ± 
7 
30 339 
± 21 
0.39 
± 
0.11 
34 ± 
7 
364 
± 32 
0.49 
± 
0.03 
17 ± 
3 
361 
± 20 
0.49 
± 
0.05 
27 ± 
5 
363 
± 55 
0.36 
± 
0.15 
40 ± 
3 
 
The average density of TPP (0, 4, 8, 12 TPP molecules per G4NH2 dendrimer) and 
N/P ratio (5, 10, 20, 30) were varied for each TPP-dendriplex. All TPP-dendriplexes were 
able to form nanoparticles with sizes ranging from 120 nm – 400 nm in diameter, most 
being in the 300 nm range (Table 4.1). The PDI ranged from 0.2-0.5, therefore 
demonstrating that stable complexes of similar sized could be formed. These PDI values 
are less than 0.7, which indicates that the sizes have some spread in their distribution but 
are still producing relatively similar sizes.  The N/P ratio and TPP density do not seem to 
greatly impact the HD of the TPP-dendriplex. The ζ of all TPP-dendriplexes were 
positively charged, ranging from +12-43 mV. No obvious trend in surface charge with TPP 
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density of the TPP-dendriplexes was seen either. SEM image (Figure 4.2) of 12TPP-
dendriplexes (N/P 30) revealed spherical nanoparticles with an average geometric 
diameter of 160 ± 50 nm. 
 
4.3.3 RNA Gel Complexation Assay 
The complexation ability of the TPP-dendriplexes was tested using a complexation 
assay. TPP-dendriplexes were added to a constant amount of siRNA (300 ng) and 
increasing the N/P ratio (amount of dendriplex compared to siRNA) for TPP-dendriplexes 
with different average densities of TPP (Figure 4.3).  
The non-complexed siRNA band can be seen in the first lane at N/P = 0.0. As the 
N/P ratio increased, the amount of non-complexed siRNA decreased.  The N/P ratios 
where no non-complexed siRNA band can be seen demonstrates full complexation with 
G4NH2-TPP to form TPP-dendriplex with the amount of siRNA present. For TPP-
dendriplex with 0 and 4 TPP groups on average, an N/P ratio of 1 was enough to ensure 
full complexation. The conjugation of TPP above the average of 4TPP on the dendrimer 
required an increase in N/P ratio from 1 to 2 to fully complex all the siRNA. For all groups, 
an N/P ratio of 2 was able to fully complex all siRNA present, which is seen as an absence 
of non-complexed siRNA band in the agarose gel (Figure 4.3).  
Figure 4.2. Scanning electron microscopy (SEM) of 12TPP-dendriplex at N/P 30. The 
geometric diameter represents ~ 340 particles.  
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4.3.4 siRNA Release via Polyanion Competition  
A measure of complex stability was assessed using heparin as a polyanion 
competitor (Figure 4.4). 
Figure 4.3. The siRNA complexation efficiency as a function of N/P ratio as visualized 
by gel electrophoresis.  The dendriplexes were prepared with various ratios of TPP (as 
indicated to the left).  The first lane contains untreated non-complexed siRNA as control 
and subsequent lanes with increasing N/P ratios as shown.  
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Heparin, a highly negatively charged anion, can act as a competitor for 
complexation relative to nucleic acids and, therefore, be used as a way to measure 
complex stability. The comparison was made between the dendriplex group containing 
no TPP (0TPP-dendriplex, N/P 30) and that with most TPP (12-TPP dendriplex, N/P 30). 
The success of decomplexation was demonstrated by the non-complexed siRNA band in 
the agarose gel. The results demonstrated less heparin was needed to fully decomplex 
the siRNA from the TPP-dendrimer for the 12-TPP dendriplex (Figure 4.4). Almost full 
decomplexation at 20 heparin (µg)/siRNA (µg) is achieved for 12TPP-dendriplex.  
However, for the complex formed with the dendrimer without TPP, most of the siRNA is 
still complexed until 30 heparin (µg)/siRNA (µg). Therefore, a reduction in complex 
stability can be observed upon the conjugation of TPP to the surface of the dendrimer.  
 
 
Figure 4.4. Polyanion competition assay visualized by gel electrophoresis. The 
stability of the dendriplexes was tested for 0TPP-dendriplex (N/P 30) and 12TPP-
dendriplex (N/P 30) by exposing each to increasing amounts of heparin. C = siRNA 
only, used as a control. 
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4.3.5 In Vitro Gene Knockdown 
The gene knockdown ability of the TPP-dendriplexes was tested in vitro by the 
delivery of siRNA targeting eGFP gene in eGFP-expressing A549 cells. The results 
(Figure 4.5) are expressed as the percent of eGFP knockdown (% eGFP knockdown). 
 
Figure 4.5. In vitro gene knockdown of eGFP expression in stably expressing eGFP 
A549 cells. The dendriplexes (Dplex) were prepared at N/P ratio of 30 with eGFP 
siRNA and G4NH2-TPP conjugates.  The specificity of the knockdown was performed 
by comparing dendriplexes with a scramble eGFP sequence (-siRNA) to the correct 
corresponding eGFP sequence (+siRNA). Non-complexed siRNA (siRNA) was used 
as a negative control and the commercial reagent Lipofectamine 2000 (L) was used 
as a positive control. 20 pmol of siRNA (80 nM) was used for each sample while the 
amount of dendrimer-TPP ranged from 1.2-11.5 µg (0.3-2.4 µM) depending on the 
desired N/P ratio and TPP density of TPP-dendrimer sample.  * represents a statistical 
difference (p < 0.05) between the non-complexed +siRNA and various +siRNA groups, 
while ρ represents a statistical difference of +siRNA between indicated groups as 
analyzed by One-Way ANOVA followed by Tukey’s Multiple Comparison Test (n ≥ 3) 
(p < 0.05), n.s.d. = not statistically different. 
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A scramble sequence ((-) siRNA) was used as a negative control to account for 
off-target effects and compared with the eGFP sequence ((+) siRNA). Also, the effect of 
N/P ratios and varying TPP densities were compared to naked siRNA delivery and with 
the commercial siRNA delivery vehicle Lipofectamine® 2000. All N/P ratios were chosen 
above where full complexation is known to occur between the siRNA and the TPP-
dendrimers, as demonstrated by the complexation assay. 
There was no significant difference seen between the (-) siRNA and (+) siRNA 
sequences for 0TPP-dendriplex at N/P 10, and 4TPP-dendriplex at N/P of 20, and naked 
(-) siRNA and (+) siRNA sequences, which may indicate that any gene knockdown seen 
may only be due to off-target effects and not due to the successful siRNA delivery and 
gene knockdown. All other groups when comparing the (-) siRNA and (+) siRNA TPP-
dendriplexes and various controls, a statistically significant difference was observed, 
which demonstrates that eGFP knockdown was above and beyond any off-target effects. 
All groups at all the N/P ratios demonstrated a significant increase in eGFP knockdown 
when compared to delivering (+) siRNA alone to the cells. At N/P 5, all TPP-dendriplexes 
were able to knockdown the eGFP gene but showed no statistical difference between any 
group and showed only moderate knockdown compared to Lipofectamine® 2000. As the 
N/P ratio increased (N/P 10, 20, & 30), changes in gene knockdown efficiency between 
the various TPP-dendriplexes was observed.  In general, an increase in TPP density and 
increase in N/P ratio lead to an increase in gene knockdown efficiency. 
The most effective TPP-dendriplex system was found to be 12TPP-dendriplex at 
N/P ratio of 30 with % eGFP knockdown at 45 ± 5 %. This group was used to formulate 
mannitol microparticles suitable for pulmonary delivery.  After formulation in mannitol, 
104 
 
 
 
gene knockdown efficiency of the recovered dendriplexes was unchanged to 49 ± 11% - 
Figure 4.5 – N/P30 12TPP-SD. The results can be directly contrasted with the positive 
control, Lipofectamine® 2000, which showed a gene knockdown ability at 73 ± 2%.  
4.3.6 In Vitro Cytotoxicity 
The toxicity of the TPP-dendriplex nanocarrier was also tested in vitro against 
A549 cells at the same incubation period (48 hours) and concentrations utilized in the in 
vitro gene knockdown experiments, using TPP-dendriplexes formulated at N/P 30 – the 
N/P ratio that resulted in highest gene knockdown efficiency. The results reveal no 
significant difference in toxicity between the TPP-dendriplexes and that of the control (no 
dendriplex), demonstrating no cell toxicity at the concentrations tested (Figure 4.6).  
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Figure 4.6. Viability of eGFP A549 cells contacted with G4NH2-TPP-siRNA 
dendriplexes (12TPP-dendriplexes) formed at N/P 30, as measured with an MTS 
assay after a 48-hour incubation with the dendriplex.  The concentration of the 
dendriplex used was the same as the in vitro knockdown experiments.  Statistical 
analysis was run between the control group (no dendriplex) representing 100 % cell 
viability, and the dendriplex formed with G4NH2 with varying TPP density.  One-Way 
ANOVA followed by Tukey’s Multiple Comparison Test (n ≤ 3).  n.s.d. = not statistically 
different. 
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The toxicity of 12TPP-dendriplex was also tested at the same incubation period of 
48 hours and increasing concentrations of 12TPP dendriplex but maintaining the N/P 30 
ratio - the system (N/P ratio and TPP density) with highest gene knockdown efficiency 
(Figure 4.7). 
 
The highest concentration for which no cell toxicity was seen for 12TPP-dendriplex 
at N/P 30 was 0.08 µM siRNA / 2.4 µM 12TPP-dendrimer, while 0.16 µM siRNA / 4.8 µM 
12TPP-dendrimer led to a statistically significant decrease in % cell viability (73 ± 3%). 
The concentration used for in vitro gene knockdown experiments was 0.1 µM siRNA / 3.0 
µM 12TPP-dendrimer. This was also considered a concentration that did not affect cell 
viability (Figure 4.6) and correlates with these findings (Figure 4.7). 
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Figure 4.7. The cell viability of eGFP A549 cells contacted with G4NH2-12TPP 
dendriplex (12TPP-dendriplex) formed at N/P 30 as measured by the MTS assay after 
48 h incubation and increasing dendriplex concentration. * represents the statistical 
analysis between the control group indicated at 0 µM representing 100 % cell viability 
and those of increasing concentrations, as analyzed by One-Way ANOVA followed by 
Tukey’s Multiple Comparison Test (n ≤ 3).  n.s.d. = not statistically different. 
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4.3.7 Preparation and Characterization of 12TPP-Dendriplex/Mannitol 
Microparticles  
The system that displayed the highest in vitro gene knockdown ability (12TPP-
dendriplex at N/P 30) was selected for formulation into inhalable microparticles using 
mannitol as the excipient. The 12TPP-dendriplex/mannitol microparticles were formed 
using the spray drying technique and characterized by LS, SEM, and gel electrophoresis. 
The percent yield of the powders prepared by spray drying was 76 ± 5%. The 
nanocomplexes were loaded with high efficiency into the microparticles - 75.1 ± 6.7% 
relative to theoretical payload.  The payload of siRNA within the TPP-dendriplex-mannitol 
microparticles was determined by densitometry - 0.025 ± 0.004% (wt/wt, n=3).  
The microparticles were visualized using SEM (Figure 4.8) revealing a smooth and 
spherical shape. 
  
 
 
Figure 4.8. Scanning electron microscopy (SEM) of dendriplex/mannitol microparticles 
prepared by spray drying.  The geometric diameter of dendriplex/mannitol particle 
(inset) represents the average of over 300 particles.  Higher magnification image is 
shown as inset. 
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The geometric diameters of microparticles was also qualitatively assessed by SEM and 
compared to the solvated diameter (SD) utilizing LS where the 12TPP-
dendriplex/mannitol microparticles were dispersed in HPFP, a model propellant.  The 
results revealed a geometrical diameter of 2.4 ± 0.9 µm and a SD of 4.2 ± 0.5 µm. The 
redispersability of the dendriplexes encapsulated within the microparticles upon 
breakdown in aqueous media is an important factor for lung deposition and intracellular 
internalization of siRNA. LS results (Table 4.2) revealed that the HD of the 12TPP-
dendriplex reconstituted from the microparticles (340 ± 154.5 nm) was similar as that of 
freshly prepared dendriplex (363 ± 55 nm) indicating the 12TPP-dendriplex structure 
remained intact during the spray drying process.  
Table 4.2. Hydrodynamic diameters (HD), Polydispersity Index (PDI), and zeta potential 
(ζ) of 12TPP-dendriplex (N/P 30) before formulation in mannitol-based microparticles and 
after reconstitution in DI H2O.  Light Scattering performed in DI water. 
 HD (nm) PDI ζ (mV) 
Dendriplex 363 ± 55 0.36 ± 0.15 +40 ± 3 
+27 ± 7 Reconstituted dendriplex  340 ± 150 0.20 ± 0.02 
 
The surface charge of the 12TPP-dendriplex remained positive in both cases, 
however, did decrease from +40 mV to +26.5 mV – note that the media in which they 
were measured is slightly different, as the reconstituted dendriplexes were measured in 
the presence of mannitol. 
4.3.8 The in vitro Aerosolization of 12TPP-Dendriplex/mannitol Microparticles 
Formulated as Dispersions in HFA-based pMDIs 
The 12TPP-dendriplex/mannitol microparticles were tested for their aerosol 
performance utilizing an in vitro lung model, the Anderson Cascade Impactor (ACI), for 
the pMDI formulations. The ACI comprises eight different stages representing different 
areas of lung deposition, and the amount of deposition was determined either by 
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quantifying the siRNA levels (densitometry) or the siRNA and the total mass of 
microparticles (siRNA + mannitol) in each plate (Figure 4.9). The aerosol characteristics 
of the pMDI formulations, including respirable fraction (RF), fine particle fraction (FPF), 
mean mass aerodynamic diameter (MMAD), and geometric standard deviation (GSD) 
were determined (Table B1). The % deposition of the siRNA/microparticles on the various 
stages of the ACI have indicated that besides the IP and AC, highest deposition of siRNA 
(on respirable stages) was on stages 3, 4 (Figure 4.9).   
 
The FPF calculated for the pMDI formulations by mass method was 50.3 ± 2.6% 
and by the siRNA densitometry was 53.7 ± 3.0%, demonstrating good correlation 
between the two methods. MMAD was determined to be 3.8 ± 0.2 µm (mass method) and 
 Figure 4.9. Deposition of 12TPP-dendriplex/mannitol microparticles on different 
stages of the Andersen Cascade Impactor (ACI) from a pMDI formulation at a flow rate 
of 28.3 L/min, as determined by siRNA densitometry method and particle mass 
method.  pMDI formulations at 2 mg microparticles/1 mL HFA227 propellant at 25C 
and saturation pressure of propellant.  The payload of siRNA in microparticle is 0.025% 
wt/wt.  The results were based on 20 actuations and represented with mean ± s.d. 
(n=3).  Statistical analysis was performed with Student t-test (*p<0.05).  AC: actuator, 
IP: induction port, 0-7: plate 0-7, and F: filter.  
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3.6 ± 0.1 (µm siRNA densitometry method), while the calculated GSD was 1.4 ± 0.1 (mass 
method) and 1.8 ± 0.2 (siRNA densitometry method). 
4.3.9 The in vitro Aerosolization of DPI Formulation of 12TPP-Dendriplex/Mannitol 
Microparticles  
The inhalable 12TPP-dendriplex/mannitol microparticles were also tested as a 
formulation for dry powder inhalers (DPIs). The in vitro deposition of the DPI formulation 
loaded in the RotahalerTM was also assayed at 28.3 L/min and 75% relative humidity using 
8-stage ACI equipped with a preseparator. The deposited particles on each stage were 
collected, and the siRNA was visualized with gel electrophoresis and quantified by 
densitometry (Figure 4.10). 
 
The aerosolization parameters were further calculated based the deposition data 
(Table B2). A relatively large interparticulate cohesion was seen for the 12TPP-
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Figure 4.10. Deposition of 12TPP-dendriplex/mannitol microparticles on the different 
stages of Andersen Cascade Impactor (ACI), as determined by siRNA densitometry 
method.  The 10-20 mg micron particles loaded into capsule were released into ACI 
from Rotahaler® (DPI formulation) at 25°C, 75% relative humidity, and a flow rate of 
28.3 L/min for 4 s inspiration.  The results are represented with mean ± s.d. (n=3).  IH: 
inhaler, IP: induction port, 0-7: plate 0-7, and F: filter.   
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dendriplex/mannitol microparticles, where 49.6 ± 2.4% was retained in the inhaler device 
and capsule.  The particles with low micron size tend to be sticky due to the propensity to 
reduce surface energy upon aggregation.268  In addition, the residual water content in 
mannitol microparticles can exacerbate the stickiness via capillary force.269 ED, RF, and 
FPF were 50.4 ± 2.4%, 41.5 ±2.6%, and 38.5 ± 3.1%, respectively. MMAD and GSD 
based on deposition data were 4.8 ± 0.3 µm and 1.4 ± 0.2, respectively (Table B2). 
4.4 Discussion 
There are many potential advantages in developing effective carrier-based 
systems for siRNA intracellular delivery190, 270 and innovative strategies for local delivery 
of siRNA to the lungs 270, 271 for the treatment of a variety of pulmonary disorders.  The 
literature strongly suggests that synthetic polymers may be employed for enhanced 
siRNA delivery to various tissues.272, 273 PAMAM dendrimers are particularly attractive as 
their surface chemistry can be used not only to provide complexation sites with siRNA, 
and in the process reduce siRNA degradation and enhance cellular uptake,274, 275  but 
can also be modified to control important aspects of siRNA delivery upon cellular 
internalization and potentially be used to target intracellular organelles.261  Motivated by 
recent literature work that demonstrates that linear polymers modified with phosphonium-
containing groups can enhance the delivery of siRNA to the cell cytoplasm,276 and that 
TPP-modified dendrimers are effective carries for pDNA,237 in this work we investigate 
the effect of TPP conjugation on the surface of G4NH2 on their efficacy in delivering siRNA 
to the cell cytosol and to silence genes in an in vitro model of the pulmonary alveolar 
epithelium.  In this context, we were successfully able to formulate G4NH2-TPP-
dendriplexes (or simply TPP-dendriplexes) with various TPP densities and N/P ratios that 
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formed positively-charged nanoparticles (ca. 300 nm). Importantly, we also investigate 
particle engineering strategies that can address the formulation of such siRNA-dendrimer 
complexes in portable inhalers for pulmonary delivery of siRNA. In this case, we 
demonstrated successful micron-particle formulation of TPP-dendriplex systems (12TPP-
dendriplex/mannitol microparticles) for pMDIs and DPIs.  
Firstly, the effect of the TPP density and N/P ratio on the influence of TPP-
dendriplexes ability to successfully deliver siRNA to lung alveolar cells in vitro was 
investigated. Certain characteristics such as complexation ability of TPP-dendrimer to 
siRNA was influenced by increasing presence of TPP on the dendrimer. The amount of 
TPP-dendrimer required to fully complex siRNA increased with the increase in TPP 
density (Figure 4.3) as well as requiring less heparin to separate the siRNA from the 
dendrimer (Figure 4.4) which demonstrates that a looser association between the TPP-
dendrimer and siRNA. While complexes with dendrimer with both TPP and no TPP 
remain positively charged, the TPP-modified dendrimer contained a positive charge that 
is delocalized by the hydrophobic phenyl rings present, thus decreasing the binding ability 
of dendrimers to siRNA. Therefore, this difference in complex stability cannot be attributed 
due to differences in surface charge but are more likely related to the hydrophobic nature 
and steric effects of the phenyl rings present in TPP. Consequently, the loose 
complexation of siRNA with the TPP-dendrimer may provide for a strategy to modulate 
siRNA release, which is a critical step when the nanocarriers reach the cytosol,277 and 
thus overcome an existing challenge in the use of bare cationic PAMAM dendrimers. 
Subsequently, the gene knockdown ability of the TPP-dendriplexes was also 
affected by TPP density and N/P ratio.  An increase in gene knockdown efficiency was 
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observed with an increase in both TPP density and an increase in N/P ratio, as seen by 
the increase in % eGFP knockdown in eGFP-expressing A549 cells (Figure 4.5).  
However, the modification with only 4 TPP molecules per dendrimer did not show any 
increase in transfection ability. Therefore, a threshold of TPP density is required to be 
able enhance transfection ability of dendrimers: >1/16 surface functionalization (greater 
than 4 TPP molecules per 64 available surface groups on G4NH2 PAMAM dendrimer). 
12TPP-dendriplex at N/P of 30 resulted in the highest transfection efficiency (45 ± 5%), 
and was higher than our previous study of unmodified dendriplexes in the same cell line 
(22-37%)96 and what is reported here as a function of N/P ratio (8-25%). 
This increase in transfection ability may be due to several factors. This includes a 
weaker complexation of siRNA with 12TPP dendrimer allowing for facilitated 
decomplexation once the TPP-dendriplex has been internalized into the cell - based on 
evidence seen with the complexation and polyanion competition assays. A balance 
between complexation and decomplexation of the siRNA once internalized into the cell 
must be reached for high gene transfection.278 If the electrostatic interaction is too strong 
between the dendrimer and siRNA, this can lead to a failure in siRNA release and gene 
knockdown,278 which may be a reason for lower transfection ability of 0TPP-dendriplex. 
Other reports have shown that the addition of heparin and other anionic oligomers 
increase the transfection ability of PAMAM/DNA complexes, suggesting that not as strong 
association between the DNA and dendrimer in the presence of heparin could allow for 
higher transfection ability.279, 280 Therefore, the looser association between dendrimer and 
siRNA may account for some increase gene knockdown seen. However, it is also known 
that TPP-modified PAMAM dendrimers can lead to enhanced cellular internalization of 
113 
 
 
 
dendrimers compared to unmodified dendrimers,33, 261 and this effect depends on TPP 
density.261 This could potentially lead to higher amounts of siRNA being delivered to cells 
over time. Other factors, including increased mitochondrial targeting and efficient 
endolysosomal escape of the dendrimer with TPP may also play important roles in the 
increased transfection ability.237 The transfection ability could also be potentially 
increased if an increase of TPP density on dendrimer were to occur, however, this would 
have to be balanced with potential toxic effect TPP modification can impart, as seen in 
our previous work.261 
The toxicity of TPP-dendriplexes was also monitored to make sure any off-target 
effects were not due to overt toxicity. Off-target effects can include toxicity of the gene 
vector itself 281, 282 and similarities in (-) siRNA mRNA motifs not specifically targeted by 
siRNA.283, 284 These off-target effects are not uncommon, as seen in the use of the 
Lipofectamine® 2000 commercial reagent, and may be difficult to avoid since they are 
not well-understood.285  No significant toxicity of the TPP-dendriplexes (N/P 30) was seen 
for concentrations used in the eGFP knockdown experiment (Figure 4.6), which 
demonstrate the off-target effects seen by delivery of (-) siRNA cannot be attributed to 
toxicity of the TPP-dendrimer. Since the 12TPP-dendriplex at N/P 30 demonstrated the 
highest transfection efficiency, toxicity studies with increasing concentrations of the TPP-
dendriplex was performed to determine the highest concentration of complex that could 
be used without any toxicity seen on the cell model (Figure 4.7). In this case, the 
maximum amount of siRNA that can be delivered to A549 cells in vitro with the TPP-
dendrimer constructs without toxic effects fell between 20-32 pmol of siRNA (0.10-0.16 
µM siRNA/3.0-4.8 µM 12TPP-dendrimer). This contrasts greatly with Lipofectamine® 
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2000 where toxic effects were seen against A549 cells at a concentration of 4 ug/mL, 
which corresponds to 20 pmol of siRNA delivery (Figure B1). This concentration of 
Lipofectamine® 2000 was the concentration utilized in the gene knockdown experiments, 
which may have contributed to some of the off-target effects seen for Lipofectamine® 
2000 as well as demonstrating its limitations in terms of safe siRNA delivery. Therefore, 
the TPP-dendriplex system compared to Lipofectamine® 2000 has the potential to deliver 
more siRNA with less toxic effects.  
From the in vitro knockdown and toxicity studies, the dendriplex with 12TPP and 
at 30 N/P ratios have emerged as the most promising system and was thus selected to 
be tested in the development of the portable oral inhalation formulations for pulmonary 
delivery. There are lots of potential benefits in providing patients with a range of devices 
that they can choose from when dealing with pulmonary drug administration, including 
compliance,286 which is why formulations for both pMDIs and DPIs were developed.  
PAMAM dendrimers have been utilized for pulmonary delivery in vivo77, 78, 116, 287 and 
formulated for use in nebulizers,258  pMDIs96, 127 and DPIs.288 A key aspect of the design 
of oral inhalation formulations is the particle aerodynamic diameter emitted from the 
device, which should fall within the range of 1-5 µm.99, 216  
A strategy to deliver such dendriplexes, whose geometric size are quite different 
from the aerosol requirements for deep lung deposition, is to engineer particles with non-
active ingredients encapsulating the TPP-dendriplexes and having appropriate micron-
sizes. Spray drying provides for an easy and scalable strategy to engineer particles with 
a well-defined size range and morphology.97, 289 Mannitol has been widely used as a 
promising excipient in portable inhalers as early studies demonstrated improvement in 
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respiratory symptom and quality of life of lung dysfunction-stricken patients.290 Spray 
drying has been also recently used to prepare microparticles of mannitol and siRNA-
loaded PLGA nanoparticles for dry powder formulation.265 However, in that study, the 
performance (aerosol characteristics) of the powder formulation was not tested in vitro. 
We also recently investigated the use of spray drying to form microparticles for metered-
dose inhaler formulations of siRNA-dendriplexes.96 Based on the successes of these 
previous studies, we investigated the ability of engineering microparticles of TPP-
dendriplexes and mannitol using spray drying, and the aerosol characteristics of the 
resulting formulations in both pMDI and DPI form. Spray drying 12TPP-dendriplex system 
in mannitol produced desired geometric sizes that are required for within desired size 
ranges.  
We also investigated the characteristics of reconstituted TPP-dendriplexes 
(dendriplexes after spray drying with mannitol and dissolution of mannitol in water) 
compared with TPP-dendriplex before the generation of the microparticles as to maintain 
as close as possible the original characteristics of the dendriplex. The 12TPP-dendriplex 
and reconstructed 12TPP-dendriplex revealed similar nanoparticle sizes, and the surface 
charge remained positive but was lower after formulation in mannitol. This may be due to 
the presence of mannitol within the system. Also, the 12TPP-dendriplex/mannitol 
microparticles revealed a slight increase in % eGFP knockdown but not statistically 
different from 12TPP-dendriplexes strongly suggesting that biological activity of siRNA 
remains unaffected upon spray drying (Figure 4.5).  
Consequently, 12TPP-dendriplex/mannitol microparticles were further tested for 
their aerosol performance in pMDI and DPI formulations in vitro using an Anderson 
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Cascade Impactor (ACI). An ACI, comprised with eight stages, has been widely 
recognized as an adequate in vitro lung model to assess the aerosol performance of the 
pMDI and DPI formulations in which various aerosol performance characteristics/values 
can be determined.291 Median mass aerodynamic diameter (MMAD) is defined as median 
of airborne particle mass distribution with respect to aerodynamic diameter,96 signifying 
the aerodynamic diameter which half of the aerosolized drug mass is below the diameter 
stated.292  Geometric standard deviation (GSD) is always reported with MMAD, showing 
the variability of particle size distribution, the spread of the aerodynamic diameters from 
the median.96, 292 Both the MMAD and GSD values for the pMDI and DPI formulations 
demonstrated appropriate values suitable for deep lung deposition efficient deposition in 
deep lung (Table B1, Table B2).293  
One key aerosol characteristic that was measured is the fine particle fraction 
(FPF). The FPF is an indicative of the efficiency of deep lung deposition of inhalation 
formulations, with aerodynamic diameters of less than 5 µm.294  The FPF is considered 
an important aerosol characteristic to determine the therapeutically beneficial proportion 
of the siRNA that can reach the lower lung airways (trachea to alveoli). The FPF of the 
pMDI formulation (Table S1) is comparable to commercial HFA-based pMDI formulations 
of small molecule therapeutics (range on average 30-55%),295 whose formulation and 
device are extensively optimized before reaching the market.  These results are also 
consistent with our previous particle engineering strategies whereby biodegradable 
polymers were employed to encapsulate siRNA-G4NH2 dendriplexes, where we reported 
an FPF of ca. 49 ± 6 % for dendrimer-siRNA complexes (no TPP).96 The DPI formulation 
revealed an FPF (Table B2) that falls in the reported range that varies from 12 to 40% of 
117 
 
 
 
emitted dose among different DPIs.296 Therefore, this formulation falls within what is 
generally seen with DPI formulations. In conclusion, the particle PMDI and DPI 
formulation strategies were successful in producing microparticles containing inhalable 
siRNA with suitable aerosol characteristics.   
4.5 Conclusion 
Synthetic siRNA can be an effective therapeutic in the treatment of a number of 
lung diseases. In this work, we evaluated the impact of TPP surface modification of 
G4NH2 dendrimers on the modulation of their interaction with siRNA, and subsequently 
on the gene knockdown ability of the dendriplexes in an in vitro model of the pulmonary 
epithelium. The presence of TPP on the dendrimer surface resulted in enhanced eGFP 
gene knockdown in eGFP-A549 cells.  Dendriplexes with the dendrimers containing the 
highest surface density of TPP (G4NH2-12TPP) and at N/P 30 showed the best gene 
knockdown efficiency compared to all other systems, including G4NH2-0TPP. The 
improvement in transfection efficiency was associated with looser complexation of siRNA 
with dendrimer and may also be associated with other factors including mitochondrial 
targeting, enhanced cellular internalization, and more efficient endolysosomal escape of 
the TPP-dendriplexes. The G4NH2-12TPP-dendriplexes were also formulated in portable 
inhalers to assess their potential for the local delivery of siRNA to the pulmonary 
epithelium. G4NH2-12TPP-dendriplexes were spray-dried with mannitol resulting in 
micron particles with high encapsulation efficiency.  These particles were formulated in 
pMDIs and DPIs, with resulting aerosol characteristics that are conducive to deep lung 
deposition (FPF of ca. 50% and 39%, respectively), while the formulation and 
aerosolization had no impact on the transfection efficiency of the G4NH2-12TPP-
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dendriplexes. The proposed G4NH2-12TPP-dendriplexes and their aerosol formulations 
hold promise in the local delivery of siRNA to the lung epithelium for the treatment of 
relevant pulmonary diseases. 
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CHAPTER 5 – SYNTHESIS OF ASYMMETRIC DENDRIMERS CONTAINING DOX AND 
VARIOUS SURFACE MODIFICATIONS BY CLICK CHEMISTRY 
 
5.1 Introduction 
 Of all the polymeric nanocarriers, dendrimers have shown great promise in the 
delivery of various drugs, peptides, antibodies, and genetic materials (DNAs/siRNAs) into 
intracellular targets within cells, as well as altering the pharmacokinetics and 
biodistribution.36, 47 Dendrimers are hyperbranched tree-like polymers with nanometer 
sizes containing a central core, repeating branching units (known as dendrons) with a 
multitude of surface groups.35 They are characterized by their unique properties including 
monodispersity, small tunable sizes, and multiple surface groups for modification, 
reproducible pharmacokinetics, and controlled therapeutic release.33, 36 This allows for 
the increase in the solubility and bioavailability of therapeutics attached covalently, 
encapsulated, or complexed with, and allow for multiple attachments for therapeutics as 
well as targeting ligands and surface modulators that can enhance pharmacokinetics and 
biodistribution while reducing unwanted side effects.34, 36 These characteristics make 
dendrimers an attractive choice for polymeric drug delivery.  
It is known that he endocytic internalization and intracellular trafficking within cells 
can affect the therapeutic performance.46 There are several mechanisms of cellular 
transport across cellular membranes including endocytosis, passive diffusion, and 
paracellular transport.47 It has been demonstrated that major factors that influences 
cellular internalization and intracellular trafficking of dendrimers, as well as their in vitro 
and in vivo toxicity is the size (molecular weight and generation) and the surface 
chemistry.47, 297 Of dendrimers, PAMAM dendrimers were the most extensively studied. It 
was found that PAMAM dendrimers were more readily transported across epithelial 
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barriers compared with water-soluble linear polymers.47 Charged dendrimers have shown 
increase permeability compared to neutral dendrimers. Cationic amine-terminated (-NH2) 
were demonstrated the highest permeability compared to anionic carboxyl-terminated (-
COOH) dendrimers, in which -NH2 decreases with size as -COOH increases with size.47 
 However, these parameters (molecular weight, generation, and surface charge) 
can also largely dependent on cell type taken up.47 Studies on human lung alveolar 
epithelial adenocarcinoma cells (A549) revealed PAMAM G4-COOH anionic dendrimers 
were internalized by caveolae-mediated endocytosis whereas cationic G4-NH2 and 
neutral G4-OH dendrimers were internalized by non-clathrin, non-caveolae-mediated 
mechanisms that involved electrostatic interactions or other non-specific fluid-phase 
endocytosis.108 Also, it was demonstrated that cationic G4-NH2 dendrimers, once 
internalized were found more in peripheral vesicles, whereas anionic G4-COOH and 
neutral G4-OH dendrimers were found in lysosomes.108 When it comes to polarized 
epithelial cells such as Caco-2 or Calu-3, paracellular transport can also occur.287, 298 In 
this case Kitchens et al. demonstrated extensive studies on dendrimer size (generation 
and MW) and surface charge (neutral, anionic, cationic) on the ability to permeate Caco-
2 cells, demonstrating similar trends as described above.298 However, a reduction in 
transepithelial electrical resistance (TEER) readings was seen for cationic PAMAM -NH2 
dendrimers and with anionic PAMAM -COOH dendrimers within a specific size range 
(G2.5-3.5), demonstrating enhanced permeability of dendrimers by opening of tight 
junctions suggesting PAMAM dendrimers are also transported through paracellular route. 
This was not seen for neutral PAMAM -OH dendrimers.298 Therefore, it is important not 
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only to understand dendrimer properties, but how those propertied influence the cellular 
environment in which you intend to expose them to.  
Modifications to the dendrimer surface including addition of linear water-soluble 
polymers like poly(ethylene)glycol (PEG) and lipophilic molecules like lauryl chains can 
also influence the cellular internalization pathways and intracellular trafficking. Addition of 
PEG to dendrimers been shown to modulate PAMAM dendrimer properties by decreasing 
toxicity, improving circulation time, protecting therapeutic payload, increasing aqueous 
compatibility, and modulating cellular internalization.287 The modification of G3-NH2 
PAMAM dendrimers with PEG on surface was able to demonstrate decrease 
internalization within polarized Calu-3 cells (human lung epithelial cells), however, 
increased transport across monolayer via transcellular and paracellular routes.287 This 
was further demonstrated in vivo when these dendrimers were delivered via pulmonary 
route, in which high peak plasma concentrations were seen when G3-NH2 PAMAM 
dendrimers were PEGylated demonstrating dendrimers being transported across the 
lungs into systemic circulation.287 The addition of lauryl groups has also be added to 
dendrimers to modulate decrease toxicity (cationic dendrimers), increased internalization 
by interactions with the fluidity of the membrane and regulation of paracellular route.110 
G3-NH2 dendrimers modified with two lauroyl chains was found to be internalized by 
caveolae-dependent and clathrin-dependent endocytosis as well as micropinocytosis with 
trafficking to endosomes and lysosomes in an human colon adenocarcinoma cell line – 
HT-29.109 It was also demonstrated that G2-G4 PAMAM -NH2 dendrimers modified with 
lauroyl chloride was able to decrease toxicity of cationic dendrimers as well as increase 
transport across Caco-2 cells via transcellular and paracellular routes.110 
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Understanding internalization pathways and cellular trafficking can in the specific 
cell type of interest had important implications in choosing and designing correct type of 
nanocarrier and drug-nanocarrier conjugation. This has been demonstrated with the 
efficacy of methotrexate (MTX) conjugated to cationic vs anionic dendrimers. Anionic-
MTX dendrimers were 25 times more efficacious then cationic-MTX dendrimers in which 
there higher localization and increased residence time in lysosomes was seen for anionic-
MTX dendrimers.47  Therefore, designing the correct dendrimer system, conjugation 
between therapeutic and dendrimer, and route of delivery must all be coordinated in order 
to achieve the highest efficacy.  
Recent advances in dendrimers has also been established by formation of 
dendrimers formed from polyester-based materials. Bis-MPA polyester dendrimers, first 
described by Ihre, et al.,161 and have been shown to provide an alternative dendrimer 
compared to PAMAM as demonstrating decreased toxicity compared to G4 PAMAM 
dendrimers, as well as providing a more biodegradable and biocompatible option. We 
have previously demonstrated that the use of Bis-MPA polyester dendrimers and 
PEGlyated bis-MPA dendrimers demonstrating decreased internalization and increased 
transport of dendrimers across Calu-3 epithelium as seen with PAMAM dendrimers.164, 
287 The increased interest in multifunctionality has expanded the pursuit of asymmetric or 
heterobifunctional dendrimers.40 However, little is known on the internalization pathways 
and cellular trafficking of such heterobifunctional dendrimers and how this can influence 
drug release and overall efficacy in vitro and in vivo.   
Considering these aspects, the goal of this study was to synthesize dendrons 
containing different surface chemistries that could potential alter cellular internalization 
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and cellular trafficking, which attached with drug could influence overall efficacy of drug-
polymer conjugate. Here we modified Generation 5 Bis-MPA polyester dendrons with 
various modifications to change surface chemistry including cationic amine-terminated (-
NH2), anionic carboxy-terminated (-COOH), neutral hydroxy-terminated (-OH), 
hydrophilic PEGylated (-PEG), and hydrophobic lauryl-modified (-LA) functionalities. The 
chemical synthesis and characterization of all modified dendrons were established.  
5.2 Materials and Methods   
5.2.1 Materials 
32 hydroxyl, 1 azide, generation 5, 95% (N3-G5-OH), succinic anhydride (SA), 
glutaric anhydride (GA), 2,5-dihydoxybenzoic acid (DHB), were purchased form Sigma-
Aldrich (St Louis, MO, USA). N,N-Diisopropylethylamine (DIPEA) was purchased from 
TCI Co., Ltd. (Tokyo, Japan). Dichloromethane (DCM), hexane, dimethylformamide 
(DMF), dimethyl sulfoxide (DMSO), ethyl ether (Et2O), and methanol (MeOH) were 
purchased from VWR International (Radnor, PA, USA). 1-dodecanol (lauryl alcohol, LA), 
1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), 4-
(Dimethylamino)pyridine (DMAP), N,N-Dimethylformamide (DMF), anhydrous, 99/8+%, 
6-(Boc-amino)hexanoic acid (AHA-Boc), and 4M Hydrogen chloride in 1,4-dioxane was 
purchased from Alfa Aesar (Haverhill, MA, USA). Dimethyl Sulfoxide-D6 (with TMS - 0.03 
vol%), Methanol-D4, and magnesium sulfate anhydrous were purchased from EMD 
Millipore (Burlington, MA, USA). Deuterium Oxide (D2O, 99.9%) was purchased from 
Cambridge Isotope Laboratories, Inc. (Tewksbury, MA, USA). Poly(ethylene)glycol 1000 
monomethyl ether (PEG) was purchased from Fluka (Mexico City, Mexico).  
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5.2.2 Conjugation of lauryl alcohol (LA) with succinic anhydride (SA) form lauryl-
succinic acid (LA-SA) 
Lauryl alcohol (LA) was modified to contain carboxyl group by addition of succinic 
anhydride (SA) for form LA-SA product. 1.205 ml (5.37 mmol) of LA was reacted with 
1.07727 g (10.77 mmol) of succinic anhydride (SA) with 3.651 ml (21.47 mmol) of N,N-
Diisopropylethylamine (DIPEA) in a mixture of  11 ml DCM/DMF (6:5, v/v) at room 
temperature for 24 h. The solvents were removed, and product was redissolved in 50 ml 
ethyl ether followed by extraction with hexane. The hexane was removed by rotary 
evaporation (Buchi Rotavapor® R-3) (40°C) to obtain white/pink crystal product. The LA-
SA product was characterized with MALDI-TOF (Voyager-DE PRO, JBI Scientific) and 1H 
NMR (Bruker NanoBay Avance III 400 MHz NMR spectrometer). 
5.2.3 Conjugation of LA-SA to Azido-G5-OH (N3-G5-OH) dendron to form Azido-G5-
LA  
N3-G5-LA was synthesized by addition of 16.82 mg (4.49 µmol) of polyester bis-
MPA dendron – 32 hydroxyl, 1 azide, generation 5, (N3-G5-OH) with 26.05 mg (90.95 
µmol) of LA-SA, 27.12 mg (141.46 µmol) of EDC, and 16.79 mg (137.43 µmol) of DMAP 
in 3 ml of DMF and left to stir at room temperature for 3 days. The DMF solvent was 
removed by high vacuum. The product was redissolved in 1 ml of DMSO and put on 
dialysis against DI water for 24 h using Spectra/Por® 7 RC membrane dialysis tubing 
(MWCO = 1 kDa). The product was removed from dialysis tubing adding a small amount 
of DMSO. The DMSO solvent was removed by high vacuum to obtain sticky clear product. 
The N3-G5-LA product was characterized using MALDI-TOF, 1H NMR and Light 
Scattering (Malvern Zetasizer Nano ZS).  
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5.2.4 Conjugation of polyethylene glycol (PEG) with succinic anhydride to form 
PEG-SA  
  5.44 g (5.44 mmol) of Poly(ethylene)glycol 1000 monomethyl ether (PEG) was 
modified by addition of 1.08172 g (10.81 mmol) of SA with 3.671 ml (21.07 mmol) of 
DIPEA in 2.5 ml of DMF and stirred at room temperature for 24 h to form PEG-SA. PEG-
SA product was then precipitated in 70 ml of cold ethyl ether followed by suction filtration. 
The precipitated product was then dissolved in 75 ml of acidic water (pH 3.0) and 
extracted with dichloromethane (DCM), 3 x 50 ml. The collected DCM with PEG-SA 
product was dried over anhydrous magnesium sulfate overnight, followed by filtration and 
removal of DCM solvent by rotary evaporation (40°C). The PEG-SA product was 
redissolved in DI water, frozen, and lyophilized to obtain white crystal. The PEG-SA was 
characterized by MALDI-TOF and 1H NMR. 
5.2.5 Conjugation of succinic anhydride (SA) to N3-G5-OH to form N3-G5-SA 
10.08 mg (2.69 µmol) of Polyester bis-MPA dendron – 32 hydroxyl, 1 azide, 
generation 5, (N3-G5-OH) was added with 295.27 mg (268.43 µmol) of PEG-SA catalyzed 
by 86.46 mg (450.99 µmol) of EDC and 50.82 mg (415.98 µmol) of DMAP in 3.8 ml of 
DMF and allowed to react at room temperature for 5 days. The DMF solvent was removed 
by high vacuum followed by dialysis against DMSO using Spectra/Por® 7 RC membrane 
dialysis tubing (MWCO = 8 kDa) for 24 hours. The excess DMSO was removed by high 
vacuum to leave sticky clear product. The N3-G5-PEG product was characterized with 
MALDI-TOF, 1H NMR, and Light Scattering. 
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5.2.6 Conjugation of Boc-6-Ahx-OH to N3-G5-OH dendron followed by Boc 
deprotection to form N3-G5-NH2 dendron 
Amine modification of dendron was synthesized by addition of 10.56 mg (2.82 
µmol) N3-G5-OH dendron with 52.73 mg (227.98 µmol) 6-(Boc-amino)hexionic acid 
(AHA-Boc), 66.61 mg (347.45 µmol) of EDC, and 44.98 mg (368.18 µmol) of DMAP in 
5.1 ml in DMF and allowed to react for 9 days at room temperature. The DMF solvent was 
subsequently removed by high vacuum without further purification. The Boc deprotection 
was performed by addition of 1 ml of 4 M HCl in 1,4-dioxane for 30 min at room 
temperature. The solvent was then removed by rotary evaporation followed by dialysis 
against DMSO using Spectra/Por® 7 RC membrane dialysis tubing (MWCO = 1 kDa) for 
2 days. After dialysis, the DMSO solvent was removed by high vacuum to leave sticky 
clear product. The N3-G5-NH2 product was characterized by MALDI-TOF, 1H NMR and 
Light Scattering.  
5.3 Results 
5.3.1 Conjugation of lauryl alcohol (LA) with succinic anhydride (SA) form lauryl-
succinic acid (LA-SA) 
 Lauryl alcohol (LA) was modified with succinic anhydride (SA) to form LA-SA as 
seen in Scheme 5.1.  
Scheme 5.1. The modification of LA to contain -COOH group by addition of succinic 
anhydride (SA) to form LA-SA. 
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The characterization of LA-SA with 1H NMR and MALDI-TOF can be found in Figure 4.1. 
LA-SA: 1H-NMR (MeOD, 400MHz, ppm): δ 4.08 (t, 2H), 2.58 (s, 4H), 1.63 (m, 2H), 1.30 
(s, 18H), 0.90 (t, 3H). MALDI-TOF MS: 309.7.  
 
 
5.3.2 Conjugation of LA-SA to Azido-G5-OH (N3-G5-OH) dendron to form Azido-G5-
LA 
LA-SA was added to the surface of N3-G5-OH dendron to form N3-G5-LA as seen 
in Scheme 5.2. 
Figure 5.1. A) Chemical structure of LA and LA-SA and the corresponding B) 
1
H NMR 
and C) MALDI-TOF spectra.  
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The characterization of N3-G5-LA with 1H NMR and MALDI-TOF can be found in Figure 
5.2. N3-G5-LA: 1H-NMR (DMSO-d6, 400MHz, ppm): δ 4.10-3.43 (m, 170H), 2.37-2.22 
(m, 48H), 1.68-1.53 (m, 32H), 1.24 (s, 216H), 1.19-1.04 (m, 92H) 0.85 (t, 36H).  MALDI-
TOF MS: 6965.5. LS ζ-potential: +27 ± 6 mV 
 
5.3.3 Conjugation of polyethyleneglycol (PEG) with succinic anhydride to form 
PEG-SA. 
Poly(ethylene) glycol monomethyl ether (PEG, MW:1000) modified with succinic 
anhydride (SA) to form PEG-SA as seen in Scheme 5.3. 
Scheme 5.2. The modification of N3-G5-OH dendron to contain lauryl surface by 
addition of LA-SA to form N3-G5-LA; Azido = N3. 
Figure 5.2. A) Chemical structure of N3-G5-OH and N3-G5-LA, and the corresponding 
B) 
1
H NMR and C) MALDI-TOF spectra.  
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The characterization of PEG-SA with 1H NMR and MALDI-TOF can be found in Figure 
5.3. PEG-SA: 1H-NMR (D2O, 400MHz, ppm): δ 4.28 (m, 2H), 3.69 (s, 172H), 3.37 (s, 
32H), 2.69 (s, 4H).  MALDI-TOF MS: 1123.6.  
 
5.3.4 Conjugation of PEG-SA to N3-G5-OH to form N3-G5-PEG dendron 
PEG-SA was added to the surface of N3-G5-OH dendron to form N3-G5-PEG as 
seen in Scheme 5.4. 
Scheme 5.3. The modification of PEG to contain -COOH group by addition of SA to 
form PEG-SA. 
Figure 5.3. A) Chemical structure of PEG and PEG-SA, and the corresponding B) 
1
H 
NMR and C) MALDI-TOF spectra.  
130 
 
 
 
 
The characterization of N3-G5-PEG with 1H NMR and MALDI-TOF can be found in Figure 
5.4. N3-G5-PEG: 1H-NMR (DMSO-d6, 400MHz, ppm): δ 4.31-4.11 (m, 133H), 3.51 (s, 
2580H), 3.24 (s, 245H), 2.51 (m, 60H), 1.24 (s, 216H), 1.16-1.00 (m, 92H). MALDI-TOF 
MS: 20277.1. LS ζ-potential: -13 ± 4 mV. 
 
5.3.5 Conjugation of succinic anhydride (SA) to N3-G5-OH to form N3-G5-SA 
Succinic anhydride (SA) was added to the surface of N3-G5-OH dendron to form 
N3-G5-SA as seen in Scheme 5.5. 
Scheme 5.4. The modification of N3-G5-OH with PEG by addition of PEG-SA to form 
N3-G5-PEG. 
Figure 5.4. A) Chemical structure of N3-G5-OH and N3-G5-PEG, and the 
corresponding B) 
1
H NMR and C) MALDI-TOF spectra.  
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The characterization of N3-G5-SA with 1H NMR and MALDI-TOF can be found in Figure 
5.5. N3-G5-SA: 1H-NMR (DMSO-d6, 400MHz, ppm): δ 4.19.-4.12 (m, 129H), 2.52-2.41 
(m, 128H), 1.59-1.33 (m, 8H), 1.20-1.14 (m, 92H). MALDI-TOF MS: 6960.6. LS ζ-
potential: -30 ± 8 mV. 
 
5.3.6 Conjugation of Boc-6-Ahx-OH to N3-G5-OH dendron followed by Boc 
deprotection to form N3-G5-NH2 dendron 
Scheme 5.5. The modification of N3-G5-OH to contain -COOH surface by addition of 
SA to form N3-G5-SA. 
Figure 5.5. A) Chemical structure of N3-G5-OH and N3-G5-SA, and the corresponding 
B) 
1
H NMR and C) MALDI-TOF spectra.  
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Boc-6-Ahx-OH was added to the surface of N3-G5-OH dendron to form N3-G5-Boc 
followed by subsequent Boc deprotection to form N3-G5-NH2 as seen in Scheme 5.6. 
 
The characterization of N3-G5-NH2 with 1H NMR and MALDI-TOF can be found in Figure 
5.6. N3-G5-NH2: 1H-NMR (DMSO-d6, 400MHz, ppm): δ 4.18.-4.04 (m, 108H), 3.51-3.41 
(m, 14H), 2.74-2.73 (m, 52H), 2.37-2.27 (m, 52H), 1.59-1.47 (m, 108H) 1.32-1.31 (m, 
56H), 1.19-0.96 (m, 92H). MALDI-TOF MS: 6685.9. LS ζ-potential: +48 ± 7 mV.  
 
 
Scheme 5.6. The modification of N3-G5-OH to contain -NH2 surface by addition of A) 
AHA-Boc followed by B) Boc deprotection to form N3-G5-NH2. 
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5.4 Discussion 
 Recently, the versatility and complexity of dendrimer synthesis has been explored 
for various biological and drug delivery applications.39-41 Bis-MPA polyester dendrimers 
have emerged as an alternative improvement on other dendrimers such as PAMAM 
dendrimers by being biodegradable via hydrolysis (not seen with PAMAM) and more 
biocompatible (less toxic and less immunogenic).38 Heterobifunctional (AKA bow-tie, 
Janus-type) asymmetric Bis-MPA polyester dendrimers have gained interest due to their 
multifunctionality.45, 167 However, the major drawback remains the complexity of synthesis 
in such type of systems.167 In this study, we present here a facile way of modifying the 
surface of Azido-G5-OH polyester Bis-MPA dendrons with various surface modifications: 
-COOH (anionic), -NH2 (cationic), hydrophilic (-PEG), hydrophobic (-Lauryl), and 
unmodified neutral (-OH).  
Figure 5.6. A) Chemical structure of N3-G5-OH and N3-G5-Boc, and N3-G5-NH2, and 
the corresponding B) 
1
H NMR and C) MALDI-TOF spectra.  
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Here, successful synthesis and characterization of the surface modifications N3-
G5-OH polyester Bis-MPA dendrons are described and characterized. A summary of 
overall modifications is described in Table 5.1.  
Table 5.1. Characterization of modified Azido-G5-OH dendrons *MW based on 
MALD-TOF results.  
Dendron Group # Modified MW (g/mol)* ζ potential  
(mV) 
N3-G5-OH -OH (hydroxyl) 32 3742.8 +31 ± 6 
N3-G5-SA -COOH (carboxyl) 32 6959.4 -30 ± 8 
N3-G5-NH2 -NH2 (amine) 26 6685.9 +48 ± 7 
N3-G5-PEG -PEG 15 20277.1 -13 ± 4 
N3-G5-LA -lauryl 12 6966.6 +27 ± 6 
 
The neutral N3-G5-OH remained unmodified from the company it was purchased with 32 
-OH surface groups available for attachment. Surface charge measured by LS was found 
to be positively charged, mainly due to the presence of the azido group (-N3). Once 
conjugated to other dendron to form dendrimer, without presence of azido, a decrease in 
surface charge more towards neutral is expected, which was seen when two dendrons 
were conjugated to form -OH dendrimer when overall dendrimer became negatively 
charged (Appendix 5 -Section C5). All bonds within the polyester dendron as well as 
surface modifications are linked by ester groups. This maintains the biodegradability of 
the dendrons via hydrolysis. However, the hydrolysis of dendrons may be affected by the 
presence of various surface groups, as was seen in PEGylation of TMPG4OH polyester 
dendrimers, in which the degradation was delayed from starting after 5 hours for 
TMPG4OH and delayed to 5 days at physiological conditions (pH = 7.4, 37°C),164 and 
can have large implications in terms of stability in vivo. However, to this date, no polyester 
dendrimer degradation profile has been measured in vivo demonstrating a need for 
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further investigation.  Of the modifications an anionic carboxyl group (-COOH) was 
modified to the surface to all available 32 surface groups. The surface charge measured 
by LS demonstrates an overall negative charge, a reversal seen from unmodified 
dendron, and can represent an anionic surface modification. An amine (-NH2) modified 
dendrimer was also successfully attached to the N3-G5-OH dendron to form N3-G5-NH2. 
Of the 32 groups available, 26 groups were modified to amine. A positive surface charge 
was measured by LS and proved to be larger than that of unmodified N3-G5-OH dendron, 
demonstrating an overall positive surface charge providing a cationic surface, which is 
believed to be maintained after the conjugation of dendron to form an asymmetric 
dendrimer. To provide hydrophilic and hydrophobic surfaces, the N3-G5-OH dendron was 
modified with PEG and lauryl groups, respectively. N3-G5-PEG had a modification of 15 
of the surface groups while lauryl had a surface modification of around 12 of the surface 
groups. The surface charge for N3-G5-PEG became overall negatively-charged (Table 
4.1). It was expected to provide a more neutral charge to dendron as PEG has proven to 
do so previously.164 The presence of some negative charge may be due to the fact of a 
small presence of PEG-SA, in which SA itself containing carboxyl group may be 
attributing to the negative charge measured from LS. The surface charge for the N3-G5-
LA was positively charged, however, slightly less than N3-G5-OH dendron and not overall 
statistically different. Therefore, the presence of LA did not affect the overall surface 
charge of the dendron. Overall, the various surface modifications represent different 
surface properties, which has been shown to affect cellular internalization and cellular 
trafficking of various dendrimers before.47 
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These surface modifications have implications on drug delivery by altering the 
cellular internalization and cellular trafficking into cells.47 Depending on the cell type and 
surface modification on dendron, varied cellular internalization pathways as well as 
cellular trafficking can occur. This can influence efficacy of drug conjugated to polymer 
systems in which the type of linker containing a liable bond between drug and polymer 
can be effectively broken. Such linkers include peptide bonds and pH-sensitve bonds (cis-
aconityl, hydrazine, acetal).186 These linkers need to be internalized and trafficked to 
correct location in order to have optimal linker breakage and controlled release of the 
drug. Also, implications on cell type and route of administration can play a huge role in 
drug efficacy and need to be tailored for specific drug delivery applications.36, 47 
With the success in surface modifications on N3-G5-OH have been established, a 
drug conjugation to another dendron using a linker will have to take place. In this case, 
the use of doxorubicin (DOX) as our model drug will be linked to the Acet-G5-OH Bis-
MPA polyester dendrons using a small peptide linker between the dendron and DOX for 
enzymatically controlled release. A chemical scheme strategy for modifications has been 
proposed (Schemes C1-C4). A peptide linker Gly-Phe-Leu-Gly (GLFG) was chosen to be 
at cleavable linker between DOX and Acet-G5-OH. This GFLG linker strategy has been 
utilized for DOX conjugation to polymer previously.299, 300 GLFG linker is enzymatically 
degraded by protease cathepsin B,186 which and upregulated in many cancerous 
tumors.301 They are expressed constitutively, and the protein and mRNA levels has been 
found localized in perinuclear vesicles (lysosomes) and vesicles in the cytoplasm and cell 
periphery where its main function is to assist in cell degradation processes associated 
with tumor proliferation, invasion, and metastasis.301 Therefore, once internalized into 
137 
 
 
 
cells, the bond between the DOX can be released by enzymatic degradation of GFLG 
peptide, allowing for controlled release of the DOX. We currently have formulated GFLG-
DOX in which synthesis and characterization can be found in Appendix C – Sections C2 
and C3. Modification of Acet-G5-OH dendron was also required for formation of -COOH 
surface functionality. This -COOH allows for amide formation between the dendron and 
GFLG-DOX, which has also been synthesized and characterized (Appendix C – Section 
C4, Scheme C3. Therefore, the conjugation between the acet-G5-GA and GFLG-DOX 
has been proposed (Scheme C4). The potential of this conjugation scheme has been 
tested on a G4 carboxyl-terminated PAMAM dendrimer with success. A matter of 
upscaling GFLG-DOX product remains the limiting factor. 
Another question to consider is the formation of the asymmetric dendrimers from 
GFLG-DOX containing dendron and the dendrons modified with various surface 
modalities. Each dendron contains an acetylene and azide group, which can be 
conjugated through Azide/Alkyne cycloaddition click chemistry.168 A modification of the 
chemistry proposed by Ackermann, et al.302 was tested between Acet-G5-OH and N3-
G5-OH dendrons. Due to the steric hindrance of these two molecules, modifications in 
the protocol were required to increase yield of dendrimer formation from dendrons and 
size exclusion chromatography allowed for successful purification of dendrimer formed 
from dendrons (Appendix C – Section C5, Scheme C5, Figure C2). This strategy can be 
applied to connect GFLG-DOX containing dendron and the dendrons modified with 
various surface modalities. The limitations may occur based on difficulty in chemistry 
involved in these reactions to from asymmetric dendrons, which remains the main 
challenge for this type of dendrimer formation for drug delivery. However, the potential 
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benefits may be elucidated once these asymmetric dendrimers can be tested in vitro and 
in vivo.  
5.5 Conclusions 
 The potential benefits from formation of asymmetric dendrimers for drug delivery 
needs to be further explored, especially in terms of cellular internalization and cellular 
trafficking, pharmacokinetics and pharmacodynamics of such systems and how it can 
influence drug efficacy. The largest challenge in formation of asymmetric dendrimers is 
the synthesis of such complex polymers.45 Here, we proven a facile way to modify the 
surface of N3-G5-OH Bis-MPA polyester dendrons with varying surface groups with 
different surface characteristics. The addition of DOX conjugated through GFLG linker to 
acet-G5-OH dendron has been proposed and use of click chemistry and size exclusion 
chromatography to form asymmetric dendrimers has been tested. The potential in such 
asymmetric dendrimers remains to be elucidated in order to optimize drug efficacy.  
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CHAPTER 6 – LOCALLY ADMINISTERED IMMUNOMODULATORS FOR 
MACROPHAGE REPOLARIZATION AND COMBINATION CHEMOTHERAPY FOR 
THE TREATMENT OF LUNG CANCERS  
 
6.1 Introduction 
 Tumor associated macrophages (TAMs) are the most abundant cell-type besides 
cancerous cells found within the tumor microenvironment (TME), and are known to 
influence tumor initiation, growth, and metastasis.80, 81 TAMs are derived from circulating 
monocytes and preclinical studies have demonstrated enhanced therapeutic 
performance when TAMs entry to TME is blocked or when TAM phenotype is 
manipulated.81 TAM phenotypes are seen as a continuous spectrum, however, can be 
classified into two opposing types: M1 and M2. M1 TAMs are known as classically 
activated macrophages and are known to be antitumor, proinflammatory, and 
immunostimulatory.81 M2 TAMs are known to be protumor, anti-inflammatory, 
immunosuppressive, and proangiogenic.80, 81 The presence of M2 TAMs are found in 
early stages of tumors as well as the metastatic stages, and especially in cases when 
tumors have been treated with chemotherapeutics.20, 81 Many preclinical and clinical 
studies have demonstrated that TAM density, and more specifically small M1/M2 ratios 
(high density of M2), is correlated with poor prognosis, which has lead TAMs to be an 
attractive therapeutic target in many cancer types.81, 222 Resistance to therapy can be 
correlated with M2 TAM presence, and is known to inhibit tumor response mediated by T 
cells, promotes tumor proliferation, progression, invasion, metastasis, and 
angiogenesis.20, 80 
 Macrophage polarization is critically controlled by the colony-stimulating factor 1/ 
colony-stimulating factor 1 receptor (CSF1R/CSF1R) signaling process.20, 80 
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CSF1/CSF1R signaling promotes proliferation and recruitment to tumors of myeloid cells 
and differentiation of these myeloid cells into M2 TAMs.82 The CSF1R+ macrophages 
have been correlated with poor survival in several tumor types.20 The inhibition of CSF1R 
by has been recently tested preclinically and clinically demonstrating selective reduction 
of M2 TAMs or polarization of M2 TAMS to M1 phenotype.80, 222 An increase in M1/M2 
ratio by increasing M1 phenotype and/or decreasing M2 phenotype has shown improved 
efficacy in cancer treatment, alone or in combination with other therapies, extending 
survival in many types of cancer.222  
There are a range of antibodies and small molecules known to target and inhibit 
CSF1R. These include monoclonal antibodies (RG7155, IMC-CS4) that inhibit the 
extracellular domain and small molecule inhibitors (CY11645, GB2580, BLX945, 
PLX5622, PLX3397) that inhibit the intracellular kinase domains of CSF1R.222 Despite 
the success of antibody treatments, they remain highly costly, which limit potential benefit 
and usage.303 Therefore, the use of small molecules has become an attractive choice for 
CSF1Ri. Of these, the one currently commercially available and is currently undergoing 
numerous clinical trials is PLX3397.20 
 PLX3397 (PLX) is an example of a small molecule inhibitor of CSF1R (CSF1Ri). 
PLX is a tyrosine kinase inhibitor, when given orally, and demonstrated increased efficacy 
in treatment preclinically82, 225 and is currently undergoing clinical trials.20, 80 PLX prevents 
intracellular phosphorylation of CSF1R on kinase domains, thus inhibiting CSF1R 
activation.222, 225 The inhibition of CSF1R thus repolarize M2 TAMs to M1 and/or 
selectively reduce M2 TAMs, thus increasing overall M1/M2 ratio.83 PLX has been used 
a monotherapy as well as in combination with chemotherapeutics, irradiation, anti-
141 
 
 
 
angiogenic therapies, and other immunotherapies for treatment of variety of tumors 
including breast and lung tumors.20, 82 The prevalence of PLX in clinical trials as a 
monotherapy and in combination with other treatments demonstrates its potential as a 
immunomodulator influencing TAMs within the TME.  
Of these, the combination of PLX with doxorubicin (DOX) remains of interest. DOX 
is a common chemotherapeutic that is administered patients who have metastatic form 
of breast cancer and delivered intravenously (IV).71 However, DOX has limitations in 
terms of clinical benefit including limited aqueous solubility, rapid elimination from blood 
circulation, and severe cardiomyopathy.304-306 Despite these issues with DOX, 
conjugation to polymeric nanocarriers such as polyamidoamine dendrimers (PAMAM) 
can overcome some of these limitations by enhancing drug solubility, enhance 
pharmacokinetics and pharmacodynamics, and  reduce unwanted side effects.34, 36 
Recently, our group has investigated the potential of conjugation of DOX to PAMAM 
dendrimer (DDOX) and its pulmonary delivery, demonstrating controlled drug release, 
increased efficacy to treat secondary lung tumors from B16F10 murine metastatic 
melanoma, increased drug dose to target site, and reduced cardiotoxicity.77 Therefore, 
the testing of DDOX and PLX in combination was by pulmonary administration (PA) may 
provide a synergetic effect and increase overall treatment efficacy.  
Consequently, the efficacy of PLX alone or in combination remains to be explored. 
The combination of PLX with DOX and DDOX has not been tested for synergistic 
interactions. The use of PLX given via other routes besides oral has also not been 
evaluated. Therefore, this study was conducted to investigate the potential synergistic 
effect of PLX with DOX/DDOX for treatment of lung tumors metastasized from metastatic 
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breast cancer to the lungs (secondary lung tumors) upon pulmonary administration. 
Efficacy of PLX alone or in combination when administered intravenously (IV) was also 
evaluated as control. The treatments (PLX, DOX, and DDOX) were tested in vivo on 4T1-
induced lung metastases established in female BALB/C mice. This, thus represents an 
immune competent syngeneic model. Preliminary results investigating the effectiveness 
of treatment strategies was evaluated and, and modulation of macrophages from M2 to 
M1 phenotypes are reported here. These studies are ongoing in our laboratories to fully 
assess the potential of TAM reprograming agents and combination with chemotherapy 
(immunochemotherapies) in combination with pulmonary administration as well as with 
the use of nanotechnologies to enhance the performance of these therapies. 
6.2 Materials and Methods   
6.2.1 Materials 
 Penicillin/Streptomycin Solution was purchased from Gemini Bio-Products (West 
Sacramento, CA, USA). Puromycin Dihydrochloride, Powder (Corning®), Dulbecco's 
Modification of Eagle's Medium (DMEM), Corning®, 4.5 g/L glucose, L-glutamine [-] 
sodium pyruvate, N-methylmorpholine (NMM), isobutyl chloroformate (IBCF), anhydrous 
dimethyl sulfoxide (DMSO), dimethylformamide (DMF), and methanol (MeOH) were 
purchased from VWR International (Radnor, PA, USA).  Fetal Bovine Serum (FBS), USA 
Origin, was purchased form Serum Source International (Charlotte, NC, USA). 
Generation four, succinamic acid, poly(amidoamine) (PAMAM) dendrimer (G4-SA) 
provided in water was purchased from Dendritech Inc. (Midland, MI). D-luciferin 
Potassium Salt was purchased form Syd Labs. (Natick, MA, USA). Doxorubicin 
hydrochloride salt (DOX•HCl) was purchased from LC Laboratories (Woburn, MA, USA).  
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Pexidartinib (PLX3397, PLX) was purchased form Chemgood (Glen Allen, VA, USA). 
Tert-Butyl carbamate (TBC), trifluoracetic acid (TFA), triethylamine (TEA), 2,5-
dihydroxybenzoic acid (DHB), and Tween #80 was purchased from Sigma Aldrich (St 
Louis, MO, USA). Dimethyl Sulfoxide-D6 (with TMS - 0.03 vol%) and magnesium sulfate 
anhydrous were purchased from EMD Millipore (Burlington, MA, USA). Spectra/Por® 7 
RC membrane dialysis tubing (MWCO = 3 kDa) was purchased from Spectrum 
Laboratories, Inc. (Rancho Dominguez, CA, USA). Amicon Ultra-15 centrifugal filter 
(NMWL = 3,000) was purchased from MilliporeSigma (Burlington, MA, USA). Thin layer 
chromatography (TLC) silica gel 60 F254 purchased from Merck KGaA (Darmstadt, 
Germany). 
6.2.2 Synthesis and Characterization of G4SA-hyd-DOX (DDOX)  
The synthesis and characterization of doxorubicin conjugated to G4SA PAMAM 
dendrimer (1 mol eqv) to form was described in detail, previously.77 Breifly, G4SA (3.80 
µmol) was mixed with NMM (1.07 mmol)  and IBCF (1.02 mmol) in a mixture of 
DMSO/DMF (10/90, v/v) at 0°C for 5 min before the addition of TBC (0.243 mmol), in 
which the reaction was kept at 0°C for an additional 30 min followed by continuation of 
the reaction at room temperature for 48 h. The DMSO/DMF solvent mixture was removed 
under high pressure and product was redissolved in 0.1 M Phosphate buffer (pH = 10.00) 
followed by deionized (DI) water and purified using Amicon Ultra-15 centrifugal filter to 
form G4SA-TBC. The G4SA-TBC product was frozen and lyophilized. The removal of Boc 
groups from TBC occurred by addition of G4SA-TBC in TFA/DCM (80/20, v/v) stirred at 
0°C for 30 min. The solvents were again removed, and product was purified by 
redissolving it in 0.1 M Phosphate buffer (pH = 10.00) followed by DI water and purified 
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using Amicon Ultra-15 centrifugal filter. The water was removed by freezing and 
lyophilizing the product – G4SA-hyd. The addition of DOX (34.48 µmol) was done by 
dissolving G4SA-hyd (1.05 µmol) in with DOX in methanol and using TFA (16 mol eqv) 
as acid catalyst. The reaction was allowed to occur for 24 hours followed by removal of 
methanol solvent, redissolved in water, and purified by Amicon Ultra-15 centrifugal filter. 
The final G4SA-hyd-DOX (DDOX) product was frozen and lyophilized to obtain sticky red 
product. The product was fully characterized by MALDI-TOF (Voyager-DE PRO, JBI 
Scientific) and 1H NMR (Bruker NanoBay Avance III 400 MHz NMR spectrometer). 
6.2.3 Cell Culture 
Mouse stage IV breast cancer cell line (4T1) was kindly gifted by Dr. Arun Rishi 
from Oncology Department in School of Medicine at Wayne State University. 4T1 cells 
were grown on 75 cm2 cell culture flasks (Corning®) in DMEM medium supplemented with 
10% FBS and 1% antibiotics (AB) (100 U/mL Penicillin and 100 µg/mL Streptomycin) and 
cultured at 37°C with 5% CO2. 4T1-luc-tdTomato cells were also grown on 75 cm2 cell 
culture flasks (Corning®) in DMEM + 10% FBS + 4 µg/ml puromycin and cultured at 37°C 
with 5% CO2. 
6.2.4 Animals for In Vivo Experiments 
Female BALB/C mice (8-10 weeks, 16-20 g) mice were purchased by Jackson 
Laboratory (Bar Harbor, ME, USA). Male and Female BALB/C mice (3-4 weeks) were 
also purchased from Jackson Laboratory and bred at Massey Cancer Center at Virginia 
Commonwealth University. Purchased or bred female BALB/C mice (8-10 weeks) were 
used for further study. The mice were housed in 12 h light/dark cycles with food and water 
provided ad libitum and acclimatized a minimum of one week prior to any experiment 
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performed. All animal experiments were performed in accordance with guidelines 
established by Institutional Animal Care and Use Committee at Virginia Commonwealth 
University.  
6.2.5 Transformation of 4T1 Cells to Express tdTomato Fluorescence and 
Luciferase Bioluminescence.  
 To determine the minimum concentration required to kill all 4T1 cells, a Puromycin 
cell kill curve was performed following the protocol by DharmaconTM and measured by 
MTT assay (Molecular Probes). Briefly, 10,000 cells/well of 4T1 cells were seeded into a 
96-well plate (CoStar®, Corning Inc.) and left overnight. The following day, increasing 
puromycin concentrations (0-10 µg/ml) were in DMEM + 10% FBS were exposed to the 
cells for 48 h. After 48 h, medium was removed and 110 µl of 1 mM MTT solution was 
added to each well and incubated for 4 h at 37°C, 5% CO2. 75 µl was removed and 60 µl 
of DMSO was added to each well and incubated at same conditions above for an 
additional 10 minutes. Subsequently, the absorbance was measured at 540 nm using 
Synergy H1 microplate reader (BioTek). Cell viability at each concentration was 
calculated as follows: % Cell viability = (absorbance of treated cells/absorbance of control 
cells) x 100%. 
 4T1 cells were genetically modified to express firefly luciferase and tdTomato 
(bright red fluorescent protein) according to modified protocols from GenTarget307 and 
protocol provided by Dr. Yemelyanov and Dr. Bhalla from Northwestern University. 
Briefly, 25,000 4T1 cells (P14-P15 passages) were seeded in each well a 24-well 
microplate cultured with 500 µL of DMEM+10%FBS+1% AB at 37C and 5% CO2.  The 
following day, 0.833 µl lentivirus containing luciferase and tdTomato expression (1010 
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TU/ml) (pFULT Ubi>Luciferase-2TA-dtTomato, Skin Disease Research Center, 
Northwestern University) was mixed with polybrene (8 µg/ml final concentration) in DMEM 
and mixed at room temperature for 5 min to form viral transduction mixture. 500 µl of viral 
transduction mixture was added to each well after each well was washed one with 1xPBS. 
The plate was then incubated at 37C and 5% CO2 gently rocking overnight. The following 
day, the medium containing the virus was replaced with fresh DMEM +10% FBS+ 1%AB 
for 2.5 h. A new batch of transduction mixture was made and added for an additional 8 
hours and allowed to incubate at 37C and 5% CO2 while gently rocking. The medium 
was then removed and replaced with fresh DMEM+10% FBS+ 1% AB allowed to incubate 
for an additional 72 hours. After the 72 hours, the cells were removed from the 24-well 
microplate and transferred to a T-25 flask with the addition of puromycin-selective 
medium (DMEM + 10% FBS + 4 µg/ml puromycin) to select for only cells that express the 
lentivirus. The cells grew under these conditions until they reached confluency. The 
modified cells were then sorted twice using tdTomato fluorescence expression by 
fluorescence-activating cell sorting (FACS, SC Aria- BD FACSAria™ II High-Speed Cell 
Sorter, Flow Cytometry Shared Resource Core, Virginia Commonwealth University). After 
sorting 4T1-luc-tdTomato cells were cultured in DMEM+10%FBS+1%AB+4 µg/ml 
puromycin. Cells were monitored with flow cytometry before in vivo experiments were 
performed (CytoFLEX Flow Cytometer, Beckman Coulter).  
6.2.6 In Vitro Bioluminescence Kinetics Assay of 4T1-luc-tdTomato cells 
To assess the bioluminescence of transfected 4T1-luc-tdTomato cells, kinetics of 
bioluminescent property was performed in IVIS imaging.  4T1-luc-tdTomato cells were 
seeded in a 96-well microplate at 12,500, 25,000, 50,000 and 100,000 cells per well or at 
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15,625, 31,250, 62,500, 125,000 and 250,000 cells per well in DMEM medium. A final 
concentration of 150 µg/ml of luciferin was added to each well and images were taken at 
0.5, 3, 5, 10, and 20 min using the IVIS imaging system (Xenogen IVIS Spectrum 
Preclinical In Vivo Imaging System, Cancer Mouse Models Developing Shared Resource 
Core, Virginia Commonwealth University). The in vitro kinetics of the bioluminescent 
signal was determined by plotting total flux vs time for each cell concentration.   
6.2.7 Evaluation of 4T1-luc-tdTom Metastatic Growth to the Lungs in Female 
BALB/C mice 
The first study comprised of 100 µl of 1xPBS containing 100,000 4T1-luc-tdTomato 
cells were injected IV into the tail vein of female BALB/C mice (10 weeks of age). The 
tumor growth was monitored in vivo and ex vivo by measurement of bioluminescent signal 
produced by 4T1-luc-tdTomato cells using IVIS imaging system (Xenogen IVIS Spectrum 
Preclinical In Vivo Imaging System, Cancer Mouse Models Developing Shared Resource 
Core, Virginia Commonwealth University). Imaging was performed on days 5, 8, 11, 14, 
and 18 post IV tail vein injection. All animals were sacrificed on Day 18 where ex vivo 
imaging was conducted with the lung tissue. In the second study, 100 µl of 1xPBS 
containing 250,000 4T1-luc-tdTomato cells were injected IV into the tail vein of five female 
BALB/C mice (10 weeks old). The tumor growth was monitored in vivo and ex vivo by 
measurement of bioluminescent signal produced by 4T1-luc-tdTomato cells using IVIS 
imaging system. Imaging was performed on days 5, 7, 9, and 12 days post IV injection. 
One animal was sacrificed on each day where ex vivo imaging was conducted with the 
lung tissue. For the in vivo imaging, D-luciferin (150mg/kg) substrate was added to each 
animal via subcutaneous injection and exposed to isoflurane for 10 min prior to being 
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imaged in the IVIS imaging system. For ex vivo imaging, each lung was soaked in 5-10 
mL 1XPBS containing 300µg/ml of luciferin prior to imaging. StudyLog Desktop was used 
to record and monitor animal health during the experiments. Living Image 4.5.5 Software 
(Perkin Elmer) was used to analyze images. Only analysis of upper portion of mouse was 
analyzed for in vivo images, since establishment of lung tumors was the main interest of 
this study. 
6.2.8 In vivo efficacy of PLX3397 for the treatment of Lung Metastases  
 Female BALB/C mice (8-10 weeks) were injected with 250,000 4T1-luc-tdTomato 
cells in 100 µl of 1x PBS to establish lung metastasis. IVIS imaging (Xenogen IVIS 
Spectrum Preclinical In Vivo Imaging System, Cancer Mouse Models Developing Shared 
Resource Core, Virginia Commonwealth University) was performed starting at 5 days 
post tumor inoculation and continued every other day till day of sacrifice to monitor tumor 
growth in vivo. Prior to treatment, mice were randomized into treatment groups. 
Treatments of (I) vehicle (1xPBS containing 5% Tween and 1% DMSO, v/v); (ii) 1 mg/kg 
of PLX3397 (PLX), (III) free doxorubicin (DOX), or (IV) PAMAM G4SA-hydDOX conjugate 
(DDOX) in vehicle or a combination of (V) 1 mg/kg of DOX and 1 mg/kg of PLX or (VI) 1 
mg/kg of DDOX and 1 mg/kg of PLX was given either intravenously through retroorbital 
injection (90-140 µl) or through pulmonary administration (PA) by intratracheal intubation 
(20-30 µl). DDOX synthesis in characterization has been previously described.127 Mice 
were anesthetized by isoflurane exposure for 5-10 min before either administration was 
conducted. Briefly, for intratracheal intubation, anesthetized mice were laid on their back 
and hung by their incisors with thread on a SurgiSuite Surgical Platform (Mouse 
Endotracheal Intubation Kit, Kent Scientific, Torrington, CT, USA). The angle of the 
149 
 
 
 
mouse throat to the board was placed at 45°. A soft 20 G catheter was inserted into the 
mouse trachea guided by Trans-Tracheal illuminator containing fiber optic cable lighted 
by LED light. Once catheter was inserted into the trachea, the drug solution in vehicle 
was added to catheter, and the mice inhaled the solution into the lungs. Mice were kept 
under anesthesia during the process. All mice were returned to the cage and monitored 
after treatment to ensure no adverse effects from treatment. Treatments was given once 
on days 7, 9, 11 post tumor inoculation for a total of three treatments. The drugs used in 
combination were formulated in one solution and administered together. Mice were 
monitored daily for behavior, food intake, grooming, and body weight. Mice were 
euthanized on day 15 post tumor inoculation. On day the mice were euthanized, in vivo 
IVIS imaging was performed followed by ex vivo IVIS imaging of lungs – in same 
procedure as discussed in section 7.2.6 – and lungs weighed to assess overall lung tumor 
burden.  
6.2.9 Measurement of Macrophage Polarization by Flow Cytometry 
Flow cytometry was utilized to assess the macrophage populations and TAM 
phenotypes (M1/M2) in the lungs. Mouse lungs taken on Day 15 post tumor inoculation 
were diluted in 0.5 ml of Liberase TL Roche (Sigma)/RPMI medium solution and cut into 
pieces in a 15 mL falcon tube. The lungs were then incubated at 37°C for 25 min shaking. 
10 ml of Wash Buffer (RPMI medium + 10% FBS) was added to each tube and samples 
where than filtered using 100 µm filter followed by centrifugation at 350 x g for 5 minutes. 
Sample of extracted cells were then resuspended in 1-2 ml of Wash buffer where cell 
suspension was adjusted to concentration of 1-5 x 106 cells/ml. The cells are then 
centrifuged at 350xg for 3 min and resuspended in 40 µl of FcBlock (2.4G2 sup) with 40 
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µl of 2x antibody dilution and stain is added and incubated on ice for 20 min. 200 µl of 
FACS buffer (1L PBS+ 5g BSA+1ml 0.5M EDTA) was added and centrifuged again at 
350 x g for 3 min, then resuspend the cells in 80-200 µl of FACS buffer and run in samples 
through flow cytometer (The BD LSRFortessa-X20™). The antibody stains included 
CD11b (clone M1/70, eBioscienceTM), F4/80 (clone BM8, BioLegend®), MHC II (clone 
M5/114.15.2, TONBO Biosciences), and CD206 (clone MR5D3, AbD Serotec).  
6.2.10 Statistical Analysis.   
All data is presented as a mean ± standard deviation. One-way or Two-way 
analysis of variance (ANOVA) followed by Tukey’s Multiple Comparison Test was 
performed utilizing GraphPad Prism 7.00 software.  Means were considered statistically 
significant if p < 0.05.  
6.3 Results 
6.3.1 Synthesis and Characterization of G4SA-hyd-DOX (DDOX) 
 The formation of DOX conjugated by carboxyl-terminated PAMAM dendrimer by 
linkage through a hydrazine linker to form G4SA-hyd-DOX (DDOX) was fully described in 
detail, previously.77 The synthetic scheme, 1H NMR, and MALDI-TOF characterization 
can be found in Appendix D – Scheme D1, Figure D1. Each NMR and MALDI-TOF for 
each step in the synthesis is summarized here.  
G4SA-TBC: 1HNMR (DMSO-d6, 400MHz, ppm):  δ 9.52 (s, 32.30H, -NHBoc in 
TBC), 8.67 (s, 29.58H, -NHCO- in TBC), 7.89-7.70 (m, 156.84H, -NHCO- in G4COOH), 
3.06 (m, 372.38H, -CONHCH2- (He) in G4COOH), 2.63-2.56 (m, 328.45H, -NCH2- (Hd) 
and -COCH2CH2CO (Hjr3) in G4COOH), 2.41 (m, 126.38H, -CH2N- (Hb,c) in G4COOH), 
2.29 (m, 150.53H, -CH2CH2CONHNH- (succinic methylene, Hjr2) in G4COOH), 2.18 (m, 
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248.00H, -CH2CO- (Ha) in G4COOH), 1.36 (m, 305.54H, -(CH3)3 in TBC). MALDI-TOF 
m/z (Da): 20531.79.  
G4SA-hyd: 1HNMR (DMSO-d6, 400MHz, ppm): δ 9.02 (s, 19.06H, NH2NHCO- in 
hydrazide), 8.03 (m, 175.56H, -NHCO- in G4COOH), 3.05 (m, 258.24H,  -CONHCH2- (He) 
in G4COOH), 2.620 (m, 188.96H, -NCH2- (Hd) and -COCH2CH2CO- (Hjr3) in G4COOH), 
2.41 (m, 87.18H, CH2N- (Hb,c) in G4COOH), 2.23 (m, 151.22H, -CH2CONHNH2 (succinic 
methylene (Hjr2) in G4COOH), 2.18 (m, 248.00H, -CH2CO- (Ha) in G4COOH). MALDI-
TOF m/z (Da): 17780.33.  
G4SA-hyd-DOX (DDOX): 1HNMR (DMSO-d6, 400MHz, ppm): δ 9.02 (s, 20.41H, 
NH2NHCO- in hydrazide), 8.05 (m, 167.13H, -NHCO- and Ar-H in G4COOH and DOX), 
5.26 (s, 11.99H, -CH- in DOX), 4.89 (d, 12.72H, -CH- in DOX), 4.570 (m, 24.72H, -CH2OH 
in DOX), 4.17 (s, 11.02H, -CH- in DOX), 3.94 (s, 35.23H, -OCH3 in DOX), 3.05 (m, 
255.54H,  -CONHCH2- (He) in G4COOH), 2.620 (m, 217.26H, -NCH2- (Hd) and -
COCH2CH2CO- (Hjr3) in G4COOH), 2.41 (m, 109.82H, CH2N- (Hb,c) in G4COOH), 2.29 
(m, 152.93H, -CH2CONHNH2 (succinic methylene (Hjr1, jr2) in G4COOH), 2.18 (m, 
248.00H, -CH2CO- (Ha) in G4COOH), 1.86 and 1.65 (d, 23.96H, -CH2- in DOX), 1.12 (s, 
36.10H, -CH3 in DOX). MALDI-TOF m/z (Da): 23860.59. The resulting DOX loading in 
the DDOX was as 22% w/w, conjugation of on average 11 DOX per dendrimer. 
6.3.2 Transformation of 4T1 Cells to Express tdTomato Fluorescence and 
Luciferase Bioluminescence  
 4T1 murine mammary carcinoma cells (animal model for stage IV human breast 
cancer) were transformed to contain tdTomato fluorescence to track cells via flow 
cytometry and luciferase bioluminescence to track tumor cells in vivo using a lentivirus 
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that contained puromycin resistance. Firstly, a puromycin kill curve (Figure D2) was 
conducted to find the minimum concentration to kill all 4T1 cells that would not contain 
puromycin resistance (4T1-WT). It was found that a minimum of 4 µg/ml was required to 
kill all 4T1-WT cells (Figure D2). This allows for selection of cells only containing lentivirus 
to be cultured and maintained over various subcultures of transformed cell line. The 4T1-
WT cell line was then transformed with lentivirus and sorted by cell sorting using tdTomato 
fluorescent expression as successful integration of lentivirus into cells. The cells were 
therefore, renamed as follows: 4T1-luc-tdTomato. Successful selection and high 
expression of lentivirus in cells was checked and maintained using tdTomato expression 
measured by flow cytometry (Figure 6.1). Figure 6.1 demonstrates the difference in 
fluorescent expression of 4T1-WT and 4T1-luc-tdTomato using A) dot plots and B) 
histogram plots to demonstrate a good expression and good separation of the two 
populations of cells. This allows for distinction of cell expressing fluorescence from those 
that are not expressing the tdTomato fluorescence, demonstrating the 4T1-luc-tdTomato 
cell having 99% expression of tdTomato fluorescence. The tdTomato expression was 
checked and maintained throughout experiment and checked using flow cytometry with 
4T1-luc-tdTomato cells maintaining tdTomato expression at 97% or above.  
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6.3.3 In Vitro Bioluminescence Kinetics Assay of 4T1-luc-tdTomato cells 
 The bioluminescence from firefly luciferase was also demonstrated in vitro by 
running cells through in vitro bioluminescence kinetics assay. Results from 4T1-luc-
tdTomato cells seeded at densities 250k, 125k, 62.5k, 31.25k and 15.265k were 
evaluated over time for bioluminescent expression after addition of d-luciferin to cells 
(Figure 6.2). Figure 6.2A is a representative IVIS image of total flux signal given from the 
A 
B 
Figure 6.1. Flow cytometry results of 4T1-luc-tdTomato cells after puromycin selection 
and sorting twice from cell sorter. A) Dot plots and B) histogram plots of wild-type 4T1 
(green) and 4T1-luc-tdTomato cells (blue) distinguish a distinct cell population based 
on tdTomato fluorescence.   
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cells, and the kinetics (Figure 6.2B) at different cell densities was plotted. 
  
The presence of signal indicated bioluminescent and presence of firefly luciferase was 
incorporated into the 4T1-luc-tdTomato cells. Also, the kinetics reveals that the 
bioluminescent signal at every cell density increases till around 10 min, in which it 
plateaus till 20 min. After 20 min, the bioluminescent signal begins to decline at every cell 
density tested. A 250k cell density was chosen to match the maximum number of cells 
used for tail vein (TV) injection into BALB/C mice.  The results also provide for a time 
window in which in vivo bioluminescence needs to be performed to evaluate tumor burden 
at peak bioluminescence levels. 
6.3.4 Evaluation of 4T1-luc-tdTom Metastatic Growth to the Lungs in Female 
BALB/C mice 
 An evaluation of tumor growth rate of lung metastases established by tail vein (TV) 
injection of 4T1-luc-tdTomato cells was performed. Initially, 100k cells were injected in TV 
of female BALB/C mice. In vivo IVIS images of the dorsal and ventral side of mice from 
Figure 6.2. In vitro kinetics assay of 4T1-luc-tdTomato cells. A) IVIS images of cells 
seeded in 96-well plate (cell numbers listed – max of 250,000 cells/well) and exposed 
to d-lucifiern, each repeated in triplicate; B) plot of kinetics of bioluminescent signal 
(total flux) over time at different cell densities. 
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Day 5 to Day 18 after TV injection were imaged and the total (sum) flux was evaluated 
(Figure 6.3). The total flux between days was evaluated (comparison between total flux 
on Day 5 vs 8, Day 8 vs, Day 11, Day 11 vs Day 14, and Day 14 vs Day 18) to determine 
between which days the largest increase tumor growth was seen. The largest increase in 
total flux was seen between Day 8 and 11 for all mice, with an average increase in flux 
by 11 ± 6 times in the total flux  seen on Day 11 as compared to Day 8 for the three mice 
evaluated. Other days saw a total increase in total flux signal by 5.0 ± 1.2 times from Day 
5 to Day 8, 7 ± 3 times from Day 11 to Day 14, and 4 ± 2 times from Day 14 to Day 18.  
 
Figure 6.3. Preliminary tumor growth experiment. A) IVIS images of mice from day 5 
go day 18 after TV injection of 100k 4T1-luc-tdTomato cells. B) Measurement of total 
flux from IVIS images by combined signal from the dorsal and ventral side of each 
mouse focused in the lung region area.  
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 To evaluate the establishment of lung metastases more directly, a second group 
of female BALB/C mice were injected via TV with 250k 4T1-luc-tdTomato cells, in which 
a mouse was sacrificed on different days and lungs were imaged directly with IVIS. The 
results of in vivo IVIS imaging and IVIS imaging of the lungs was compared and evaluated 
over 12 days post TV injection (Figure 6.4). Based on these results, the total flux over 
various days demonstrated the same trend for in vivo IVIS images and ex vivo lung IVIS 
images. Both demonstrated the highest total flux increase between day 9 and day 12 post 
TV injection of cells (Figure 6.4) with an increase in 5.5 times the signal of total flux for in 
vivo images and 9.3 times for ex vivo lungs from total flux measured on Day 12 compared 
to that of Day 9.  
 
 
Figure 6.4. Preliminary tumor growth experiment from TV injection of 250k 4T1-luc-
tdTomato cells. A) in vivo IVIS images of dorsal and ventral side of mouse over 12 days 
post TV injection of tumor cells. B) IVIS images of lungs taken on specific days after 
TV injection. The number below lung refers to mouse number. C) Total flux (flux of 
ventral and dorsal images combined focused on lung region) from in vivo IVIS images 
of mice over various days post TV injection. D) Total flux taken from lungs on each day. 
157 
 
 
 
6.3.5 In vivo efficacy of PLX3397 (PLX) for the treatment of Lung Metastases  
The efficacy of treatment of breast cancer lung metastases established by 4T1-
luc-dtTomato cells was evaluated for DOX, PLX, DDOX and combination treatments. The 
first experimental set was used to compare vehicle (as negative control) with pulmonary 
administration (PA) of DOX, PLX and the combination of DOX with PLX at a dose of 1 
mg/kg with combination at a dose of 1 mg/kg for each drug. A second experimental set 
evaluated the PA of DDOX, DDOX+PLX, and IV administration of PLX alone. The overall 
treatment strategy can be seen on Figure 6.5. 
 
 
After 3 treatments, all mice were sacrificed (day 15 post tumor inoculation), and the lung 
tissue was directly evaluated (Figure 6.6 and 6.7). The total flux of lungs for both groups 
as measured by IVIS of the lung tissues demonstrated no significant difference in overall 
Figure 6.5. The in vivo treatment strategy plan in treatment of lung metastases induced 
by 4T1-luc-tdTomato cells. 250k cells were injected TV in female BALB/C mice. 
Monitoring of tumor growth began by in vivo IVIS imaging of mice on Day 5 post tumor 
inoculation and continued for every other day till Day 15. Treatment was given three 
times on days 7, 9, and 11 post-tumor implantation. Mice were sacrificed on Day 15. 
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tumor burden between any of the groups as seen in p values calculated after One-way 
ANOVA analysis followed by Tukey’s Multiple Comparison Test (Figure 6.6).  
 
A trend can be noted, however, in which the overall tumor burden measured by 
total flux of tumor cells was least in PLX groups when delivered PA as well as IV, 
Figure 6.6. Evaluation of lung tumor burden by ex vivo imaging of lungs using IVIS. 
A) & D) Ex vivo lung images of treatment groups. B & E) corresponding total flux of 
lungs by combining flux of lungs imaged on two sides for each group as evaluated 
from IVIS images. C & F: Corresponding p-values comparing total flux of groups after 
running One-Way ANOVA analysis followed by Tukey’s Multiple Comparison Test. All 
drugs were given via pulmonary route except PLX# group seen in D) in which PLX was 
delivered IV route.  
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indicating potential of the macrophage immunotherapy treatment. Surprisingly, DOX 
alone did not help decrease tumor burden, with results similar to the control group 
(vehicle). The DOX+PLX group demonstrated a lower tumor burden on lungs, but not as 
effective as PLX alone, indicating that DOX is actually negating any positive effects of 
PLX. It is noted that DOX not only does not provide for an effective treatment, but it is 
also very toxic. Animals treated with DOX alone or in combination with PLX had a 
significant decrease in body weight (Figure D3) as well as increase in overall lung weight 
(Figure 6.7). DDOX and combination of DDOX+PLX delivered via the pulmonary route 
demonstrated overall tumor burden to be almost similar with PLX delivered IV, which 
showed slightly lower tumor burden (Figure 6.6). The change in body weight (Figure D3) 
and overall lung weights (Figure 6.7) for these groups showed no significant differences.  
To provide a more representative version of the in vivo data when measuring total 
flux of each mouse, the % tumor growth rate was calculated by normalization of total flux 
signal from Day 7 post tumor inoculation (1st treatment day) to be comprised of 100% 
tumor growth (Figure D3). Since total flux for each mouse varied, a way to try to compare 
rate of tumor growth was to normalize total flux signal. The normalization at 100% tumor 
growth rate occurred on Day 7 post tumor inoculation since this corresponded to the first 
day of treatment. The % tumor growth rate calculated by in vivo total flux (combined dorsal 
and ventral images) revealed similar trends (Figure D4, Table D1) to the results discussed 
above. However, for combination DOX+PLX group, the overall % tumor growth rate was 
shown to be the highest of all groups, which is not demonstrated when imaging of lungs 
only, and was statistically different from PLX group on Day 15 (Figure D4). This may be 
due to total flux captured in vivo was also capturing metastasis to other sites besides 
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lungs, such as lymph nodes and bone, in upper portion of mouse. Therefore, if DOX+PLX 
demonstrated lower results in lungs, it may not correspond to effective treatment to other 
sites.  However, no group proved to have any significant difference from vehicle, our 
negative control. Trends for DDOX, DDOX+PLX, and PLX (given IV) in % tumor growth 
rate (Figure D4, Table D1) proved to show similar trends as the tumor burden measured 
by the lungs (Figure 6.6). The DDOX+PLX group showed highest % tumor growth by Day 
15 as compared to DOX alone, and which PLX demonstrated the lowest % tumor growth 
by day 15. Overall, for both experimental groups, PLX delivered by PA and by IV 
demonstrated lowest tumor burden by Day 15.  
 
 
 
Figure 6.7. Average lung weight for corresponding group with A) representing first 
experimental group in which all drugs were given via pulmonary route and B) the 
second experimental group in which DDOX and DDOX+PLX were given pulmonary 
route and PLX# was given IV route, (*p<0.05, **** p<0.0001, n.s.d. = not statistically 
different). 
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6.3.6 Measurement of Macrophage Polarization by Flow Cytometry 
The macrophage population and macrophage polarization within the lungs of mice 
from Day 15 (n=3) post-tumor implantation was assessed by flow cytometry (Figure 6.8).  
 
In these exploratory experiments, total TAMs and M1 and M2 population was measured 
during the first set of experiments where all drugs were delivered via the pulmonary route. 
The overall number of macrophages found in the lung samples of PLX treated animals 
was lower than the vehicle (negative control). On the other hand, total macrophage 
Figure 6.8. Macrophage tracking by flow cytometry. A) % total of macrophages 
compared to all cells in lung sample. B) % of Cells considered M1 TAM phenotype. 
C) % of cells considered that of M2 TAM phenotype.    
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population in the lungs for DOX and DOX+PLX treatment groups resulted in an overall 
increase in number of macrophages (Figure 6.8A).  The percentage of cells considered 
M1 TAM phenotype increased and M2 TAM phenotype decreased for PLX group when 
compared to the vehicle (Figure 6.8). The DOX group had similar % of cells to be of M1 
phenotype and lower % of M2 cells as compared to control, while the combination group 
revealed a lowering of both M1 and M2 TAM percentages when compared to the vehicle.  
6.4 Discussion 
 Metastatic relapse is typically accompanied by MDR, which is the main cause of 
cancer death for most cancer patients6, 7, 23. Breast cancer remains the leading type of 
cancer in terms of new cases for women in the USA, and the metastatic form of breast 
cancer most commonly metastasizes to the lung, along with liver and bone, and lymph 
nodes.2, 7, 8 The metastatic form of breast cancer remains the leading cause of death in 
these patients and where current clinical intervention proves unbeneficial.9, 10 Not 
including only breast cancer, but secondary lung tumors (tumors that metastasize to the 
lung) can be found in 30-55% of all cancer patients.6 Therefore, a push for alternative 
treatments including immunotherapy have given a new therapeutic strategy to treat 
patients not only with primary lung cancers, but also secondary tumors that metastasize 
to the lungs. The small molecule immune modulator PLX is an attractive therapeutic agent 
as it has shown great efficacy as a monotherapy and combination therapy and is currently 
being studied in many current clinical trials.20, 82 In this investigation, we seek to evaluate 
the potential of locally delivered PLX to the lung tissue as a strategy to treat primarily and 
secondary lung cancers, and the impact of combination therapies with cytoreductive 
agents (in this case DOX). DOX itself is used as one of the main chemotherapies in the 
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late stages of advanced breast cancer,71 making it a relevant choice for this metastatic 
breast cancer model used in this study. A more direct delivery route for the treatment of 
primary and secondary lung tumors is an attractive strategy. Advantages of the pulmonary 
route include the fact that it is a non-invasive route of delivery to lungs, it has higher lung 
selectivity to direct more drug to target lung tumor sites, and lower systemic exposure to 
reduce off-target effects.72, 73 It can also serve as a non-invasive systemic delivery route 
by lungs having a large alveolar surface area and thin epithelial air-blood barrier allowing 
for rapid absorption of molecules from the alveolar space to the blood stream.73 This is 
attractive for metastatic models which some circulating cancerous cells can also be 
targeted, as for example the lymph nodes, the first site of metastases from lung cancer. 
Reducing systemic toxicity is critical not only to cytoreductive agents, but also to 
immunotherapies, including CSF1Ris, that have also demonstrated associated toxicities 
and a direct route of administration to the targeted tissue may help overcome challenges 
that may prevent their use alone or in combination. The combination of pulmonary route, 
chemotherapy, and immunotherapy, and nanotechnology for controlled and targeted 
delivery of the cytoreductive agents (nanochemoimmunotherapy) was tested to assess 
its potential for the treatment of primary and secondary lung tumors.  
In this case, a breast cancer metastatic in vivo needed to be established. The 
establishment of a transformed 4T1 cell line (murine mammary adenocarcinoma), a 
mouse cell model for stage IV human breast cancer, was the first step in this study.  It 
was transformed to incorporate fluorescent and bioluminescent properties by 
incorporation of a lentiviral vector containing tdTomato and firefly luciferase. The 
tdTomato fluorescent expression allowed for the tracking of the tumor cells via fluorescent 
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property utilizing flow cytometry (Figure 6.1). The bioluminescence from the luciferase 
allowed for visualization and monitoring of tumor growth rate in vivo and directly of lung 
tissues ex vivo with the use of IVIS imaging. These 4T1 cells were referred to as 4T1-luc-
tdTomato. The puromycin resistance was also added to the lentivirus to allow for selective 
selection of 4T1 cells that only contain vector, allowing for subculturing of the cells without 
loss of expression. The success of such an established cell line was monitored by both 
checking of fluorescent signal (Figure 6.1) and bioluminescent signal (Figure 6.2) and it 
is being continuously monitored to assure quality.  
Once the 4T1-luc-tdTomato cell line was established, a tumor growth rate study 
was conducted to evaluate the effectiveness of tail vein (TV) injection of cells to establish 
tumors in the lungs. This was conducted in female BALB/C mice, as these tumor cells are 
syngeneic to this strain of mouse. TV injection of 4T1 cells into BALB/C mice was 
evaluated previously, and compared to 4T1-luc2 cells implanted subcutaneously, 
orthotopically, and via TV.308 It was concluded that lung metastasis from breast cancer 
when established by orthotopic injection or TV injection did not show any significant 
differences in gene profiles, and they were thus considered genetically similar. 308 This 
conclusion confirms TV injection of 4T1 cells to form breast cancer lung metastasis is a 
relevant in vivo model of secondary lung cancer.  
Based on in vivo IVIS images (Figure 6.3) and ex vivo images of lungs (Figure 6.4) 
as a function of days post tumor implantation, it was demonstrated that around one week 
is required for the tumor cells to establish in the lungs and to begin to expand 
exponentially. A good correlation between the in vivo and ex vivo images was also seen. 
These results, therefore, also established that the tumor growth could be monitored in 
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vivo as the study was being conducted. The establishment of which day to start treatment 
was also determined based on the tumor growth profile.  Day 7 post tumor implantation 
was selected based on establishment of tumor by this day This is different from studies 
starting treatment at day 0. Therefore, our work more closely mimics what typically 
happens in the clinic for tumors when metastases had already ensued. 
The pulmonary delivery of PLX, DOX, DOX+PLX, DDOX, and DOX+PLX was 
evaluated for treatment of lung metastasis established by 4T1-luc-tdTomato cells in 
female BALB/C mice as direct pulmonary delivery to the lungs provides a relevant route 
to treat such metastasis as discussed above. However, IV administration of PLX was also 
tested as control – PLX is typically dosed orally.  The first set of comparisons were of 
pulmonary delivered DOX, PLX, DOX+PLX, as compared to the vehicle, the negative 
control (no treatment). The second set of comparisons was conducted on an experimental 
group in which DDOX, DDOX+PLX groups administered via the pulmonary route and a 
third group where PLX was administered the IV route. 
The results seen from evaluating tumor burden on lungs via total flux from tumor 
cells ex vivo (Figure 6.6) reveals that there was no statistical significant difference within 
the various groups tested. Therefore, none of the treatments demonstrated efficacy by 
Day 15 post tumor inoculation. These exploratory experiments reveal few trends and 
allowed us to draw some important conclusions, however, that may guide the next set of 
experiments.  
Another way to look at tumor burden is to measure the % growth relative to the last 
day the tumor was monitored before treatment. This strategy is also important as it takes 
into account natural variability among the animals within a group and between groups as 
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this particular model is susceptible to significantly different rates of growth compare to for 
example xerograph models implanted subcutaneously.   
The % tumor growth evaluated from in vivo IVIS images is shown in Figure D3 and 
p values calculated on Day 15 in Table D1. Their results show somewhat similar trends 
as with the ex vivo imaging of the lungs. The DOX and DOX+PLX treatments upon PA 
revealed a higher tumor growth rate compared to vehicle., indicating not only lack of 
efficacy from the cytoreductive therapy, but an unwanted effect that promotes tumor 
growth.  The DOX+PLX group showed the highest % tumor growth rate, which differs 
from the total flux seen in the lungs ex vivo.  These results are statistically different 
(greater rate of growth) from the PLX group by Day 15 post tumor inoculation. 
Interestingly DDOX+PLX also demonstrated the highest % tumor growth by Day 
15 (although no statistical differences noted). Therefore, the combination of PLX and DOX 
or DDOX did not provide a synergistic action, and actually seemed to provide the opposite 
effect on tumor burden (% tumor growth). The combination of these two drugs given 
together proved to be a poor combination.  
The main trend seen with all the groups is that the delivery of PLX alone either by 
pulmonary delivery or by IV delivery demonstrated the most effective decrease in tumor 
burden. This demonstrates that PLX alone could potentially act as a monotherapy for 
treatment of breast cancer metastasis or be used in combination with other therapies. 
Another major aspect to be noticed is that DOX at 1 mg/kg dose, when delivered 
the pulmonary route, proved to be highly toxic to the mice with this tumor model, in both 
DOX treatment group and DOX+PLX treatment group. Toxicity was observed by the 
decrease in average body weight of the mice (Figure D3) starting after treatment, as well 
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as increase in lung weight in those groups (Figure 6.7) to a large extent due to 
inflammation and not overall tumor burden, which remained statistically insignificant 
(Figure 6.6). This was somewhat surprising, given that the same dose was used 
previously in B16F10 (melanoma in C57Bl/6) induced lung tumor model without any 
toxicity and with significant reduction in tumor burden.77 However, changes in drug 
formulation and animal model may have contributed to this result.  
Therefore, an alternative DOX treatment was decided to be tested to ascertain if 
tumor burden and toxicity of DOX could be reduced/avoided. DDOX was chosen, as our 
group had demonstrated DDOX to be more effective than free DOX in a previous study 
in a B16F10-induced lung tumors.77 DDOX also had the lowest IC50 value (0.96 µM) in 
vitro (Table D2) when tested against other DOX formulations (Figure D5). The DDOX 
formulation did prove to decrease the toxicity of DOX at same free DOX equivalent 
concentration (1 mg/kg) – as seen with the lack of any significant drop in mouse weight 
(Figure D2) and no inflammation in lungs or increase in lung weight (Figure 6.7). However, 
despite these benefits, it still did not prove to be better than PLX alone.  
Overall PLX alone when given through pulmonary route or through IV route has 
proven here to have the best chance of treatment for lung metastasis from breast cancer. 
It is worth noticing that the expected dose of PLX expected to reach the lungs is very 
small upon IV administration. Given its efficacy, we expect to be able to reduce the total 
dose of PLX necessary upon PA to achieve same level of efficacy at IV. Upon finding the 
right combination of PLX and cytoreductive therapy, lower doses of the combination may 
lead to efficacy and reduced overall toxicity. 
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Many reports reveal that no dose limiting toxicities were found in phase 1 and 2 
clinical studies of CSF1R inhibitors,20 which correlates with this investigation. However, 
some dose limiting toxicities may occur at maximum tolerated dose and should be noted. 
One Phase 3 clinical trial using PLX3397 had 2 of 121 patients experience non-fatal 
serious liver toxicity, which led to suspension of the trial (NCT02371369).20 If this was due 
to inhibition of other receptor kinases in liver remains unclear.20 Also, whether this toxicity 
would be seen if delivered via other routes (IV and PA) compared to oral delivery is also 
unknown. But if liver toxicity could be avoided by alternative route of delivery, this would 
be an incentive to deliver PLX via alternative routes. 
In terms of mechanism of action of PLX, some preliminary results were performed 
with the help of the Bos group at VCU (tagging of lung tumor cell suspension provided 
and data analysis). PLX treatment was seen to induced macrophage polarization from 
M2 to M1 as seen in flow cytometry results (Figure 7.8). An overall decrease in 
macrophage population was seen compared to vehicle control, with an increase in M1 
TAMs and decrease in M2 TAMs demonstrating a 3-fold overall increase in M1/M2 ratio 
(from ca. 4 to ca. 12). Therefore, a decrease in overall TAMs as well as repolarization did 
occur with PLX treatment, an indication that this CSF1Ri is affecting overall TAMs found 
within the lungs on this secondary model.  
 Overall efficacy was not determined from this study as no statistical differences 
were seen in treatment groups. However, based on these results, PLX alone has the best 
indication to expand on these preliminary results, as combination therapies and different 
treatment regiments are evaluated. For example, a longer study may prove overall 
efficacy of PLX alone in both delivery routes (PA and IV) and is currently being studied in 
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the group. Also, the dosing schedule for PLX and maximum tolerated dose could also be 
explored to enhance overall efficacy. An overall more in-depth study of macrophage 
population and interaction with other immune cell populations (T effector and T regulatory 
cells) is desired to provide more insight into the role of PLX in modulation of the immune 
system. PLX also downregulates CSF1R by inhibition of phosphorylation of kinase 
domain on the receptor. This could be further elucidated the mechanism of tumor 
inhibition when looking at amount of phosphorylation seen in CSF1R on TAMs to 
understand the molecular mechanism of PLX.  
 PLX in combination with other therapies could also enhance efficacy.  The 
combination of PLX and other CSF1R inhibitors with immune checkpoint therapies has 
the highest number of clinical trials to date.20 Immune-checkpoint therapies have 
revolutionized immune therapy for cancer treatment. A combination of CSF1Ri and T-
cell-enhancing therapies (PD1/PDL1 inhibitors) have shown synergistic action and 
proven to be effective when PD1/PDL1 inhibitors were shown limited efficacy on its 
own.309  This combination has led to many clinical trials in Phase 1/2 stages to determine 
dosing, safety, and clinical efficacy, with results yet to be remaining.20 Therefore, this 
combination of PLX with PD1/PDL1 inhibitor could prove to be a synergistic combination 
and should be tested in breast cancer metastasis model established here.  
6.5 Conclusion 
 Treatment of primary and secondary lung tumors remain a significant clinical 
challenge in which current standard of care with cytoreductive therapies offer relatively 
small clinical benefit. This study focused on the treatment of secondary lung tumors 
metastasized from breast cancer in order to evaluate a new treatment strategy for lung 
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metastases that includes (i) immunotherapy with a macrophage reductive and 
repolarization agent (PLX); (ii) combination of cytoreductive therapy (DOX) and 
immunotherapy (immunochemotherapy); and (iii) use of dendrimer nanocarriers for 
improved efficacy and reduced toxicity of cytoreductive agent in combination with CSF1Ri 
(nanochemoimmunotherapy).  
Here pulmonary delivery of DOX, PLX, PAMAM G4SA-hyd-DOX (DDOX) and 
combination of PLX with DOX or DDOX formulations was tested via pulmonary delivery 
on an in vivo model of 4T1-induced secondary lung tumors in female BALB/C mice.  It 
was demonstrated that of all treatment groups, PLX alone proved to show the most 
promising strategy by showing the lowest tumor burden on lungs when PLX was delivered 
PA or IV, and no dose-limiting side effects. Surprisingly, free DOX alone or in combination 
with CSF1Ri showed significant toxicity and no ability to reduce tumor burden. 
PLX seems to work by leading to an overall decrease in TAMs and TAM 
repolarization as demonstrated via flow cytometry. However, efficacy and most effective 
dosing schedule as well as total dose remains to be further investigated. Also, a 
combination with immune-checkpoint therapies has also a potential for a synergistic 
combination treatment strategy, which was not seen with DOX and PLX. Therefore, 
immunotherapy with PLX remains a promising therapy for treatment of metastatic breast 
cancer to the lungs.  
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CHAPTER 7 – CONCLUSIONS AND FUTURE DIRECTIONS 
 Lung cancer remains the number one cause of cancer death in the United States.2 
Approximately 57% of cases are diagnosed at the metastatic stage, with a 4.7% five-year 
survival rate.3  Treatment success is radically different in other types of cancers such as 
prostate cancer where rate of incidence has fallen 10% annually from 2010-2014 and has 
a 5-year survival rate of 99%.2, 3 Not only lung cancer, but secondary lung tumors found 
in 30-55% of all cancer patients .6 Most metastatic tumors cannot be cured with existing 
therapies.12 Chemoresistance (multi drug resistance – MDR) that develops intrinsically or 
acquired becomes the final leading cause of death in these patients.6, 9, 11, 22 MDR 
develops from a variety of changes that occur within tumor cells and the complex 
characteristics of the tumor microenvironment (TME). Several mechanisms of resistance 
are utilized by tumors concurrently or consecutively, thus making treatment effectiveness 
difficult.24 Current therapies often have slowed tumor progression or alleviated symptoms, 
but rarely lead to a cure.12 Immunotherapy, including the use of checkpoint inhibitors has 
shown promise in which alternative therapies have not proven beneficial. However, only 
a relatively small fraction of tumor types and of patients have been benefited so far.20, 21 
Immunotherapies are unfortunately not devoid of toxicity, and this is an important issue 
that is becoming more obvious and relevant as the number of new immunotherapy-based 
regimens are rapidly growin.17 Establishing new treatments, alone or in combination, that 
can (i) increase the rate of survival of lung cancer patients at early stages or at later 
stages when metastatic relapse and MDR may have developed, and (ii) reduce intrinsic 
toxicity associated with the various treatments is, therefore, of great potential relevance 
in pulmonary oncology. 
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Here we described alternative treatment modalities with pre-clinical studies that 
suggest their potential to help address the onset of MDR and potentially prolong the rate 
of survival of patients with primary and secondary lung tumors. We use a combination of 
local lung targeting (high payload to relevant site with reduced systemic toxicity), 
nanocarriers (modulation of the interaction with the physiological environment), 
intracellular/organelles targeting (repurposing cytoreductive therapies), siRNA as 
therapeutic agent (selective target apoptotic pathways), and macrophage repolarization 
immunotherapy (use TME to support other therapies) are reported.  
 The main conclusions from these studies and suggested overall future directions 
are discussed here: 
(i) We were able to develop mitochondrial-targeted dendrimer nanocarriers 
(DNCs) as a platform for the repurposing of chemotherapeutics with potential applicability 
in the treatment of MDR in primary and secondary lung tumors. Mitochondria have 
become attractive targets for cancer therapies since they play a crucial role in cellular 
homeostasis and intrinsic apoptosis and have altered functions in tumors.48, 50 TPP, a 
common mitochondrial targeting agent, has been utilized to target small molecules54-57, 92 
as well as various nanocarriers 87-89 for delivery of therapeutics and treatment tumors and 
MDR-associated tumors. We are the first group to directly address TPP density and effect 
of PEG linker between TPP (PEGTPP) on cellular internalization, toxicity, and 
mitochondrial targeting of dendrimers, including PAMAM. We demonstrated this as a 
potential delivery platform for therapeutics to address issues with MDR.  
  Here, we were able to determine that TPP attachment to G4NH2 PAMAM 
dendrimers lead to an enhancement of mitochondrial targeting of these dendrimers. TPP 
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was either directly conjugated (G4NH2-TPP) or through PEG linker (G4NH2-PEGTPP). 
PEG was added as a flexible linker between G4NH2 dendrimer as PEG has desirable 
characteristics including increasing solubility, biocompatibility, enhanced 
pharmacokinetics and modulation of interaction between the dendrimer and the 
physiological environment.116, 122, 241 Both strategies demonstrated significant 
mitochondrial targeting as compared with G4NH2 without TPP. G4NH2-TPP groups 
demonstrated an increase in targeting with increase in density, while G4NH2-PEGTPP 
demonstrated significant mitochondrial targeting without being affected by degree of 
PEGylation present. Modulation in overall toxicity and internalization was seen as TPP 
density varied, with an increase in in vitro toxicity and cellular internalization in G4NH2-
TPP with increasing TPP-density, whereas G4NH2-PEGTPP has decreasing in vitro 
toxicity when PEGTPP density is above 5 per dendrimer (>8% coverage). Therefore, 
modulation of the properties of G4NH2 dendrimer can be achieved with the presence of 
PEG without affecting the overall mitochondrial targeting ability. It was concluded, 
therefore, that both direct and indirect conjugation, separately or in combination, are 
potential strategies for the delivery of therapeutics to the mitochondria, which can be 
utilized to address MDR and treatment of primary and secondary lung tumors.  
 More work is required to test overall efficacy of TPP-dendrimer targeted strategy. 
G4NH2-TPP and G4NH2-PEGTPP dendrimers can be further modified upon conjugation 
of a chemotherapeutic agent directly to the dendrimer One chemotherapeutic that has 
shown efficacy when targeting mitochondria is DOX.54-57, 94, 177, 182The Complex I in the 
electron transport chain in mitochondria can modify DOX into a more reactive 
semiquinone radical, resulting in increased ROS production and higher oxidative 
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stress.178, 179 DOX may also inhibit Complex I and II, increasing ROS production, which 
can ultimately lead to induction of apoptosis.178, 179 The conjugation of DOX to a 
mitochondrial-targeted dendrimer nanocarrier or conjugation of DOX with TPP (DOXTPP) 
and then to dendrimer should be considered and tested in vitro and in vivo.54-57, 177 This 
may prove to be an effective strategy to address drug resistance, particularly when 
combined with pulmonary delivery. 
(ii) We developed siRNA/TPP-DNC complexes as a platform for pulmonary 
delivery of siRNAs with potential applicability in the treatment of MDR in primary and 
secondary lung cancer. siRNA delivery to the lungs can be utilized to address MDR by 
modulating genes overexpressed in tumors and assist in apoptosis induction when 
delivered alone or in combination with other treatments.58 However, efficient siRNA 
delivery to lung tumors has many challenges including physiological barriers and cellular 
internalization barriers. Here, we were able to demonstrate the enhancement of in vitro 
transfection ability of siRNA in lung alveolar cells by the use of dendrimer-TPP conjugates 
to form nanometer scale TPP-DNCs complexes with siRNA, and the successful aerosol 
formulations of those complexes in both pMDIs and DPIs. This provides an overall 
platform for local siRNA targeting to the lungs that can be utilized to help address MDR 
and treat primary and secondary lung tumors.  
The impact of TPP surface modification on G4NH2 dendrimers was evaluated for 
their interaction with siRNA and their overall gene knockdown ability in an in vitro model 
of the pulmonary epithelium at various TPP densities and varied N/P ratios (amount of 
dendrimer vs siRNA in the complex). The eGFP knockdown ability in eGFP-A549 cells of 
dendrimers was enhanced with the presence of TPP on the dendrimer surface with 
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G4NH2-12TPP, and at N/P 30 demonstrating the highest gene knockdown efficiency. 
Improvements with transfection ability was associated with looser complexation between 
the siRNA and G4NH2-TPP dendrimer and could be associated with other factors 
including mitochondrial targeting, heightened cellular internalization, and more effective 
endolysosomal escape. Micron-sized particles were engineered by G4NH2-12TPP-
dendriplexes being spray dried with mannitol. We demonstrated that such micron 
particles are conducive to deep lung deposition when formulated in pMDIs and DPIs. We 
have also shown these to be viable formulations in that siRNA maintained its biological 
activity during the preparation of the micron particles, formulation and delivery (in vitro 
model of the lung). Therefore, this strategy provides for a platform for efficient siRNA 
delivery to the lungs. 
Further work can help be performed to help elucidated the potential of this strategy 
in context of lung tumors and MDR by delivering siRNA that targets well-known genes 
that are overexpressed in lung tumors. In this context, the gene targets of most interest 
have been Bcl-2 and Survivin. Bcl-2 is a protein cell survival and cell death by prevention 
of intrinsic (mitochondrial-dependent) apoptosis in which it interacts with other Bcl-2 
family proteins on the outer mitochondrial membrane.204, 205 It has been implicated in MDR 
and associated with poor prognosis.22 Survivin is a member of the Inhibitor of Apoptosis 
Protein (IAP) family68, 206 and promotes cell survival by inhibiting caspases, proteins 
known to implement programmed cell death.66, 95, 206, 207 Survivin expression is not 
normally found in adult tissues, but has been expressed in high levels in NSCLC, and 
also shown unfavorable prognosis, increase recurrence rates, and tumor resistance in 
these instances.66, 206, 209 Therefore, the delivery of siRNA containing gene sequences 
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that target Bcl-2 or Survivin have great potential in addressing MDR in lung tumors, and 
should be tested utilizing the strategy we presented here in vitro and in vivo. This strategy 
can also be tested as a combination therapy, where gene targets and other treatment 
modalities (chemo- or immuno-therapies, for example) are used to elicit synergistic 
effects.  
(iii) We were able to synthesize dendrons with various surface chemistries and 
a cytoreductive molecule (DOX). Conjugation of these asymmetric dendrons has the 
potential to enhance therapeutic efficacy of the chemotherapeutic and in combination with 
local lung delivery be used in the treatment of MDR in primary and secondary lung 
cancers. As the complexity and versatility in dendrimer chemistry increases, so does the 
opportunities to use such versatile carriers in biomedical applications.39-41 Bis-MPA 
polyester dendrimers have been demonstrated to be highly biocompatibility and are also  
degraded under physiological conditions.38 They are thus highly desirable as drug 
delivery carriers. The multifunctionality of Bis-MPA asymmetric dendrimers have thus 
tremendous potential, but their chemistry remains highly complex. 45, 167  
 In this work, we were able to synthesize and characterize various surface 
modifications to N3-G5-OH polyester dendrons for the potential formation of asymmetric 
dendrimers containing DOX and varying surface chemistries unmodified neutral (-OH), -
COOH (anionic), -NH2 (cationic), hydrophilic (-PEG), and hydrophobic (-Lauryl) 
functionalities. All surface modifications were made via a liable ester bond. Overall, the 
various surface modifications represent different surface properties, which have 
implications in altering cellular internalization and trafficking pathways, and thus their 
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intracellular fate, as seen with other dendrimers,47 but with a highly controlled and 
asymmetric chemistry. 
 While dendrons have been prepared, due to the complexity of the synthesis, the 
preparation of the asymmetric dendrimers was not accomplished during this work and will 
be part of future work in our group. A potential strategy of DOX conjugation to an acet-
G5-GA dendron via a -GFLG- peptide linker has been proposed. The formation of GFLG-
DOX remains the limiting factor, and the synthesis of such will remain to be executed in 
the future. The synthesis and purification of asymmetric dendrimers form dendrons 
containing GFLG-DOX on one side and varying surface chemistries has also been tested 
and proposed. These strategies can be utilized to form final asymmetric dendrimers via 
click chemistry.  
 Once asymmetric dendrimer chemistry is completed, the testing in vitro and in vivo 
is recommended to be conducted. Cellular internalization and intracellular trafficking, and 
drug efficacy in vitro will be conducted to elucidate how asymmetric surface chemistries 
can affect cellular internalization mechanisms, and thus influence overall DOX efficacy. 
The delivery of such systems via PA route should be conducted in order to address how 
asymmetry and varying surface chemistries could affect overall drug efficacy. This can 
be compared to results of DOX directly conjugated to a polyester dendrimer to elucidate 
the effect of high asymmetry.  These nanocarriers should be also tested in MDR tumors 
to elucidate the impact of asymmetry. 
(iv) We were able to assess the impact locally delivered, TAM-targeting 
immunotherapy with potential applicability in the treatment of MDR in primary and 
secondary lung tumors. Metastatic tumors are associates with poor prognosis and drug 
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resistance, and remains the main cause of cancer death and challenge in pulmonary 
oncology.6, 7, 23 Modulation of TAMs by CSF1Ri have shown great promise in many 
current clinical trials.20, 82 In this investigation, we sought to determine the ability of a 
CSF1Ri (PLX) alone or in combination with a cytoreductive agent in its free form (DOX) 
or conjugated to PAMAM dendrimers (DDOX) to reduce the tumor burden in an in vivo 
model of secondary lung cancer (breast cancer lung metastases) upon PA administration. 
This works represents the first to test the delivery of PLX via pulmonary route as potential 
treatment secondary lung tumors and potential to address MDR. This is relevant as such 
therapies have potential associated toxicities, and local administration may help mitigate 
undesirable effects, and thus potentially allow studies with combination therapies as well 
(where those therapies may also have their own associated toxicity).  
 PA of DOX, PLX, DDOX and combination of PLX with DOX or DDOX formulations 
was tested in an in vivo model of 4T1-induced secondary lung tumors in female BALB/C 
mice. No treatment groups were able to demonstrate statistical significant differences 
form the control. However, trends for PLX alone indicated an overall decrease in tumor 
burden when delivered via PA, and incurring in no adverse effects, thus suggesting 
potential of the proposed strategy. Preliminary results also suggest that groups that 
received PLX treatment lead to an overall decrease in TAMs number and TAM 
repolarization towards a higher M1/M2 ratio.  
 Future work in related to such strategy is to explore different regimens of PLX and 
combination therapies. First, the overall efficacy of PLX alone via IV and PA should be 
determined by lengthening the overall study to measure survival in this tumor model. A 
more effective dosing schedule as well as dose-escalation studies could reveal increased 
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efficacy and determine if any adverse reactions with PLX can be reached, as well as the 
potential to reduce dose upon PA administration. The combination of TAM 
reduction/repolarization with immune-checkpoint therapies has also a potential as a 
synergistic combination treatment strategy.20 The solubility of PLX also remains a 
problem in which a complex formulation including DMSO and Tween are required to 
solubilize PLX. Therefore, new nanoformulations to increase overall solubility of PLX are 
greatly desired and should be studied in future work.  
In conclusion, this work and future work has represented potential treatment 
strategies to address MDR and for the treatment primary and secondary lung tumors. We 
have demonstrated mitochondrial targeting, pulmonary siRNA delivery, use of novel 
polyester asymmetric dendrimers, and pulmonary delivery of CSF1Ri as potential 
platforms for treatment of primary and secondary lung tumors as well as address issues 
concerning MDR. These strategies present varied alternative pathways that when used 
alone or combined can greatly affect outcome in patients with poor prognosis, and could 
in other context, be used to treat other alternative disease states in the lungs.  
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APPENDIX A 
SUPPORTING INFORMATION FOR CHAPTER 3 
Supporting Information. The characterization of G4NH2-TPP and G4NH2-PEGTPP 
conjugates as described by 1H NMR (Figure A1).  The structure with associated bonds 
as well as the spectra is given for each conjugate.   
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A 
B 
Figure A1. 1H NMR spectra of the A) G4NH2-FITC-TPP and B) G4NH2-FITC-
PEGTPP dendrimer conjugates in D2O at 400 MHz on Aligent Mercury Spectrometer.  
The chemical structures are shown above with the corresponding peak shifts. 
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APPENDIX B 
SUPPORTING INFORMATION FOR CHAPTER 4 
 
Table B1. Deposition of dendriplex mannitol micron particles (weight) and siRNA 
(densitometry) on different stages of the Andersen Cascade Impactor (ACI) from a pMDI 
formulation at a flow rate of 28.3 L/min.  pMDI formulations at 2 mg microparticles/1 mL 
HFA227 propellant at 25 oC and saturation pressure of propellant.  The payload of siRNA 
in microparticle is 0.025% wt/wt.  The results were based on 20 actuations and 
represented with mean ± s.d. (n=3).  AC: actuator, IP: induction port, 0-7: plate 0-7, and 
F: filter. RF, FPF, MMAD and GSD refer to respirable fraction, fine particle fraction, mass 
median aerodynamic diameter and geometric standard deviation, respectively. 
Stage Mass of microparticles (mg) Mass of siRNA (ng) 
AC 0.36 ± 0.08 80 ± 8 
IP 0.69 ± 0.06 121 ± 6 
0 (9.0-10.0 µm) 0.08 ± 0.03 34 ± 19 
1 (5.8-9.0 µm) 0.14 ± 0.04 38 ± 11 
2 (4.7-5.8 µm) 0.17 ± 0.05 62 ± 11 
3 (3.3-4.7 µm) 0.55 ± 0.16 105 ± 15 
4 (2.1-3.3 µm) 0.32 ± 0.05 76 ± 11 
5 (1.1-2.1 µm) 0.12 ± 0.05 46 ± 9 
6 (0.7-1.1 µm) 0.04 ± 0.02 24 ± 14 
7 (0.4-0.7 µm) 0.03 ± 0.01 33 ± 7 
F (<0.4 µm) 0.03 ± 0.01 12 ± 8 
RF (%) 59 ± 6 66 ± 3 
FPF (%) 50 ± 3 54 ± 3 
MMAD (µm) 3.8 ± 0.2 3.6 ± 0.1 
GSD 1.4 ± 0.1 1.8 ± 0.2 
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Table B2. siRNA Deposition on the different stages of Andersen Cascade Impactor (ACI), 
as determined by densitometry.  The 10-20 mg micron particles loaded into capsule were 
released into ACI from Rotahaler® (DPI formulation) at 25°C, 75% relative humidity, and 
a flow rate of 28.3 L/min for 4 s inspiration.  The results are represented with mean ± s.d. 
(n=3).  IH: inhaler, IP: induction port, 0-7: plate 0-7, and F: filter. ED, RF, FPF, MMAD and 
GSD refer to emitted dose, respirable fraction, fine particle fraction, mass median 
aerodynamic diameter and geometric standard deviation, respectively. 
 
 
 
 
 
 
 
 
 
 
Stage Mass of siRNA (ng) 
IH 1860 ± 90 
IP 330 ± 130 
0 (9.0-10.0 µm) 260 ± 40 
1 (5.8-9.0 µm) 215 ± 15 
2 (4.7-5.8 µm) 354 ± 9 
3 (3.3-4.7 µm) 310 ± 7 
4 (2.1-3.3 µm) 225 ± 7 
5 (1.1-2.1 µm) 81 ± 7 
6 (0.7-1.1 µm) 81 ± 4 
7 (0.4-0.7 µm) 29 ± 14 
F (<0.4 µm) 2 ± 2 
ED (%) 50 ± 2 
RF (%) 42 ± 3 
FPF (%) 39 ± 3 
MMAD (µm) 4.8 ± 0.3 
GSD 1.4 ± 0.2 
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Figure B1. The cell viability of A549 cells contacted with Lipofectamine® 2000 reagent at increasing 
concentrations as measured by the MTS assay after 48 h incubation.  Statistical analysis between the 
control group indicated at 0 µM representing 100 % cell viability and those of increasing 
concentrations was analyzed by One-Way ANOVA followed by Tukey’s Multiple Comparison Test (n < 
7). **p ≤ 0.01, *** p < 0.001, n.s.d. = not statistically different. 
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APPENDIX C 
SUPPORTING INFORMATION FOR CHAPTER 5 
C1. Materials 
Polyester-32-hydroxyl-1-acetylene bis-MPA dendron, generation 5, 97% (Acet-
G5-OH), glutaric anhydride (GA), 2,5-dihydoxybenzoic acid (DHB), 4-Nitrophenol, and 
piperidine, were purchased form Sigma-Aldrich (St Louis, MO, USA). Doxorubicin 
hydrochloride salt (DOX•HCl) was purchased from LC Laboratories (Woburn, MA, USA). 
The H-Gly-2-Cl-Trt resin was purchased from AAPPTEC (Louisville, KY, USA). Fmoc-
glycine, Fmoc-L-leucine, Fmoc-L-Phenylalanine, N,N′-Diisopropylcarbodiimide (DIC), 
and 1-Hydroxybenzotriazole hydrate (HoBt) were purchased from Chem-Impex 
International (Wood Dale, IL, USA). 2,2,2-Trifluoroethanol (TFE) and N,N-
Diisopropylethylamine (DIPEA) was purchased from TCI Co., Ltd. (Tokyo, Japan). Acetic 
Acid (AcOH), dichloromethane (DCM), dimethylformamide (DMF), dimethyl sulfoxide 
(DMSO), ethyl ether (Et2O), methanol (MeOH) were purchased from VWR International 
(Radnor, PA, USA). 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 
(EDC), N,N-Dimethylformamide (DMF), anhydrous, 99/8+%, N-Hydroxysuccinimide, 
98+% (NHS), copper (I) Iodide, and 4M Hydrogen chloride in 1,4-dioxane was purchased 
from Alfa Aesar (Haverhill, MA, USA). Acetonitrile was purchased from Avantar 
Performance Materials (Center Valley, PA, USA). Dimethyl Sulfoxide-D6 (with TMS - 0.03 
vol%) and magnesium sulfate anhydrous were purchased from EMD Millipore (Burlington, 
MA, USA). Deuterium Oxide (D, 99.9%) was purchased from Cambridge Isotope 
Laboratories, Inc. (Tewksbury, MA, USA). Sephadex LH-20 were purchased from GE 
Healthcare Bio-Science (Uppsala, Sweden). 
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C2. Synthesis of GLFG-Fmoc peptide 
Resin-GLFG-Fmoc peptide (0.5 mmol) was synthesized on a Liberty Blue 
Automated Microwave Peptide Synthesizer (CEM, Matthews, NC, USA) using a standard 
protocol for solid-phase peptide synthesis (Scheme B1). GLFG-Fmoc was cleaved from 
the resin by diluting product in a mixture of AcOH/TFE/DCM (1:1:8) stirring at room 
temperature for 0.5 h. The resin was filtered off and solution collected and diluted in 
hexane (15 x volume). The solvents were removed utilizing rotary evaporation and 
product collected giving a white solid. The GLFG-Fmoc was characterized by 1H NMR 
and MALDI-TOF. 
Fmoc-GFLG: 1H NMR (DMSO-d6400 MHz, ppm) : 0.84 (d, -CH3, 3H, Leu), 0.88 (d, -
CH3, 3H, Leu), 1.49 (t, -CH2, 2H, Leu), 1.61 (sept, -CH, 1H, Leu), 2.78 (dd, -CH, 1H, Phe), 
3.04 (dd, -CH, 1H, Phe), 3.49-3.73 (m, 4H, Gly), 4.22-4.56 (m, 4H), 7.22 (d, -CH, 4H, 
Phe), 7.31-8.18 (m, 9H) MALDI-TOF: Obtained: [M+Na]+ 637.52; [M+K]+ 653.47 
Calculated: 614.70 Da 
Scheme C1. Deprotection of GLFG-Fmoc from the resin. AcOH: acetic acid, TFE: 
Trifluoroethanol, DCM: dichloromethane. G-L-F-G: Peptide of glycine-leucine-
phenylalanine – glycine.  
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C3. Synthesis of GFLG-DOX by Conjugation of DOX to GLFG-Fmoc followed by 
deprotection of Fmoc 
Conjugation of GFLG-DOX can be seen in Scheme B2. To conjugate DOX to the 
GLFG-Fmoc peptide, 30 mg (0.05 mmol) of GLFG-Fmoc, 10.4 mg (0.075 mmol) of 4-
Nitrophenol were dissolved in 2 ml of DMF and cooled down to ~0°C using ice/water bath.  
14.37 mg (0.075 mmol) EDC in 200 L of DMF was added dropwise to the reaction and 
left to react stirring at ~0°C for 30 min. The reaction was then allowed to reach room 
temperature and allowed to react for an additional 12 h. After 12 h, the reaction was again 
cooled down to ~0°C using an ice/water bath in which 34.8 mg (0.06 mmol) of DOX 
dissolved in 500 µl of DMF and added to the reaction followed by the addition of 10 µl 
(0.06 mmol) of DIPEA. The reaction was allowed to stir for an additional 48 h. After the 
Scheme C2. A) Conjugation of DOX to GLFG-Fmoc to form DOX-GLFG-Fmoc, B) 
Deprotection of Fmoc from DOX-GLFG-Fmoc to form DOX-GLFG. EDC: (1-(3-
Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride DIPEA: N,N-
Diisopropylethylamine,  DMF: dimethylformamide. 
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reaction was competed, the solvent was removed under high vacuum.  The crude product 
was purified using a Sephadex LH-20 column (2 x 25 cm) with MeOH as the eluent. The 
fractions were checked with MALDI-TOF for the Fmoc-GFLG-DOX product, and fractions 
containing product were combined and MeOH solvent removed by rotary evaporation. 
Fmoc-GFLG-DOX MALDI-TOF was as follows: MALDI-TOF: Obtained: [M+Na+] 1,162.3; 
[M+K+] 1,178.1 Calculated: 1,139.4 Da 
The Fmoc-GFLG-DOX was deprotected using a solution of 20% piperidine in DMF 
and allowed to react for 30 min. The solvent was removed by high vacuum and 
redissolved in small amount of DMF in which the product was precipitated in cold Et2O. 
The precipitate was collected by centrifugation to form a pellet (5000 rpm, 5 min, 4°C) in 
which supernatant was removed. The excess ether was removed by airflow resulted in 
deep red product – GFLG-DOX. The GFLG-DOX product was characterized by MALDI-
TOF. GFLG-DOX: MALDI-TOF Obtained: [M+Na+] 940.3; [M+K+] 956.3 Calculated: 
917.37 Da 
C4. Conjugation of Glutaric anhydride (GA) to Acet-G5-OH dendron to form Acet-
G5-GA dendron 
 Modification of Acet-G5-OH to contain carboxyl group can be seen in Scheme B3. 
Scheme C3. The modification of Acet-G5-OH dendron to contain -COOH group by 
addition of GA to form Acet-G5-GA. Acet-G5-OH: Acetylene Generation 5 Bis-MPA 
polyester dendron, DIPEA: N,N-Diisopropylethylamine,  DMF: dimethylformamide. 
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20.19 mg (5.5 µmol) Acet-G5-OH was reacted with 62.76 mg (550.0 µmol) of GA with 
104.8 µl (616.2 µmol) of DIPEA in 1.5 ml of DMF and allowed to stir at room temperature 
for 24 h to form Acet-G5-GA dendron. Following the reaction, the Acet-G5-GA product 
was purified by the removal of DMF solvent by vacuum followed by dialysis against DMSO 
using Spectra/Por® 7 RC membrane dialysis tubing (MWCO = 1 kDa, Spectrum 
Laboratories, Inc., Rancho Dominguez, CA, USA) for two days. The product was removed 
from dialysis and DMSO solvent removed by vacuum, redissolved in 1xPBS (pH = 7.4) 
and filtered using Amicon Ultra-15 centrifugal filter (NMWL = 3,000, MilliporeSigma, 
Burlington, MA, USA) against 1xPBS followed by DI water. The product was then 
collected from the Amicon filter, frozen, and lyophilized in freeze dryer (Labconco, Kansas 
City, MO, USA) to obtain white powder. The Acet-G5-GA product was characterized by 
MALD-TOF and 1H NMR (Figure C1). Acet-G5-GA: 1H-NMR (D2O, 400MHz, ppm): δ 
4.29-4.23 (m, 124H), 2.37 (t, 64H, J=7x(2)), 2.17 (t, 64H J=7.2x(2)), 1.78 (t, 64H 
J=7.2x(2)) 1.30-1.24 (m, 93H). MALDI-TOF MS: 7329.0. 
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Figure C1. A) Chemical structure of Acet-G5-OH and Acet-G5-GA and the 
corresponding B) 1H NMR and C) MALDI-TOF spectra.  
Scheme C4. Conjugation of DOX-GLFG to Acet-G5-GA dendron to form Acet-G5-
GA-GFLG-DOX dendron.  EDC: (1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide 
hydrochloride NHS: N-Hydroxysuccinimide, DMF: dimethylformamide. 
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C5. Azide/Alkyne Click Chemistry of Acet-G5-OH and N3-G5-OH dendrons to form 
(OH)32-[G5]-[G5]-(OH)32 dendrimer.   
 Formation of Polyester dendrimer from dendrons using click chemistry is 
described in Scheme B5.  
 
5.33 mg (1.42 µmol) of Azide (Polyester bis-MPA dendron, 32 hydroxyl, 1 azide, 
generation 5, 95%) (N3-G5-OH) and 5.01 mg (1.37 µmol) of Acetylene (Polyester-32-
hydroxyl-1-acetylene bis-MPA dendron, genration 5, 97%) (Acet-G5-OH) were added 
with 8.53 mg (44.79 µmol) of copper (I) Iodide  and 1.16 µl (6.82 µmol) of N,N-
Diisopropylethylamine (DIPEA) with 40 µl of degassed, anhydrous DMF and 400 µl of 
acetonitrile and put on thermal mixer (ThermoFisher Sceintific) shaking at 1400 rpm,  
80°C, overnight followed by 50°C for an additional 24 h. After the additional 24 h, the 
acetonitrile was removed by airflow followed by the removal of DMF by high vacuum. The 
product was then dissolved in 250 µl of 1xPBS (pH 7.4) and centrifuged to pellet excess 
copper iodide (1400 rpm, 2 min at 20°C), then loaded into 0.7 x 50 cm Econo-Column 
Chromatography Column (Bio-Rad) containing Bio-Gel P-10 Gel (2 g) in which fractions 
were collected and analyzed by MALDI-TOF. Fractions were combined, and the final 
Scheme C5. Conjugation of HO-G5-OH dendrimer from to Acet-G5-OH and N3-G5-
OH dendrons utilizing copper click chemistry. DIPEA: N,N-Diisopropylethylamine, 
DMF: dimethylformamide, ACN: Acetonitrile. 
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product characterized by MALDI-TOF (Figure C2). OH)32-[G5]-[G5]-(OH)32 dendrimer: 
MALDI-TOF MS, mass (m/z): 7393.9 LS ζ-potential: -31 ± 7 mV 
 
  
Figure C2. MALDI-TOF of purificed HO-G5-OH dendrimer after size exclusion 
chromatography. The expected MW (7393.9) as determined found for dendrimer while 
only very insignificant amount of dendrons remained in the product (Acet-G5-OH – 
3634.7, N3-G5-OH – 3770.8).  
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APPENDIX D 
SUPPORTING INFORMATION FOR CHAPTER 6 
 
Scheme D1. A) Synthesis of hydrazine bond to the G4SA PAMAM dendrimer. TBC 
is added to G4SA by addition of NMM and IBCF in DMSO/DMF (10/90, v/v) 
followed by Boc deprotection by exposure to TFA/DCM (80/20, v/v). B) DOX 
addition by hydrazone bond was completed with TFA as acid catalyst and MeOH 
as solvent. G4SA: Generation 4 PAMAM succinamic acid surface dendrimer 
DMSO: dimethylsulfoxide DMF: dimethylformamide TBC: tert-butyl carbazate 
NMM: N-Methylmorpholine IBCF: isobutyl chloroformate TFA: trifluoroacetic acid 
DCM: dichloromethane MeOH: methanol DOX: doxorubicin. 
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Figure D1. A) The chemical structure and corresponding 1H NNMR and B) the 
MALDI-TOF of G4SA, G4SA-TBC, G4SA-hyd, G4SA-hyd-DOX.  
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Figure D2. Puromycin kill curve. 4T1 cells were exposed to various concentrations of 
puromycin (0-10 µg/ml) for 48 hours to determine the minimum amount of puromycin 
to kill all 4T1 cells.  
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Figure D3. % Average body weight of mice for A) first experimental group in which all 
drugs administered were given pulmonary route and B) second experimental group in 
which DDOX and DDOX+PLX groups were given pulmonary route and PLX# was given 
IV route.   
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Figure D4. Evaluation of lung tumor burden by in vivo imaging of mice near lung region 
using IVIS. A) & C) % Tumor growth rate over time. Day 7 total flux from in vivo IVIS 
images was normalized to 100% for each mouse. B & D) The corresponding % Tumor 
growth in vivo on Day 15 – final day of experiment imaged on two sides for each group 
as evaluated from IVIS images, *p<0.05. All drugs were given via pulmonary route 
except PLX# group seen in D) in which PLX was delivered IV route.  
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Table D1. p-values calculated after One-Way ANOVA by Tukey’s Multiple Comparison 
(n≥6) for % tumor growth seen on Day 15 post tumor inoculation. 
 
 
 
 
 
 
 
 
Group p-value  
Vehicle vs. PLX 0.7766 
Vehicle vs. DOX 0.8260 
Vehicle vs. DOX+PLX 0.2276 
PLX vs. DOX 0.2762 
PLX vs. DOX+PLX 0.0329 
DOX vs. DOX+ PLX 0.6592 
DDOX vs. DDOX+PLX 0.2681 
DDOX vs. PLX# 0.9629 
DDOX+PLX vs. PLX# 0.1798 
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Table D2. IC50 values of drugs when tested against 4T1-WT cells line. This was 
conducted after 48 h incubation and measured by MTT. DOX= doxorubicin, DDOX= 
PAMAM G4COOH-DOX conjugate, DOXTPP = Triphenylphosphonium-modified 
doxorubicin, DDOXTPP = PAMAM G4COOH-DOXTPP conjugate. 
 
  
Drug IC50 Value (µM) 
DOX 1.12 
DDOX 0.96 
DOXTPP 8.53 
DDOXTPP 4.40 
Figure D5. % Cell viability (measured by MTT) of doxorubicin and modified doxorubicin 
formulations against 4T1-WT cells after 48-hour incubation. DOX= doxorubicin, DDOX= 
PAMAM G4COOH-DOX conjugate, DOXTPP = Triphenylphosphonium-modified 
doxorubicin, DDOXTPP = PAMAM G4COOH-DOXTPP conjugate. 
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 Lung cancer remains the leading cause of cancer-related deaths in the United 
States. Secondary lung tumors metastasized from other cancer sites also remains highly 
prevalent, in which most metastatic tumors cannot be cured with existing therapies. 
Chemoresistance (multi drug resistance – MDR) that develops intrinsically or acquired is 
one of the key factors leading to fatality in these patients. MDR develops form a variety 
of resistance mechanisms that can occur consecutively or concurrently, therefore, making 
most current treatments unsuccessful. Current therapies have known to slow tumor 
growth, but rarely provide a cure. Immunotherapy has seen some promise, including the 
use of checkpoint inhibitors, when other therapies have not proven beneficial. However, 
only a small fraction of tumor types and patients have benefited from this type of 
treatment, and some toxicity has been stated. Therefore, establishing new types of 
treatments, as a single therapy or combination therapy, that can i) increase the rate of 
survival in patients suffering at early or late stages (when MDR and metastasis have 
developed) of lung cancer, and ii) reduce toxicity and adverse side effects of treatments 
is of great importance in pulmonary oncology.  
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In this work we describe alternative treatment modalities that suggest their 
potential to address MDR and prolong the rate of survival in patients suffering from 
primary and secondary lung tumors. A combination of local lung targeting (high payload 
to target side and reduced systemic toxicity), nanocarriers (to modulate interactions with 
physiological environment) intracellular organelle targeting (to repurpose cytoreductive 
therapies), siRNA as therapeutic agent (to target apoptotic pathways), and macrophage 
repolarization immunotherapy (to modulate the tumor microenvironment) are reported. 
We describe the development mitochondrial-targeted dendrimer nanocarriers (DNCs) as 
a platform for the repurposing of chemotherapeutics, the development of siRNA/TPP-
DNC complexes (TPP-dendriplexes) as a platform for pulmonary delivery of siRNAs, the 
development of asymmetric dendrimers with a chemotherapeutic and varying surface 
functionalities to enhance tumor targeting and penetration, and address the impact of 
local pulmonary administration of tumor associated macrophage (TAM)-targeting 
immunotherapy. Overall, we conclude that all these strategies described above have the 
potential capability to address issues resulting from MDR and for the treatment of primary 
and secondary lung tumors. 
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